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 Introduction  
 Burden of cervical carcinoma and impact of Human 
Papillomavirus 
Cervical cancer is the fourth most common cancer in women, after breast, 
colorectal, and lung cancer (World Cancer Research Fund American Institue 
for Cancer Research, 2018). There are over 270,000 mortalities due to cervical 
cancer, and over 500,000 women are diagnosed every year worldwide (Arbyn 
et al., 2011; Graham, 2017). Cytology has been widely employed for preventing 
cervical cancer (Papanicolaou test or Pap smear test) (Hillemanns et al., 2016). 
Even with a cervical cytology screening system, cervical cancer remains the 
epidemicity, though the prevalence and motility of cervical cancer are different 
geographically (figure 1.1) (World Health Organization, 2018). Due to sufficient 
screening systems and vaccination, cervical cancer lost its predominance in 
developed countries. However cervical cancer turns out to be the second most 
common cancer in women in developing countries (Harro et al., 2001; World 
Cancer Research Fund American Institue for Cancer Research, 2018), where 
almost 80% of mortality driven by cervical cancer occurs. In South Africa, the 
estimated age standardized incidence and mortality for cervical carcinoma is 
43.1 per 100,000, and 20.0 per 100,000, respectively, in comparison to 6.0 and 
1.7 per 100,000 in Australia and New Zealand (figure 1.1) (World Health 
Organization, 2018). The tremendous difference in cervical cancer incidence 
and death in different regions may result from the challenges to effectively 
implement the screening systems and vaccination programs in developing/low-
income countries.  
Papillomaviruses are ubiquitous and have been found in a wide-range of 
different species including humans. Over 200 different types of human 
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papillomavirus (HPV) have been identified based on their DNA sequences. 
Infection with HPVs usually causes benign epithelial lesions, such as skin warts, 
but certain types of HPVs can increase the chances to develop carcinoma, such 
as cervical cancer (Brescia et al., 1986). Harald zur Hausen firstly 
demonstrated the link between genital HPV infection and cervical cancer in the 
early 1980s. Since then it was demonstrated that HPV infection is also linked 
to anal, penile, vulvar and vaginal carcinoma. In the last decades, HPVs have 
been found in head and neck cancers as well (Panwar et al., 2014) (figure 1.2). 
 
 
 
 
 
 
 
 
 
 
 
Update from GLOBOCAN 2018  
Figure 1.1 Estimates of incidence and mortality of cervical cancer (World Health 
Organization, 2018). From world health organization’s 2018 data, estimation of incidence A) 
A 
B 
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and mortality B), there is a significant difference of incidence and mortality of cervical cancer in 
different regions of the world (IARC Globocan Database, 2018). 
 
 
 
 
 
 
 
 
 
 
From Lowy, D.R. and J.T. Schiller, Cancer Prev Res (Phila), 2012.  
Figure 1.2 Prevalence of HPV-associated cancers (Lowy and Schiller, 2012). A) the 
prevalence of HPV-associated cancer worldwide; B) the prevalence of HPV-associated cancer 
in U.S. A reduction in cervical cancer incidence was observed, and meanwhile, the incidences 
of oropharynx cancers increased.  
 HPV classification and HPV- related cancer 
Among the currently identified papillomaviruses, 85 types have been 
characterized, while 120 isolates have not been fully investigated, and defined 
as potential new genotypes (Bharti et al., 2018). PV phylogenetic classification 
is based on the differences within the highly conserved L1 gene region between 
each genotype (a minimum of 10% nucleotide difference distinguishes two 
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genotypes (Kocjan et al., 2015; Van Doorslaer et al., 2017)). Up to date, five 
genera have been defined, which are α, β, γ, μ, and ν (figure 1.3) (Anonymous, 
2003; Doorbar et al., 2012; Graham, 2017; Van Doorslaer et al., 2017). 
Alternatively, HPVs are also classified according to tissue tropism into 
cutaneous or mucosal types. 
 
 
 
 
 
 
 
 
 
 
 
 
From de Villiers, E.M., Virology, 2013. 
Figure 1.3 Phylogenetic tree of PVs based on the L1 sequences of around 150 types of 
papillomavirus types (de Villiers, 2013).  
By analyzing the information of both molecular biology and epidemiology HPVs 
in the α genus mostly play an important role in genital cancer progression (de 
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Villiers, 2013) (figure 1.3). Cutaneous HPVs, including those which are related 
to non-melanoma skin cancer, mostly belong to the genera β and γ (figure 1.3) 
(Andersson et al., 2013; Fei and de Villiers, 2012; Mackintosh et al., 2009; 
Massimi et al., 2008). HPV infections do not always lead to apparent diseases, 
as the infection is transient and benign in most of the cases (Doorbar et al., 
2012; Forslund, 2007; Massimi et al., 2008), however, certain genotypes might 
present increased ability to cause persistent and difficult to treat lesions. Of 
special concern are the mucosal HPVs of the α genus, which can be subdivided 
into high-risk and low-risk types according to the oncogenic potential (Bernard 
et al., 2010). 16 types are highly linked to cervical cancer, and other anogenital 
cancers or oropharyngeal cancer: these are HPV16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68, 73, and 82 (Munoz et al., 2003). Among these high-risk HPVs, 
different prevalence occur with regard to cervical cancer: 54.4% of cervical 
cancer cases are caused by HPV16, followed by HPV18, which is responsible 
for 16.5% of cervical cancers worldwide (figure 1.4) (Crow, 2012). The other 
types of HPVs responsible for genital warts are called low-risk types (e.g. HPV6, 
11, 26, 53, 67 etc.) (Bernard et al., 2010; Hsueh, 2009). 
 
 
 
 
 
 
Updated from Crow, J.M., Nature, 2012.  
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Figure 1.4 Prevalence of HPV types in cervical cancer worldwide (Crow, 2012). The 
infection by HPV 16 is the most common cause (54.4%) of cervical cancer, followed by HPV18 
(16.5%), both of them cause around 70% of cervical carcinoma worldwide. Including other 
oncogenic HPVs types, the prevalence reaches 98%.  
 The Biology of human papillomavirus 
Papillomaviruses are non-enveloped icosahedral viruses with a double-
stranded, circular genome which is around eight thousand base pairs in size 
(McMurray et al., 2001). The HPV genome encodes five early transcribed 
genes which are E1, E2, E5, E6 and E7  encoding non- structure proteins, three 
late genes, E4, L1 and L2 helping to release the virus and encoding the viral 
capsid proteins, and a long non-coding control region (LCR), also known as the 
upstream regulatory region (URR) (Doorbar, 2005; Doorbar, 2006). When the 
virus infects cells, all five early genes start to transcribe as all the early proteins 
are important for regulating the replication of virus genes and the process of 
pathogenesis (Gao and Smith, 2016; Tommasino, 2014). Then E4, L1 and L2 
are expressed during the late phase of the viral life cycle. L1 is the major capsid 
protein, which is the main structural protein of HPVs. Five L1 monomers 
spontaneously assemble into a pentamer, which then further assemble into a 
capsid. During the assembly, the minor capsid protein L2 is positioned at the 
vertices of virus particle in the center of capsomeres (figure 1.5) (Modis et al., 
2002; Schiller and Muller, 2015) 
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Updated from Schiller and Mueller, The Lancet Oncology, 2015  
Figure 1.5 The scheme of HPV capsid protein L1 and L2 assembly (Schiller and Muller, 
2015). Five times of L1 monomers format a capsomere, 72 capsomeres assemble on virus-like 
particle, and 72 capsomeres and L2 protein encapsulated viral genome format an authentic 
virus.  
Eight β strands in the L1 protein form an antiparallel β-sandwich as the core of 
the capsomere and are labeled as B to I. These β-strands connect with loops 
BC, DE, FG and HI, which present the most of neutralizing epitopes (figure 1.6) 
(Bishop et al., 2007; Carter et al., 2003; Ludmerer et al., 1996; Roth et al., 2006; 
Sapp and Bienkowska-Haba, 2009). Because these loops are not well 
conserved among different HPVs, anti-L1 neutralizing antibodies are usually 
type-specific (Bishop et al., 2007). Most of the minor capsid protein L2 is hidden 
inside of the capsid, only residues from 60-120 at the N-terminus can reach to 
the surface of the capsid (Sapp and Bienkowska-Haba, 2009; Sapp et al., 1995). 
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Updated from B. Bishop, The Journal of Biological Chemistry, 2007  
Figure 1.6 HPV 16 L1 pentamer crystal structure (Bishop et al., 2007). Different colors 
represented separate monomer to indicate the surface loops intertwining. 
 
 The life cycle of human papillomavirus 
HPV infect the proliferating basal keratinocytes through a wound, the virus 
binds to the extracellular matrix (ECM) which is secreted by keratinocytes 
through some certain components, as well as heparin sulfate proteoglycans 
(HSPGs) which are the primary receptors of HPV (Giroglou et al., 2001). This 
interaction between HPV and their receptors induce conformational changes in 
both capsid proteins. For L1, the changes are not yet clear, but they seem to 
enhance the recognition of a neutralizing L1 epitope in the BC loop (Roth et al., 
2006; Selinka et al., 2003). Moreover, they may also induce the decrease in 
affinity of the capsid to HSPG, thereby handing over the virus to the secondary 
receptor(s). On the other hand, the interaction between the HPV capsid and 
HSPG leads to another conformational change in the L2 protein whereby the 
N-terminus of L2 is exposed and consequently cleaved by furin protease. These 
processing steps seem to be important for the exposure of the L2 cross-
neutralization epitopes (Richards et al., 2006; Roden et al., 2000). 
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The HPV genome is small and the viral DNA replicates independently of the 
cell cycle. Initially, the infected primitive cells go to transit amplifying 
proliferation, and the copy number of viral genome does not change. With                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
very few viral genes being expressed, replication factor E1 and transcription 
factor E2 are the first detected, both in RNA and protein level (Thomas et al., 
1999; Wang et al., 2009); E7 will activate the keratinocytes differentiation from 
phase G1 to S, which is important for later viral genome replication (Graham, 
2017; Roman and Munger, 2013), and also plays a critical role in the viral 
genome replication phase in cells which transfer from mid to the upper layers 
(figure 1.7) (Graham, 2017).  
In the later phase of the viral life cycle, not only the expression of E1 and E2 
increase, but also E4 and E5 (Davy et al., 2002; Graham, 2010). For the high-
risk HPVs, E4 protein is the most important regulator, and has an greatly effect 
on differentiated keratinocytes, supporting amplification of the viral genome 
(Davy et al., 2005), but not for some low-risk HPVs, such as HPV11 (Fang et 
al., 2006). E5 controls the cell division pathways (Crusius et al., 1997) by 
stabilizing EGFR and stimulating MARK activity. In the later phase, the infected 
cells differentiate, exiting the cells in the stratum spinosum, leading to a boost 
in viral gene expression and DNA replication (figure 1.7) (Doorbar, 2007; 
Roberts et al., 2018; Stanley, 2012).  
To complete the life cycle, the capsid proteins L1 and L2 are synthesized. L2 
expression precedes that of L1 (Becker et al., 2003). The major capsid protein 
L1 can self assembles into pentameric capsomeres which are transported to 
the nucleus to encapsulate the virus genome with the help of the minor capsid 
protein L2 (Nelson et al., 2002; Stauffer et al., 1998). The minor capsid protein 
L2 is required for the DNA packaging and virion assembly (Stauffer et al., 1998). 
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E2 also plays a role in the recruitment of the virus genome to the assembly sites 
during the virus assembling period (Day et al., 1998; Heino et al., 2000).  
 Persistence of Human Papillomavirus causes cervical 
cancer 
HPV is the most commonly sexually transmitted infection. Both men and 
women can transmit HPV (Castellsague et al., 2003). Multiple sexual partners 
or a sexual partner who had multiple sexual partners, sexual activities at an 
early age, having children at an early age and having multiple children are risk 
factors for HPV infections. Moreover, condom use does not help with prevention 
of HPV infection since HPVs can be transmitted by contacting infected skin, like 
labial, scrotal and anal tissue (Roden et al., 1997).  
 
 
 
 
 
 
 
 
From Stanley, M.A., Clin Microbiol Rev, 2012 
Figure 1.7 HPV life cycle in the mucosal epithelium (Stanley, 2012). The early and late viral 
gene expression in the different epithelia layers. After infection, E1 and E2 are the earliest 
translated proteins, and regulate viral replication, followed by E5, E6 and E7 expression, 
mediating genome amplification. E4 is involved not only in the regulation viral replication but 
also in cytoskeletal morphogenesis. During the late phase, L1 and L2 proteins are expressed 
and new virus particles are assembled.  
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Mostly, HPV infections are transient, 90% of the infections are cleared 
spontaneously by the immune system (Chua and Hjerpe, 1996; Ostor, 1993; 
Stoppler et al., 1996).  
Due to the life cycle of HPV, there is a limited amount of HPV viral synthesis in 
undifferentiated cells, and a great level of expression of HPV in differentiated 
cells (Bodily and Laimins, 2011; Scott et al., 2001; zur Hausen, 1996). The 
infection process normally does not activate the inflammatory response, and 
suppresses both innate and adaptive immune responses (Bodily and Laimins, 
2011). One way to suppress the innate immune response is to interfere with the 
interferon pathways (Bourgeade et al., 1980). HR HPV E6 and E7 proteins can 
both repress the transcription of interferon induced genes, such as the 
transcriptional activator STAT-1 (Bodily and Laimins, 2011; Chang and Laimins, 
2000; Nees et al., 2001). Moreover, E6 can block the kinase Tyk-2 and protein 
kinase R (PKR) which can both act as activators of STAT-1 (Stanley, 2009); E6 
also binds to IRF-3 and E7 binds to IRF-1. IRF-3 and IRF-1 are both regulators 
of interferon pathways (Bodily and Laimins, 2011; Stanley, 2009). HR E6 and 
E7 can also inhibit toll-like receptor nine (TLR 9), an important sensor of double 
strand DNA (Ghittoni et al., 2010). 
Another way to escape from innate and adaptive immune response is to inhibit 
the cytokine production in keratinocytes, which limits immune cells infiltration of 
infected tissue. In HR HPV positive keratinocytes, the expression of IL-1, IL-6, 
TNF-α, and TGF-β (Alcocer-Gonzalez et al., 2006; Arany and Tyring, 1996) 
increased, as well as the anti-inflammatory IL-10’s expression (Alcocer-
Gonzalez et al., 2006; Fichorova and Anderson, 1999). The clearance of the 
infected cells is dependent on the cell-mediated immune responses, requiring 
the filtration of CD8+ and CD4+ cells (Stanley, 2008; Stanley, 2009). However, 
HR HPVs can interrupt the infiltration of Langerhans cells and dendritic cells 
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into the infected tissue due to the cytokine changes induced by the HR HPV 
infection (Hubert et al., 1999; Stanley, 2008; Stanley, 2009). Major 
histocompatibility complex I (MHC I) expression is also downregulated in the 
course of HR HPV infection, as well as natural killer cells activity. All of these 
events contribute to an HPV persistent infection (O'Brien and Saveria Campo, 
2002; Stanley, 2009).  
The persistence of HPV infections leads to larger damage to the tissue and 
growth of the HPV lesions, which require a lot of nutrients and oxygen. In order 
to grow, the most important factor is angiogenesis induction which is regulated 
by the HIF-1 transcription factor which can be activated in hypoxia (Bardos and 
Ashcroft, 2005; Toussaint-Smith et al., 2004). There is evidence indicating that 
HR and LR HPV E7 proteins induce the expression of HIF-1 and HIF-1α 
(Nakamura et al., 2009). E7 protein can bind to pRb which controls the 
expression of several S phase specific genes and the entry into S phase 
(Munger et al., 2001). HR E6 can bind to the E3 ubiquitin ligase leading to the 
degradation of p53 to block apoptosis, and thus increasing the cellular 
proliferation and maintenance of the viral genome (Howie et al., 2009).  
Due to E6 and E7 expression, persistent infection with high-risk HPVs leads to 
pre-cancerous lesions and ultimately cervical cancer development. Over time, 
cellular genome changes with E6 and E7 amass lead to oncogenesis. The pre-
cancerous lesions are known as low- or high- grade squamous intraepithelial 
lesions. Low-grade squamous intraepithelial lesions are also referred to as 
cervical intraepithelial neoplasia grade 1 (CIN1), and high-grade squamous 
intraepithelial lesions are CIN2 or 3 which are known as the highly proliferative 
phase (figure 1.8). 
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From Woodman, C.B., S.I. Collins, and L.S. Young. Nat Rev Cancer, 2007.  
Figure 1.8 Persistent infection with HPVs lead to cervical carcinogenesis (Woodman et 
al., 2007). HPV accesses the basal cells through the microlesions in the cervical epithelium. 
After the infection, the early genes E1, E2, E5, E6 and E7 are expressed and the viral genome 
replicates. In the upper layers, HPVs genome is replicated further, L1 and L2, late genes are 
expressed, and form into capsomeres and encapsulate the viral genome in the nucleus. Then 
mature viruses are released from the dead epithelial cells and initiate a new infection. CIN1 to 
2 helps the viral genome replication and the progress to CIN3 or even invasive cancer.  
 Current commercial Human Papillomavirus prophylactic 
vaccines 
Three HPV prophylactic vaccines have become available over the last decade, 
the bivalent (HPV16 and 18), quadrivalent (HPV6, 11, 16, 18) and nonavalent 
(HPV6, 11, 16, 18, 31, 33, 45, 52, 58) vaccines (table1). They are anticipated 
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to reduce the morbidity and mortality of cervical cancer (Luckett and Feldman, 
2016). The bivalent HPV vaccine (Cervarix, GlaxoSmithKline, Rixensart) can 
preventcervical cancer caused by HPV16 and HPV18. Quadrivalent vaccine 
(Gardasil, Merck & Co, Inc.) which targets HPV6, 11, 16 and 18 was approved 
by the FDA.(Food and Drug Administration) in 2006 and can protect against 
cervical cancer caused by infection with HPV16 and HPV18, and genital warts 
caused by infection with HPV6 and HPV11. The nonavalent HPV vaccine 
(Gardasil 9, Merck & Co, Inc.) targets HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 
was proved effective in preventing high grade cervical dysplasia (Joura et al., 
2015). All three vaccines show creditable efficacy in the prevention of HPV 
infections caused by the targeted HPV (Beachler et al., 2016; de Martel et al., 
2017).  
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Table 1 Features of current commercial HPV L1 virus like particle vaccines 
All three vaccines are based on virus-like particles (VLPs) of the major capsid 
protein L1. They show high immunogenicity, but are also highly type specific. 
These VLPs do not contain the viral genome, which makes them non-infectious 
(Harro et al., 2001), but they can mimic the native viral infection, present B cell 
epitopes and induce virus neutralizing antibody production. Generally, people 
should be vaccinated against HPV before engaging in sexual activities (World 
Health Organization. Electronic address, 2017). Additionally, in order to achieve 
sufficient neutralizing antibody production against the natural viral infection, the 
vaccines need to be administrated at least 3 times during a 6 months period 
which makes vaccine routine difficult to follow due to the age of the individuals 
 2-valent  
HPV vaccine 
4-valent  
HPV vaccine 
9-valent  
HPV vaccine 
Company GlaxoSmithKline  Merck Merck 
Authorized year 2007 2006 2014 
Brand Name Cervarix Gardasil, Silgard Gardasil 9 
L1 virus-like 
particle types 
HPV16 (20 µg),      
18 (20 µg) 
HPV6 (20 µg),        
11 (40 µg), 16 (40 
µg), 18 (20 µg). 
HPV6 (30 µg),          
11 (40 µg), 16 (60 µg), 
18 (40 µg), 31 (20 µg), 
33 (20 µg), 45 (20 µg), 
52 (20 µg), 58 (20 µg) 
Cross-
protection 
HPV31, 33, 45 HPV31 Unknown 
Adjuvant ASO4 (0.5 mg 
Aluminum hydroxide 
and 50 μg 3-O-
desacyl-4”-
monophosphoryl lipid 
A [MPL]) 
0.225 mg Aluminum 
hydroxyphosphate 
sulphate 
 
0.5 mg Aluminum 
hydroxyphosphate 
sulphate 
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meant to receive the vaccine. Currently, many countries have already approved 
2 doses for girls who are younger than 15 years old (Schiller and Muller, 2015). 
These decisions are made according to the non-inferiority antibodies (Schiller 
and Muller, 2015). Evidence showed that immunizations with 2 doses of 
bivalent vaccine induced similar antibody titers after 4 years as if the vaccine 
was administered 3 times to  girls who were in 9-15 years old (Kreimer et al., 
2011).  
Antibodies are considered to target HPV during infection (Schiller and Lowy, 
2012). There are two ways that the anti-HPV antibodies induced by immunizing 
with VLP HPV vaccines reach the mucosal epithelium at the HPV infection site. 
At first, the vaccines induce serum IgG (immunoglobulin G) exuding into the 
genital tract to provide protection against HPV infection. Secondly, serum IgG 
could transude into cervico-vaginal mucus by interacting with neonatal Fc 
receptor (Mestecky et al., 2010; Nardelli-Haefliger et al., 2003).  
There are several factors that make VLP vaccines highly immunogenic. First of 
all, the size of VLPs is optimal for trafficking to the lymph nodes after injection, 
and also enables their recognition and presentation by DCs (dendritic cells) 
(Jennings and Bachmann, 2008). Secondly, VLPs can induce pro-inflammatory 
cytokines by interacting with human immunocytes, like monocytes, 
macrophages and myeloid DCs, resulting in the maturation of DCs in an acute 
phenotypic and functional manner in order to further promote adaptive immune 
responses (Lenz et al., 2005; Lenz et al., 2003; Schiller and Lowy, 2012). 
Thirdly, VLPs can induce MHC II restricted CD4+Th cells which further help the 
responses of B cells (Schiller and Lowy, 2012).  
Despite the high immunogenicity and safety that the current commercial 
vaccines offer, the VLP vaccines also have limitations. The VLP vaccines are 
expensive to produce and transport, which makes them unaffordable for most 
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low income countries which have high incident rates of HPV-linked cancer. 
Moreover, HPV VLP vaccines are type-specific, with low capacity for cross-
protection against other HPVs including some of high-risk HPVs. For examples, 
the protection induced by the bivalent VLP vaccine, which contains HPV16 and 
18 VLPs, is very potent, but the neutralizing antibodies are limited in targeting 
the other 13 high-risk HPV types which are also responsible for up to 30% 
cervical cancer. However, there is some cross-protection against very closely 
related HPVs, like HPV31, HPV33, and HPV45 in some individuals. Another 
drawback of current VLP vaccines is the need for a continuous cold chain for 
transport and storage, which is unaffordable in most developing countries. To 
achieve a certain level of neutralizing antibody, the VLP vaccines require two 
to three intramuscular injections over six months, which requires patient 
adherence to the schedule, and also sterile conditions. All of these make the 
immunization with current VLP vaccines not practical in most developing 
countries. Finally, current VLP vaccines do not possess a therapeutic function 
because they do not lead to efficient T cell responses that would regress 
already established neoplasia.  
 The next generation of HPV vaccines 
Due to the limitations of current VLP vaccines, efforts are being made to 
develop a second generation of HPV vaccines. There are certain requirements 
and expectations for second generation HPV vaccines. Primarily, the vaccine 
must evoke high immunogenicity and demonstrate a high safety profile, it must 
also provide long-term protection. Secondly, it should be much cheaper in both 
production and distribution. Thirdly, this vaccine should have a broader range 
of protection against high-risk HPV types which are not included in the current 
VLP vaccines. In addition, protection against low-risk mucosal HPVs and 
cutaneous HPVs would be beneficial. Last but not the least, it would be 
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advantageous if the second generation HPV vaccines could also achieve some 
therapeutic function.  
There are several attempts to use alternative production systems to generate 
L1 VLPs. Such as Xiamen Innovax Biotech which produces modified L1 based 
VLPs in E. coli, they already successfully completed a phase I clinical trial, a 
phase III trial is currently in preparation (Zhao et al., 2014). Despite this success, 
other companies employ yeast expression to manufacture VLPs (Bazan et al., 
2009; Hanumantha Rao et al., 2011; Schiller and Muller, 2015). L1-
recommbinant plants expression systems have also been reported with the aim 
to lower the cost of production. Unfortunately, the yield was low and the VLPs 
did not assemble properly (Giorgi et al., 2010). Another strategy is employing 
pentavalent L1 capsomers instead of L1 VLPs, which has the advantage of 
higher thermostability and low-cost because they can be easily produced in E. 
coli. However the capsomers induce lower neutralizing antibody titers and are 
less durable than L1 VLPs vaccines (Gersch et al., 2012; Schadlich et al., 2009; 
Thones et al., 2008). Another approach for L1-based vaccines involves viral or 
bacterial vectors. These methods may definitely lower the cost and perhaps the 
number of administrations compared to current commercial vaccines, but safety 
concerns come into play causing a lot of problems during the clinical trials. 
Giuseppina Cantarella et al. have combined the HPV16 L1 with the commercial 
Berna strain of the attenuated measles virus, resulting in high titres of HPV16 
neutralizing antibodies, with no influence on measles antibody production 
(Cantarella et al., 2009). Immunization with this vaccine may, however, lead to 
conflict with the measles vaccination schedule, since infants usually receive the 
measles vaccines, but it may also lead to a combined vaccine targeting infants 
which would offer protection against both measles and HPVs, if the neutralizing 
antibodies can still provide protection when these infants enter adolescence. 
Other virus vectors used in academic laboratories are adeno-associated virus 
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(AAV) and human endogenous retrovirus as genetic vaccines (Lee et al., 2010; 
Nieto et al., 2012a). The biggest advantage of L1 recombinant AAV-5 or -9 is 
that it may change the administration method actually making the vaccine 
needle free (Nieto et al., 2012a).  
To achieve broad cross-protection, L2, minor capsid proteins have been studied 
as another candidate for the second generation of a prophylactic HPV vaccine. 
L2 can induce cross-protection against different HPVs, but the neutralizing 
antibody titres are ten times lower than the antibody titres induced by the L1 
VLPs (figure 1.9) (Day et al., 2010; Pastrana et al., 2005). One copy of the L2 
protein is in each L1 capsomere with a maximum of 72 L2 molecules per capsid 
(Schiller and Muller, 2015). However, unfortunately, L2 proteins cannot induce 
neutralizing antibodies efficiently in the natural infections. Different from L1 
VLPs, the neutralizing antibodies induced by L2 can recognize linear conserved 
peptide epitopes, which provide broader cross-protection against homologous 
and heterologous HPVs (Pastrana et al., 2005; Roden et al., 2000). The ability 
to induce broad cross-protection with L2 would make the coverage of a range 
of high-risk and even low-risk mucosal HPVs by a monovalent vaccine possible, 
maybe also for cutaneous HPVs (Schellenbacher et al., 2013). There is proof 
that sera transferred from mice immunized with L2 could provide cross-
protection against HPVs in vivo despite the antibody titres being much lower 
than VLPs (Day et al., 2012). The reason behind this might be the highly 
conserved N-terminal region (amino acid 17-36) of HPV L2 (figure 1.10).(Wang 
and Roden, 2013). RG-1, a monoclonal antibody which binds specially to the 
17-36 epitope, can prevent HPV 16 infection in vivo and sera of mice that had 
been immunized with RG-1 can also neutralize HPV4, 6, 16, 18, 31, 45, 52, 58, 
BPV1 and HPV11 (Gambhira et al., 2007; Wang and Roden, 2013). Moreover, 
L2 neutralizing epitopes have been inserted into VLPs in order to increase the 
range of protection, but further evidence needs to be provided to prove if L2 
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insertion does not interfere with the display of L1 epitopes (Schellenbacher et 
al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
From Day, P.M., et al., Cell Host Microbe, 2010.  
Figure 1.9 The early stage of HPV infection, binding to HSPGs, and the scheme of how 
vaccine-induced antibodies interfere with infection (Day et al., 2010). A) HPVs at first reach 
the basement membrane via microlesions. After HSPGs-HPVs binding, L1 undergoes 
conformational changes, exposing furin cleavage site at the N-terminus of L2. HPVs are 
released from HSPGs and move to bind to the cellular entry receptor. B) the first step of 
infection, binding to HSPG can be blocked by anti-L1 antibodies. C) if the antibody 
concentration is low, then the HPVs can still bind to HSPGs and be cleaved by furin, but do not 
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interact further with the cellular entry receptors. D) in the presence of L2-antibodies, binding to 
cellular entry receptor can also be prevented.  
 
 
 
 
 
 
 
 
From Wang, J.W. and R.B. Roden, Virology, 2013.  
Figure 1.10 Representation of HPV16 L2 neutralization epitopes and protein interaction 
domains (Wang and Roden, 2013).  
The efficient induction of neutralizing antibodies is still a challenge for 
prophylactic HPV vaccines based on minor capsid protein L2. Chimeric VLP 
with L2 epitopes inserted into the surface DE loop of VLPs, with Alum-MPLA as 
adjuvant were used to immunize mice and rabbits. Cross-neutralizing 
antibodies were induced against many more HPVs than with the commercial 
ones, even against some cutaneous HPVs. This was verified by in vitro 
pseudovirus based neutralizing assay and in in vivo challenge animal models, 
and the antibodies could be detected even one year after immunization. 
Moreover, these chimeric VLPs could also induce cytotoxic T cell response 
(Schellenbacher et al., 2009). With bacteriophages as a platform vaccine 
production would be much cheaper (Tumban et al., 2012). To this end AAV 
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capsid protein was used as a platform to display HPV 16 L2 aa 17-36. The 
VLPs were found to provide cross-protect against other HPV when tested in 
vivo and in vitro, when mice and rabbits were immunized with the help of 
adjuvant Montanide (Nieto et al., 2012b). However, Montanide is not an 
approved prophylactic vaccine adjuvant. It has been proven that the AAVLPs 
vaccines could induce cross-neutralizing antibodies and the antibodies lasted 
at least 3 months. Surprisingly, the vaccine could also provide long term (6-12 
months) protection against HPV16, 31, 39, 45, 58, and 59 on skin challenge 
rabbit models (Jagu et al., 2015). The HPV16L2-MS2 VLPs, a bacteriophage 
displaying HPV 16 L2 epitopes, could induce production of L2 driven 
neutralizing antibodies that lasted three months after immunization. Moreover, 
this antigen was quite thermal stable, and production was cost efficient (Saboo 
et al., 2016). 
Epitope multiplicity can increase antigen immunogenicity (Puffer et al., 2007; 
Rubio et al., 2009). Another way to increase immunogenicity of HPV L2 
peptides and broaden their cross-protection even more was the creation of a 
concatenated multitope L2 fusion protein which included 8 L2 epitopes (aa 11-
88) from different mucosal HPVs. This antigen was evaluated. The 
concatenated L2 protein could induce high neutralizing antibody titers against 
HPV16, 18, 45 and 58, and these antibodies were stable for at least 3 months 
(Jagu et al., 2009). 
In our group, we employed different strategies to not only increase the low 
immunogenicity of L2 peptides, but to also improve the ability of cross-
protection. At first, the L2 epitopes (aa20-38) from HPV16, 31, and 51 were 
inserted into the active loop of Pyrococcus furiosus thioredoxin (Pf Trx), a small, 
non-toxic and soluble protein. This trivalent protein vaccine was evaluated in 
mice using Alum-MPLA as adjuvant. The neutralizing antibodies induced by the 
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trivalent protein could neutralize 12 HPVs in vitro, and provided protection 
against 5 HPVs in vivo (Seitz et al., 2015). In order to cover all the high-risk 
mucosal HPVs, some of the low-risk mucosal HPVs, and even some cutaneous 
HPVs, a multimerization strategy was further employed to develop antigens 
based on Pf Trx-L2. Eight L2 epitopes from different HPVs (HPV 16, 18, 31, 33, 
35, 6, 51, and 59) were inserted into Pf Trx, and antibodies induced by the 
polytope antigen could neutralize all 15 high-risk and 2 low-risk mucosal HPVs, 
but the titers were not as high as those in commercial vaccines. Furthermore, 
OVX313 was employed, a self-assembling polypeptide providing a secondary 
platform to display L2 multitopes (figure 1.11). 
 
 
 
 
 
From Spagnoli, G., et al., Sci Rep, 2017.  
Figure 1.11 Development of L2-based antigens (Spagnoli et al., 2017). The predicted 
structures of Pf Trx, and Pf Trx-HPV16 L2 (aa20-38)*3, and Pf Trx L2 OVX313 fusion protein. 
On the left panel is the native Pf Trx with the active site; the middle panel is the Pf Trx fused 
with three copies of HPV16 L2 (aa20-38) epitopes at the active site; the right panel is further 
fused the OVX313 with Pf Trx assembling into a heptamer and displaying the L2 epitopes. 
OVX313 is driven by human C4bp protein, which is a plasma glycoprotein 
complex acting as an major complement inhibitor and produced in the liver 
(Hofmeyer et al., 2013). Like Pf Trx, OVX313 also has extraordinary 
thermodynamic stability and can be produced in bacteria in large scale and 
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purified by simple thermal treatment. The native C4bp has 4 different isoforms, 
but mainly contains α chains and β chain formed into a characteristic spider- or 
octopus- like structures (Dahlback et al., 1983). OVX313 is a positively charged 
variant developed by OSIVAX, where seven α- chains link together at the C 
terminus, self-assembling into a heptametrical format, and stabilized by 
intermolecular disulfide bonds (Hofmeyer et al., 2013). It has been used as a 
platform for mono or poly peptide epitopes to increase immunogenicity since 
there is no cross-reactivity with the human C4bp counterpart (Li et al., 2016; 
Ogun et al., 2008; Spencer et al., 2012), for vaccines for both humans and 
animals. Pf Trx L2s were fused at the N-terminus of OVX313, and mice and 
guinea pigs immunized with or without adjuvant and the result was quite 
exciting. The construct could induce high titers of neutralizing antibody against 
all 15 high-risk mucosal HPVs, 2 low-risk mucosal HPVs (HPV6 and HPV11, 
causing 90% of genital warts), and some cutaneous HPVs. Currently, a phase 
I clinical trial is in preparation (Pouyanfard et al., 2018; Spagnoli et al., 2017). 
 Nanoparticles  
There are a lot of important pathogens for which vaccines are currently not 
available, such as human immunodeficiency virus, etc. Some vaccines could 
not elicit a sufficient and durable immune response against the natural 
pathogens. Therefore, researchers keep searching for a way to boost protection 
against pathogens induced by vaccines. In the development of vaccines 
technologies, several aspects need to be considered. Safety is the first concern, 
followed by avoiding poor immunogenicity, requiring co-formulation with 
adjuvants and requiring a booster injection for the purpose of maintaining the 
immunity (Karch and Burkhard, 2016). To promote a sufficient immune 
response, it is critical that the antigens presented to the immune systems are 
in the right quality and conformation (Copland et al., 2003; Schijns, 2000).  
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Nanotechnology has been widely applied in biomedicine in the past decades. 
A nanoparticle is an organized structure on the scale of 1-1,000 nm, such as 
gold, polystyrene or VLPs and is used to greatly enhance the immune response 
against different kinds of pathogens. One type of nanoparticles are 
polypeptides assemblies which can present several copies of subunits or 
epitopes of antigens in a well-designed array with organized orientations 
(Lopez-Sagaseta et al., 2016). By doing so, the nanoparticle antigens can 
mimic the interaction with immune cells not only due to the similarity of repetitive 
geometry, but also the size and shape of the natural pathogen (Lopez-Sagaseta 
et al., 2016). In order to induce an efficient immune response by vaccines, B 
and T cells need to be stimulated and activated. On the other hand, induction 
of antibodies secreted by plasma cells relies on the effective cross link between 
the B cell receptors and how well the epitopes are being displayed by the 
pathogens for recognition. Therefore, the high immunogenicity, the 
physicochemical properties, stability and cheap large scale production by E.coli 
or eukaryotic systems put nanoparticle vaccines at the frontline of vaccine 
development research (Lopez-Sagaseta et al., 2016).  
The ferritin family of proteins are detoxification proteins which are involved in 
iron storage (Yang et al., 2017; Zhao, 2010), may be applied in nanotechnology. 
Twenty-four subunits self-assemble into a nanoparticle with inner and outer 
diameters of 8 nm and 12 nm, respectively. The ferritin cage has a high thermal 
and chemical stability, and it is able to reconstitute through manipulated 
assembly and dis-assembly (Dominguez-Vera and Colacio, 2003). Drugs, 
nucleic acids and other materials can be chemically or genetically attached to 
the modifiable site on the external or internal surface of ferritin (figure 1.12) (de 
Turris et al., 2017) . All evidence suggests that ferritin could be manipulated 
easily as an antigen carrier. Moreover, the ferritin family of proteins are 
relatively easy to produce and isolate, especially Pyrococcus furiosus ferritin 
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which is notably thermally stable (Jacobs et al., 2010). All of these capabilities 
make ferritin a popular subject to study and use in nanotechnology. Some 
examples include, the use of ferritin as a bio mineralization scaffold 
(www.biaqua.com), where P.furiosus ferritin is used to prevent water pollution 
and biofouling (Jacobs et al., 2010), and as Nano devices (Yamashita et al., 
2010), medical imaging agents (Jin et al., 2014; Vande Velde et al., 2011), a 
drug delivery system for cancer treatment (Zhen et al., 2013), and as 
nanoparticle vaccines (Kanekiyo et al., 2013). 
Encapsulins are also a shell-like protein, 60 copies of the monomer assemble 
into a cage with 24 nm diameter (figure 1.12), or 180 copies of the subunit 
assemble into a shell cage approximately 80 nm across (McHugh et al., 2014; 
Sutter et al., 2008). Encapsulins are widespread in bacteria and archaea, but 
the whole function of encapsulins is not yet clear. However, there is evidence 
that encapsulins are involved in protecting cells from proteolysis or other 
challenges by increasing metabolic efficiency (Diekmann and Pereira-Leal, 
2013), or like ferritin, are involved in iron storage (Zeth et al., 2016) and in the 
trafficking and packaging of enzymes (Cannon et al., 2001; McHugh et al., 
2014). 
 
 
 
 
 
Updated from Kanekiyo, M, et al., Cell, 2015 
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Figure 1.12 Nanoparticle ferritin and encapsulin with antigen fusion site (Kanekiyo et al., 
2015). Ferritin with antigen fusion sites (red dot) assembled into 10nm nanoparticles (left), and 
encapsulin assembled into 24nm nanoparticles. The red dots indicated the engineered insertion 
sites. 
 Adjuvant’s role in vaccination 
Adjuvants are employed in vaccinations, in order to improve these vaccines 
(Coffman et al., 2010). Adjuvants have been widely employed in different 
scenarios, like immunocompromised patients, elderly people, and infants. They 
can improve the efficiency of vaccines in different ways, such as by reducing 
the number of administrations (lower vaccination frequency that achieves the 
same effect), reducing the dosage, improving the immunogenicity and may help 
stabilize the vaccine formulation (Petrovsky and Aguilar, 2004; Schijns and 
Lavelle, 2011). 
Adjuvants have been classified into different categories based on their immune 
response interactions. The first generation of adjuvants, as antigen delivery 
system, increased the antigen uptake at the injection site (Brito and O'Hagan, 
2014). These are Aluminum, liposomes, emulsions, and microparticles. The 
second category of adjuvants are combined adjuvants. They consist of the 
immune potentiators combined with the first category adjuvants. For example, 
AS04 which contains aluminum hydroxide as antigen delivery system plus 
monophosphoryl lipid A (MPL), a TLR4 agonist as an immune potentiator.  
Several factors need to be considered in selecting adjuvants. The adjuvant 
should be safe, compatible with the antigen, well tolerated, easily formulated 
with the antigens, simple to manufacture and economically feasible, etc. (Brito 
et al., 2013). Due to differences between vaccines, the choice establishment of 
the correct adjuvant is challenging.  
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For a long time, aluminum salts (also called Alum) were the only licensed 
adjuvants for humans. Alum was used as an antigen delivery system and has 
interacts in two ways with antigens. First, by electrostatic interactions, which 
depend on the isoelectric point of the antigen and the type of aluminum salt (al-
Shakhshir et al., 1994; Seeber et al., 1991). Second, ligand exchange is 
another way to enhance antigen immunogenicity, which happens when 
phosphate groups on the antigen exchange with hydroxide groups on the alum. 
Another theory implies that alum can induce a humoral immune response by a 
Th-2 biased response. An important issue for Alum is that it cannot induce 
cellular immune responses, which are needed against intracellular pathogens, 
and other pathogens which require a strong cellular response.  
In order to overcome the limitations of Alum, it was combined with 
monophosphoryl lipid A (MPLA), an immune-stimulatory molecule. Studies 
suggested that alum could enhance MPLA delivery at the injection site and 
increase the duration of cytokines (Marrack et al., 2009). MPLA is a modified 
lipopolysaccharide (LPS) and is a much less toxic than the nature LPS and can 
activate the TLR4 receptors (Casella and Mitchell, 2008). By combining MPLA 
with alum, vaccines can induce both Th1 and Th2 responses (Garcon et al., 
2007). Currently, human papillomavirus vaccine (Cervarix) and hepatitis B 
(Fendrix) vaccine employ AS04 (Alum hydroxide and MPLA) as 
adjuvant(Garcon et al., 2007).  
Another type of adjuvants used to boost the immune response against vaccines 
are emulsions. Water-in-oil emulsions are the most common. The earliest 
emulsion adjuvant was mineral oil-based water-in-oil emulsion called Freund’s 
adjuvant (Aucouturier et al., 2001; Berg, 2015). The adjuvant was never used 
for human vaccinations due to the safety concerns (Aucouturier et al., 2001). 
Right now, there are several commercial vaccines that employ emulsion based 
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adjuvants. MF59, is a squalene oil-in-water emulsions, and has been used for 
influenza vaccines (O'Hagan et al., 2013; O'Hagan et al., 2011). The 
mechanism of MF59 has been studied extensively. The updated theory is that 
MF59 creates an immune competent environment at the site of injection and 
leads to the influx of antigen presenting cells and other immune cells. In the 
meantime, MF59 have been found to also induce the increased production of 
cytokines and chemokines which can further lead to the recruitment of immune 
cells to the site of injection. By doing so, the migration of immune cells such as 
APCs is upregulated as well as the uptake of the antigens (O'Hagan et al., 2012; 
Seubert et al., 2008).  
AddaVax, another emulsion which is similar to MF59, is a squalene-based oil-
in-water nano emulsion. In Europe, it has been used in influenza vaccines 
(Calabro et al., 2013; Drulak et al., 2000). It acts in a similar way to MF59 by 
inducing both cellular Th1 and humoral Th2 immune responses.    
Currently, there are several other kinds of adjuvants employed in vaccinations 
to improve the immunogenicity of some antigens. Since there is a trend to use 
recombinant proteins, which normally have low immunogenicity, greater use of 
adjuvants is inevitable. On the other hand, adjuvants may lead to an extra effort 
to produce the vaccine, since they may complicate the formulation strategies 
and increase the cost of the vaccine.  
  Objective and aims of PhD project  
An ideal vaccine should meet the following criteria: A) it must be safe, elicit 
immune responses up to a desired level; B) it should be easily prepared, 
commercially affordable, and C) the vaccine must be chemically and physically 
stable during production, transport and administration.  
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The main objective of my thesis is the development of new HPV vaccines with 
broad antigenicity, high immunogenicity, cheap to produce and no need to cool.  
Broad specificity may be achieved by using the conserved region of the epitope 
of L2 capsid protein (aa20-38) as antigen, which is less specific than the L1-
based VLP vaccines.  
High immunogenicity shall be achieved by inserting L2 epitopes into 
nanoparticles formed with Pyrococcus furiosus thioredoxin (Pf.Trx). These 
nanoparticle vaccines can be easily produced and safe to be used since it could 
not induce auto-immuno responses. 
The choice of the adjuvant is critical for the stability and antigenicity of vaccines. 
Different adjuvants shall therefore be tested. The specific aims include: 
a) Designing, producing and characterizing nanoparticle L2 antigens. 
b) Selecting the suitable adjuvant for nanoparticle L2 antigens. 
c) Understanding the role of Pf thioredoxin on the nanoparticle L2 antigens 
d) Selecting the best antigens which can induce high titers of neutralizing 
antibodies against a large panel of HPVs including high-risk, low-risk 
mucosal HPVs. 
e) Verifying the influence of pre-existing antibodies induced by the 
immunization with nanoparticle vaccines against the nanoparticle 
scaffold on induction of anti-L2 antibodies. 
f) Checking the cross-reactivity of anti-Pf ferritin antibodies with human 
ferritin. 
g) Determining the effective dose of nanoparticle antigens by 
understanding the tendency of antibody production. 
h) Proving that the antibodies produced by nanoparticle L2 antigens can 
provide protection in an in vivo mouse model challenged with HPV. 
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 Materials 
 Biological materialsLaboratory animals 
BALB/c mice 6-8 weeks old or 16 weeks old, female, from Charles River, 
Sulzfeld. 
Guinea pig 350- to 400-g female animals, Hartley (Crl:HA),from 
Charles River, Sulzfeld. 
2.1.2 Cell lines  
HEK 293TT Human embryo kidney (HEK) cells containing two gene 
copies of SV40 large T antigen 
HeLaT K4 HeLa cells (human cervical cancer cell line; HPV18 
positive ) stably transfected with linearized expression 
plasmid containing SV40 large T antigen under control of 
the CMV promoter 
MCF-10A Human epithelial breast cancer cell line 
CHOΔfurin Chinese hamster ovary cell line producing secreted furin 
(gift from David Fitzgerald, NCI Bethesda) 
pgsa-745      Chinese hamster ovary cell line deficient for heparan 
sulfate proteoglycans, cannot produce 
glycosaminoglycans due to a non-functional 
xylosyltransferase 
Sf9 Clonal isolated from Spodoptera frugiperda sf21 cells 
TN-High-Five Ovrian cells of the cabbage looper Trichoplusia ni 
2.1.3 Bacterial strains 
Strain Genotype Company 
2. Materials 
32 
E.coli MxDH10α  genotype: F- mcrA Δ(mrr-hsdRMS-mcrBC) 
ψ80lacZΔM15 ΔlacX74  recA1 endA1 
araD139 Δ(ara, leu)7697 galU galK λ- rpsL 
nupG tonA 
Invitrogen 
E.coli Rosetta™  genotype: F- ompT hsdSB (rB-mB-) gal dcm 
pRARE (CamR) 
(Merck4Biosciences) 
Invitrogen 
E.coli SoloPack 
Gold Competent 
Cells               
genotype: Tetr Δ(mcrA)183 Δ(mcrCB-
hsdSMR-mrr)173 endA1 
supE44thi-1 recA1 gyrA96 relA1 lac Hte [F´ 
proAB lacIqZΔM15 Tn10  (TetR) Amy CamR] 
Agilent 
Technologies 
DH10 
MultiBaccre 
Electrocompeten 
E.coli 
E.coli strain harboring DH10MultiBac 
bacmid 
 
Invitrogen 
E.coli MegaX 
DH10  
This strain provides the option of blue/white 
screening on plates containing either X-Gal 
or Bluo-Gal. F- mcrA Δ(mrr-hsdRMS-
mcrBC) φ80lacZ ΔM15 ΔlacX74 recA1 
endA1 araD139 Δ(ara, leu)7697 galU galK λ 
- rpsL nupG tonA 
Invitrogen 
E.coli XL-Blue 
supercompetant 
cells  
The XL1-Blue strain allows blue-white color 
screening.recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)]. (Genes listed 
signify mutant alleles) 
 
Agilent 
Technologies 
2.1.4 Pseudovirions 
Designation Description Source 
HPV16 Gaussia Co-transfection #988 + #1998 M. Müller 
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HPV18 Gaussia Co-transfection #1165 + #1166 
+ #1998 
J. Schiller 
HPV31 Gaussia Co-transfection #1698 + #1998 T. Kanda 
HPV33 Gaussia Co-transfection #2686 + #1998 T. Kanda 
HPV35 Gaussia Co-transfection #2713 + #1998 T. Kanda 
HPV39 Gaussia Co-transfection #2712 + #1998 S. Beddows 
HPV45 Gaussia Co-transfection #2271 + #2273 
+ #1998 
J. Schiller 
HPV51 Gaussia Co-transfection #2466 + #2481 
+ #1998 
H. Seitz / M. Müller 
HPV52 Gaussia Co-transfection #1691 + #1690 
+ #1998 
J. Schiller 
HPV56 Gaussia Co-transfection #3123 + #1998 M. Müller 
HPV58 Gaussia Co-transfection #1694 + #1998 T. Kanda 
HPV59 Gaussia Co-transfection #2714 + #1998 S. Beddows 
HPV68 Gaussia Co-transfection #2687 + #1998 J. Dillner 
HPV73 Gaussia Co-transfection #3122 + #1998 M. Müller 
HPV6 Gaussia Co-transfection #1317 + #1318 
+ #1998 
M. Müller 
HPV11 Gaussia Co-transfection #3973 + #1998 M. Müller 
HPV16 Firefly Co-transfection #988 + #2818 M. Müller 
HPV18 Firefly Co-transfection #1165 + #1166 
+ #2818 
J. Schiller 
HPV31 Firefly Co-transfection #1698 + #2818 T. Kanda 
HPV33 Firefly Co-transfection #2686 + #2818 J. Dillner 
HPV35 Firefly Co-transfection #2713 + #2818 M. Müller 
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HPV39 Firefly Co-transfection #2712 + #2818 M. Müller 
HPV45 Firefly Co-transfection #2271 + #2273 
+ #2818 
M. Müller 
HPV51 Firefly Co-transfection #2466 + #2481 
+ #2818 
H. Seitz / M. Müller 
HPV56 Firefly Co-transfection #3123 + #2818 M. Müller 
HPV6 Firefly Co-transfection #1317 + #1318 
+ #2818 
M. Müller 
HPV11 Firefly Co-transfection #3973 + #2818 M. Müller 
 Materials for DNA amplification, purification and analysis 
2.2.1 Expression plasmids 
Designation Description Reference 
pGF Gaussia-GFP           
#1998 
Gaussia and EGFP gene under control of 
EF1alpha promoter 
C. Buck 
pCLucf                                 
#2818 
Firefly Luciferase under control of CMV 
promoter. Also encodes GFP under 
control of SV40 promoter 
J. Schiller 
HPV16 L1h+L2h                 
#988 
pCDNA 4.0 TO vector with humanized 
HPV16 L1 and L2 linked via IRES under 
control of CMV promoter and 
tetracycline-operator, intact SV40-ori 
M. Müller 
HPV18 L1h #1165 humanized HPV18 L1 under control of 
CMV promoter 
J. Schiller 
HPV18 L2h #1166 humanized HPV18 L2 under control of 
CMV promoter 
J. Schiller 
HPV31 L1h+L2h                
#1698 
humanized HPV31 L1 and L2 under 
control of CMV promoter 
J. Schiller 
HPV33 L1h+L2h               
#2686 
humanized HPV33 L1 and L2 under 
control of CMV promoter 
J. Dillner 
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HPV35 L1h+L2h              
#2713 
humanized HPV35 L1 and L2 under 
control of CMV promoter 
S. Beddows 
HPV39 L1h+L2h               
#2712 
humanized HPV39 L1 and L2 under 
control of CMV promoter 
S. Beddows 
HPV45 L1h                          
#2271 
humanized HPV45 L1 under control of 
CMV promoter 
S. Beddows 
HPV45 L2h                         
#2273 
humanized HPV45 L2 under control of 
CMV promoter 
J. Schiller 
HPV51 L1h                         
#2466 
humanized HPV51 L1 under control of 
CMV promoter 
T. Kanda 
HPV51 L2h                              
#2481 
humanized HPV51 L2 under control of 
CMV promoter 
T. Kanda 
HPV52 L1h #1691 humanized HPV52 L1 under control of 
CMV promoter 
J. Schiller 
HPV52 L2h #1690 humanized HPV52 L2 under control of 
CMV promoter 
J. Schiller 
HPV56 L1h+L2h 
#3123   
humanized HPV56 L1 and L2 under 
control of CMV promoter 
M. Müller 
HPV58 L1h+L2h 
#1694 
humanized HPV58 L1 and L2 under 
control of CMV promoter 
T. Kanda 
HPV59 L1h+L2h 
#2714 
humanized HPV59 L1 and L2 under 
control of CMV promoter 
S. Beddows 
HPV68 
L1h+L2h#2687  
humanized HPV68 L1 and L2 under 
control of CMV promoter 
J. Dillner 
HPV73 L1h+L2h 
#3122 
humanized HPV73 L1 and L2 under 
control of CMV promoter 
M. Müller 
HPV6L1h                          
#1317 
humanized HPV6 L1 under control of 
CMV promoter 
M. Müller 
HPV6L2h                          
#1319 
humanized HPV6 L2 under control of 
CMV promoter 
M. Müller 
HPV11L1h+L2h                          
#3973 
humanized HPV11 L1 and L2 under 
control of CMV promoter 
M. Müller 
Pf encapsulin                
#3449 
Pf encapsulin in MultiBac vector This thesis 
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Pf ferritin                              
#3447 
Pf ferritin in MultiBac vector This thesis 
Pf encapsulin-Trx-
HPV16L2(aa20-38)               
#3451 
Pf encapsulin with Pf Trx and 1 copy 
HPV16 L2 (aa20-38) in MultiBac vector 
This thesis 
Pf encapsulin-
HPV16L2(aa20-38)                
#3497 
Pf encapsulin with 1 copy HPV16 L2 
(aa20-38) in MultiBac vector 
This thesis 
Pf ferritin-Trx-
HPV16L2(aa20-38)                    
#3446 
Pf ferritin with Pf Trx and 1 copy HPV16 
L2 (aa20-38) in MultiBac vector 
This thesis 
Pf ferritin-
HPV16L2(aa20-38)                                             
#3495 
Pf ferritin with 1 copy HPV16 L2 (aa20-
38) in MultiBac vector 
This thesis 
Pf encapsulin-Trx-
HPV16L2(aa20-
38)*3               
#3547 
Pf encapsulin with Pf Trx and 3 copies 
HPV16 L2 (aa20-38) in MultiBac vector 
This thesis 
Pf encapsulin- 
HPV16L2(aa20-
38)*3                
#3546 
Pf encapsulin with  3 copies HPV16 L2 
(aa20-38) in MultiBac vector 
This thesis 
Pf ferritin-Trx-
HPV16L2(aa20-
38)*3               
#3545 
Pf ferritin with Pf Trx and 3 copies HPV16 
L2 (aa20-38) in MultiBac vector 
This thesis 
Pf ferritin-
HPV16L2(aa20-
38)*3                                         
#3544 
Pf ferritin with 3 copies HPV16 L2 (aa20-
38) in MultiBac vector 
This thesis 
Pf encapsulin- Trx-
HPVL2(aa20-38)*8                 
#3502 
Pf encapsulin with Pf Trx and 8 copies 
HPV L2 (aa20-38) from HPV 16, 18, 31, 
33, 35, 51, 59, 6 and 11  in MultiBac 
vector 
This thesis 
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Pf encapsulin- 
HPVL2(aa20-38)*8                                  
#3501 
Pf encapsulin with 8 copies HPV L2 
(aa20-38) from HPV 16, 18, 31, 33, 35, 
51, 59, 6 and 11  in MultiBac vector 
This thesis 
Pf ferritin-Trx-
HPVL2(aa20-38)*8                                         
#3500 
Pf  ferritin with Pf Trx and 8 copies HPV 
L2 (aa20-38) from HPV 16, 18, 31, 33, 
35, 51, 59, 6 and 11  in MultiBac vector 
This thesis 
Pf ferritin-
HPVL2(aa20-38)*8                                         
#3499 
Pf  ferritin with  8 copies HPV L2 (aa20-
38) from HPV 16, 18, 31, 33, 35, 51, 59, 
6 and 11  in MultiBac vector 
This thesis 
human-ferritin-GST            
#3939 
gateway clone from homo ferritin to GST- 
vector 
This thesis 
Pf ferritin-GST                    
#3504 
Pf ferritin GST-vector(#808) This thesis 
Pf thioredoxin-GST            
#2877 
Pf thioredoxin GST-vector(from Parma) This thesis 
human 
thioredoxin-GST       
#2902 
human thioredoxin GST-vector (from 
Parma) 
This thesis 
 
2.2.2 PCR primers 
All oligonucleotide listed, were order and produced at MWG Eurofins in Ebersberg, 
Germany. 
Prime Name Sequence 5' to 3' 
Pf encapsulin  
Forward Primer 
TTTTAAGCTTTTACTCCTGCAGCTCTTTCAGTTTTTTCAGAAT
CT 
Pf encapsulin 
Reverse Primer 
TTTTAAGCTTTTATTCCAGTACGACGATAGCTTCCGGATTC 
Pf encapsulin linker 
CpoI site  
Forward Primer 
TTTTAAGCTTTTACTCCTGCAGCTCTTTCAGTTTTTTCAGAAT
CT 
Pf encapsulin linker 
CpoI site  
Reverse Primer 
TTTTAAGCTTTTACTCCTGCAGCTCTTTCAGTTTTTTCAGAAT
CTC 
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Pf encapsulin Trx 
HPV16 L2(aa20-38)  
Forward Primer 
TTTTAAGCTTTTACTCCTGCAGCTCTTTCAGTTTTTTCAGAAT
CT 
Pf encapsulin Trx 
HPV16 L2(aa20-38)  
Reverse Primer 
TTTTAAGCTTTTACGGACCGCCCCCCCCGGAGCTCCCGCCG
CCGCTTTCCAGTACG 
Pf ferritin 
Forward Primer 
TTTTGGATCCACCATGCTCTGAGCGAACGCATGCTGAAAGC
CTTG 
Pf ferritin  
Reverse Primer 
GGCCGCAAGCTTTCATTCTCCACCCTGCATC 
Pf ferritin linker CpoI 
site  
Forward Primer 
TTTTGGATCCACCATGGGCGGTCCGATGGAATCACAGGTCC
GTCAGAATCTGAG 
Pf ferritin linker CpoI 
site  
Reverse Primer 
GGCCGCAAGCTTTCATTCTCCACCCTGCATC 
Pf ferritin Trx HPV16 
L2(aa20-38)  
Forward Primer 
TTTTGGATCCACCATGATTATCGAGTATGACGGCGAAATC 
Pf ferritin Trx HPV16 
L2(aa20-38)  
Reverse Primer 
GGCCGCAAGCTTTCATTCTCCACCCTGCATC  
2.2.3 Enzymes 
Calf Intestinal Alkaline Phosphatase (CIP) NEB, Frankfurt  
Lysozyme (20 μg/ml in 1 × PBS) Sigma-Aldrich, Taufkirchen  
RNase (1 mg/ml in H2O) Roche, Mannheim  
T4 DNA ligase Invitrogen Life Technologies, 
Darmstadt 
 
QuickLigase NEB, Frankfurt  
Pfu polymerase Stratagene Agilent Tchnologies, La 
Jolla, USA 
 
KOD polymerase Novagen/Merck, Darmstadt  
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Restriction enzymes NEB, Frankfurt  
2.2.4 Media and solutions for culturing bacteria 
LB medium: 10 g Tryptone 
 
5 g Yeast extract 
 
5 g NaCl 
 
add up to 1 L with H2O, pH 7.5, 
sterilized by autoclaving 
LB agar plates: 98% LB‐medium (v/v) 
 
1.5% Bacto‐agar (w/v) 
 
autoclaved, antibiotic added when 
40° C is reached 
2.2.5 Solutions and Chemicals for DNA purification and preparation 
I. Purification of plasmid DNA 
Glucose buffer: 50 mM Glucose 
Ampicillin final concentration 100 μg/ml                      (Sigma-Aldrich, Taufkirchen) 
Kanamycin final concentration 25 μg/ml                      (Sigma-Aldrich, Taufkirchen) 
Zeocin final concentration 25 μg/ml         (Invitrogen Life Technologies, Darmstadt) 
Chloramphenicol final concentration 20 μg/ml             (Sigma-Aldrich, Taufkirchen) 
Gentamycin final concentration 10 µg/ml                             (Sigma-Aldrich, Steinheim) 
Tetracycline final concentration 25 μg/ml                            (Sigma-Aldrich, Steinheim) 
IPTG final concentration 1 mM                                              (Applichem, Darmstadt) 
Blue gal final concentration 100 µg/µl                                      (Invitrogen, Karlsruhe) 
 
X-gal final concentration 200 µg/ml                                       (Sigma-Aldrich, Steinheim) 
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10 mM EDTA 
 
25 mM Tris 
 
in H2O, pH 8.0 
Lysis buffer: 0.5 M NaOH 
 
1% SDS (w/v) 
 
in H2O 
Sodium acetate: 3 M Sodium acetate 
 
in H2O, pH 5.3 
Phenol mix: Phenol‐CIA mix 1:1 
 
100 μg 8‐hydroxyquinoline/ 350 ml 
Phenol CIA mix solution 
II. Agarose gel electrophoresis 
1 x TAE: 40 mM Tris 
 
5.71% Acetic acid (v/v) 
 
10% 0.5 M EDTA pH 8 (v/v) 
Agarose gel (1 %) 1% Agarose (w/v) 
 
1 μg/ml Ethidium bromide 
 
(10 mg/ml ethidium bromide from 
Roth) 
 
in 1 x TAE buffe 
 
 
Lambda/HindIII marker: NEB, Frankfurt 
100 bp DNA ladder plus: Fermentas Thermo Scientific, St. 
Leon Roth 
6 × DNA loading buffer Thermo Scientific 
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GeneRuler 1 kb DNA ladder Thermo Scientific 
III. Sequencing 
DNA was sent to GATC-Biotech (Konstanz) for sequencing. 
IV. Further chemicals 
20 mM dNTP mix Roche, Mannheim 
25 mM MgCl2 Novagen/Merck, Darmstadt 
10 mg/ml ethidium bromide Roth, Karlsruhe 
 Materials for protein purification and analysis 
2.3.1 Lysis buffer and elution buffer 
Lysis buffer (bacterial protein) 200 mM Kaliumacetat 
2 mM Magnesiumacetat 
1 mM DTT 
1 mM PMSF 
0.5% Tween 20                                                                      
20 mM HEPES pH 7.2 
Elution buffer(bacterial protein) 10 mM Glutathione 
in 50 mM Tris, pH 8.0 with HCl 
2.3.2 Purification column  
1ml GSTrap FF column                                   Amersha Pharmacia, Uppsala, Schweden 
Lysis buffer (insect cells protein) 5 mM MgCl2 
5 mM CaCl2 
150 mM NaCl 
0.5 mM PMSF 
0.01% Triton × 100                                                                    
20 mM HEPES pH 7.4 
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2.3.3 Gradients 
Cesium chloride solution                                 57.7% (w/v) CsCl in  
                                                                Insect cells lysis buffer 
Sucrose solution                                             30% (w/v) Sucrose in  
                                                                Insect cells lysis buffer 
2.3.4 Size-exclusion chromatography column 
Superdex200 10/300 GL                                 Amersham GE healthcare, 
                                                                Buckinghamshire, UK                  
2.3.5 Endotoxin removal 
Triton X-114                                                    Sigma-Aldrich, Taufkirchen        
2.3.6 Polyacrylamides gels 
1x TGS: 2.5 mM Tris 
1.45% glycine (w/v) 
0.1% SDS (w/v) 
in H2O, pH 8.3 with HCl 
3 x Protein loading buffer: 30% Glycerol (v/v) 
6% SDS (w/v) 
15% β-mercaptoethanol (v/v) 
0.03% Bromphenol blue (v/v) 
187.5 mM Tris 
in H2O, pH 6.8 with HCl 
Tris buffer pH 8.8: 1 M Tris 
in  H2O, pH 8.8 with HCl 
Tris buffer pH 6.8: 1 M Tris 
0.03% bromphenol blue 
in  H2O, pH 6.8 with HCl 
Recipe for 5 polyacrylamide gels: 
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15%  
separating gel 
12.5% 
separating gel 
3% 
stacking gel 
30% 
Acrylamide 20 ml 18.8 ml 1 ml 
1 M Tris 
buffer 15 ml (pH 8.8) 16.9 ml (pH 8.8) 1.3 ml (pH 6.8) 
H2O 4.2 ml 8.5 ml 7.5 ml 
10% SDS 400 μl 450 μl 100 μl 
10% APS 400 μl 450 μl 100 μl 
TEMED 20 μl 22.5 μl 15 μl 
 
Acrylamide solution Roth, Karlsruhe  
TEMED Sigma-Aldrich, Taufkirchen 
ColorPlus™ Prestained Protein Ladder NEB, Frankfurt  
Coomassie Solution GelCode® Thermo Scientific, Rockford, USA 
2.3.7 Determination of protein concentration 
Bradford reagent   BioRad,München  
BSA standard (2 μg/μl) Pierce Thermo Scientific, Rockford, 
USA 
 Materials for immunological methods 
2.4.1 Antibodies 
Designation Description Reference 
K4L220-38 cross-neutralizing mouse monoclonal 
antibody recognizing the 20-31 HPV 
L2 epitope; elicited with an E. coli 
thioredoxin-HPV16 L2(20-38)3 antigen 
I. 
Rubion 
/ M. 
Müller 
K18L220-38 cross-neutralizing mouse monoclonal 
antibody recognizing the 20-31 HPV 
I. Rubion / M. 
Müller 
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L2 epitope; elicited with an E. coli 
thioredoxin-HPV16 L2(20-38)3 antigen 
anti thioredoxin Mouse monoclonal antibody 
recognizing the Pf thioredoxin, elicited 
with an E.coli Pf thioredoxin 
M.Müller 
GAMPO GAMPO Goat-anti-mouse coupled with 
HRP, 
Dianova, 
Hamburg,Germany 
2.4.2 Adjuvants for immunization 
AddaVax 
 
Invivogen 
Aluminum hydroxide Brenntag 
Synthetic monophosphoryl lipid-A AvantiLipids 
2.4.3 Animal narcotic 
Isoflurane                                                            Baxter, Deerfield, USA 
 Materials for pseudovirions infection and neutralization 
2.5.1 Pseudovirions production and purification 
Brij 58 
 
10% Brij 58 (w/v) 
in H2O, filter-sterilized 
NaCl 
 
5 M NaCl 
in H2O, filter-sterilized 
1 × DPBS 
 
Gibco Life Technologies, Paisley, 
UK 
 
Benzonase (100,000 U/ml) Merck, Darmstadt 
TurboFect™ transfection reagent Fermentas Thermo Scientific, St. 
Leon-Roth 
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RNase A/T1 mix Fermentas Thermo Scientific, St. Leon-Roth 
OptiPrep™ (60% w/v) 
 
Sigma-Aldrich, Taufkirchen 
2.5.2 In vitro luciferase reporter gene assays 
Gaussia GLOW-Juice BIG KIT PJK, Kleinblittersdorf 
Beetle-Juice BIG KIT PJK, Kleinblittersdorf 
2.5.3 In vivo cervicovaginal mouse model and firefly luciferase reporter 
gene assay 
CMC 
(Carboxymethyl 
cellulose) 
 
4% CMC (w/v) 
in 65 °C 1 × PBS, add while 
vortexing, rotate at 37 °C 
Medroxyprogesteronacetat 30 mg/ml Depo-Provera 
(Pharmacia, Ireland) 
in 1 × PBS 
Nonoxynol-9 
 
4% Nonoxynol-9 (Spectrum, USA) 
in 4% CMC 
Beetle luciferin, Potassium salt 15 mg/ml Beetle luciferin 
(Promega, USA) in DMEM 
 Cell culture media and solutions 
2.6.1 Full media 
DMEM (293TT, HelaT K4) 
  
1% Penicillin/Streptomycin 
1% L-glutamine 
10% FCS 
DMEM (CHOΔfurin, pgsa-745) 
 
1% Penicillin/Streptomycin 
200 µM L-proline 
10% FCS 
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DMEM (MCF10A) 
  
5% Horse serum 
1% Penicillin/Streptomycin 
1% L-glutamine 
500 ng/ml Hydrocortisone 
10 μg/ml Insulin, human 
20 ng/ml EGF, human 
DMEM L2 assay medium 
  
10% FCS 
1% Antibiotic-Antimycotic 
200 μM L-proline 
 
 
DMEM, RPMI-1640 
  
Sigma-Aldrich, Taufkirchen 
DMEM:F12 
 
 
Genaxxon, Ulm 
FCS 
 
 
PAN Biotec, Aidenbach 
FCS (hybridoma) 
 
 
Gibco Life Technologies, Paisley, UK 
Horse serum 
 
 
Gibco Life Technologies, Paisley, UK 
Antibiotic-Antimycotic (100x) 
 
Gibco Life Technologies, Paisley, UK 
Penicillin/Streptomycin 
 
 
Gibco Life Technologies, Paisley, UK 
L-glutamine 
 
 
Genaxxon, Ulm 
Hydrocortisone 
 
 
Calbiochem Merck4Biosciences, 
Darmstadt 
Insulin, human 
 
 
Roche, Mannheim 
EGF, human 
 
 
PeproTech, Rocky Hill, USA 
Lysis buffer 
  
0.5% Triton X-100 (v/v) 
20 mM NH4OH 
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2.6.2 Further solutions 
0.05%, 0.25% Trypsin-EDTA 
  
Gibco Life Technologies, Paisley, UK 
Distilled water, sterile 
  
Gibco Life Technologies, Paisley, UK 
50 mg/ml Hygromycin B (for selection) 
 
Roche, Mannheim 
Heparin (#H4784) 
  
Sigma-Aldrich, Taufkirchen 
T-Carrageenan, Type V 
  
Sigma-Aldrich, Taufkirchen 
Trypan blue staining solution 
  
Fluka, Neu Ulm 
 General buffers and solutions 
1 × PBS 
  
140 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.5 mM KH2PO4 
in H2O, pH 7.4, autoclaved 
1 × PBS-0.3 % Tween 
(PBST) 
 
0.3% Tween20 (v/v) 
in 1 × PBS 
1 M Tris HCl (pH 8) 
 
1 M Tris 
in H2O, pH 8 
10 mM Tris HCl (pH 8) 
 
10 mM Tris 
in H2O, pH 8 
70% Ethanol 
  
70% Ethanol (v/v) 
in H2O 
in 1 × PBS, pH 7.4, sterilized by 
filtration 
Freezing (cryo) medium 
  
30 ml DMEM or RPMI 
15 ml FCS 
5 ml DMSO 
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BSA-blocking buffer 
  
2% BSA 
in PBST 
 
   
Methanol 
  
Sigma-Aldrich, Taufkirchen 
Ethanol 
  
VWR, Darmstadt 
Butanol 
  
AppliChem, Darmstadt 
Isopropanol 
  
VWR, Darmstadt, Fluka, Neu Ulm 
 Serology buffer 
Multiplex serology blocking buffer 1 mg/ml Casein 
in 1 × PBS 
NTA- Solution 90 g Nitrilotriacetic acid                        
150 g NaHCO3                                               
in H2O to 750 ml 
Nickel solution 10 g NiSO4                                                      
in H2O to 1000 ml 
Serum pre-incubation buffer 2 mg/ml GST-Tag lysate                          
0.5% (w/v) Polyvinyl alcohol                 
0.8% (w/v) Polyvinyl pyrrolidone        
2.5% (w/v) CBS-K super chemiblock 
in multiplex serology blocking buffer 
Storage buffer 0.05%(w/v) NaN3                                        
in multiplex serology blocking buffer 
 Chemicals 
All chemicals, unless noted otherwise, were purchased from Sigma-Aldrich 
(Taufkirchen), AppliChem (Darmstadt), Merck (Darmstadt), Roth (Karlsruhe), 
Serva (Heidelberg), Fluka (Neu Ulm), Riedel de Haёn (Seelze, Netherlands), 
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Gerbu (Gaiberg), and Life Technologies (Karlsruhe) in the highest quality 
available. 
 Kits 
StrataClone Blunt PCR Clonig Kit  
 
Stratagene Agilent Technologies, 
La Jolla, USA 
QIAGEN Plasmid Plus Maxi Kit 
 
Qiagen, Hilden 
QIAprep® Spin Miniprep Kit 
  
Qiagen, Hilden 
1 × Multiplex PCR Kit buffer 
  
Qiagen, Hilden 
QIAquick Gel extraction kit 
  
Qiagen Hilden, Germany 
Gateway® LR Clonase™ II Enzyme 
mix 
 
Life Technologies Karlsruhe, 
Germany 
 Laboratory equipment 
2.11.1 Electrical equipment 
Refrigerated tabletop centrifuge 5417R Eppendorf, Hamburg 
Tabletop centrifuge 5417R  
  
Eppendorf, Hamburg 
CHRIST Minifuge GL 
  
Heraeus, Hanau 
Multifuge 1 S-R 
  
Heraeus, Hanau 
Refrigerated centrifuge RC5C 
 
Sorvall, Newton, USA 
Refrigerated centrifuge RC-5B 
 
Sorvall, Newton, USA 
Ultracentrifuge Sorvall® Discovery 90 SE Sorvall by HITACHI, Newton, USA 
Megafuge 1.0  
  
Heraeus, Hanau 
Refrigerated tabletop centrifuge Micromax 
RF  
Thermoquest, Egelsbach 
Rotors: SLA 3000, SA-600, VTi65  
 
DuPont, Bad Nauheim 
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SW41 Ti rotor  
  
Beckmann Coulter, Brea, USA 
Vortex Genie 2™  
  
Bender and Hobein, Ismaning 
Combimag Red/RET magnetic stirrer 
 
IKA, Staufen 
MR 2000/2002 magnetic stirrer 
 
Heidolph, Kelheim 
Thermomixer 5436  
  
Eppendorf, Hamburg 
Duomax 1030 shaker  
  
Heidolph, Kelheim 
Vibramax-VXR 
  
IKA, Staufen 
800 W microwave  
  
Bosch, Gerlingen-Schillerhöhe 
GFC water bath 
  
Grant Instruments, Cambridge, UK 
UC water bath 
  
julabo, Seelbach 
CO2 incubator safe cell UV (cell culture) Sanyo, Osaka, Japan 
Microscope for cell culture, Willovert 
 
Hund, Wetzlar 
Microscope for cell culture, Diavert 
 
Leitz, Wetzlar 
Refrigerators and freezers 
  
Liebherr, Ochsenhausen 
Electrophoresis power supply 
 
Gibco BRL, Eggenstein 
Horizontal Gel Electrophoresis 
Horizon®11.14 
Gibco BRL, Eggenstein 
Electrophoresis chamber 
  
Roth, Karlsruhe 
Electrophoresis gel slides 
  
Roth, Karlsruhe 
Function line incubator 
  
Heraeus, Hanau 
C1000™ Thermal Cycler 
  
BioRad, München 
Mastercycle 
  
Eppendorf, Hamburg 
Impulse Sealer 
  
RNS Corp, Taipei, Taiwan 
MicroPulser™ Electroporator 
 
BioRad, München 
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-80°C freezer 
  
New Brunswick Scientific, 
Hamburg  
Ice maker   Hoshizaki, Willich-Münchheide 
EconoPump (peristaltic) 
  
BioRad, München 
Steril GARD® III Advance cell culture hood The Baker Company, Sanford, 
USA 
Bio GARD cell culture hood 
  
The Baker Company, Sanford, 
USA 
Multiskan EX (ELISA reader)  
  
Thermo, Waltham, USA 
1420 Multilable Counter Victor3 
 
Perkin Elmer, Norwalk, USA 
EnVision 2101 Multilabel Reader 
 
Perkin Elmer, Norwalk, USA 
Nanodrop spectrophotometer 
 
Peqlab, Erlangen 
pH meter  
  
Sartorius, Göttingen 
MilliQ ultra-pure water unit Millipore 
 
Merck, Darmstadt 
Precision balance  
  
Mettler Toledo, Gießen 
Nitrogen tank 
  
Chronos Messer, Krefeld 
French press (Emulsi Flex-C5) 
 
Avestin, Ottawa, Canada 
Multichannel pipette (1200 μl)  
 
Biozym Scientific, Hessisch 
Oldendorf 
FPLC Amersham Äkta purifier 900 
 
GE Healthcare, Uppsala, Sweden 
QIAgility  
  
Qiagen, Hilden 
Xenogen IVIS 100 imager  
  
Xenogen/Perkin Elmer, Norwalk, 
US 
BioRad GelDoc™ EZ Imager 
  
BioRad, München 
Blood tube rotator SB1 
  
Stuart Scientific, Staffordshire, UK 
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2.11.2 Common use utensils 
96-well flat bottom cell culture plates 
 
Costar, Corning, USA 
Single use filter, 0.2/0.4 μm 
 
Renner, Dannstadt 
Bottle Top Filter 500 ml, 0.22 μm 
 
Costar, Corning, USA 
Dialysis tubing, 0.023 mm 
  
Roth, Karlsruhe 
Cryo tubes, 2 ml  
  
Roth, Karlsruhe 
Electroporation cuvettes (25 × 2 mm) 
 
Peqlab, Erlangen 
ELISA plates, round bottom  
  
BD Falcon, Durham, USA 
Whatman filter paper 3MM-paper  
 
Schleicher & Schuell, Dassel 
Drying foil for SDS gels  
  
Promega, Madison, USA 
10 cm tissue culture plates  
  
Sarstedt, Newton, USA 
10 cm petri dishes  
  
Greiner, Frickenhausen 
Inoculating loop 
  
Greiner, Frickenhausen 
LIA plates, white, 96 K F‐Form 
 
Greiner, Frickenhausen 
Nitrocellulose membrane  
  
Schleicher & Schuell, Dassel 
Parafilm “M”  
  
American National Can, Chicago, 
USA 
Pasteur pipettes, plastic 
  
Greiner, Frickenhausen 
Single use pipettes (25 ml, 10 ml, 5 ml), sterile  BD Falcon, Durham, USA 
Filter tips (1000 μl, 200 μl, 20 μl, 10μl)  
 
Starlab, Hamburg 
Cell scraper 
  
Sarstedt, Newton, USA 
50 ml centrifuge tubes 
  
Nalgene, Nunc, Wiesbaden 
500 ml centrifuge tubes 
  
Nalgene, Nunc, Wiesbaden 
Ultracentrifuge tubes Herolab 13.2 ml  
 
PA Beranek, Weinheim 
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Quick seal Vti65 centrifuge tubes  
 
Beckmann Coulter, Brea, USA 
1000 μl and 200 μl pipette tips 
 
Greiner, Frickenhausen 
1.5 ml and 2 ml reaction tubes  
 
Eppendorf, Hamburg 
0.5 ml and 1.5ml LoBind Protein tubes 
 
Eppendorf, Hamburg 
PCR reaction tubes 
  
Roth, Karlsruhe 
15 ml reaction tubes 
  
TPP, Trasadingen, Switzerland 
50 ml reaction tubes 
  
Greiner, Frickenhausen 
X-ray film 
  
Amersham, München 
X-ray  
  
cassette Roth, Karlsruhe 
Syringes and needles  
  
BD Falcon, Durham, USA 
50 ml reagent reservoir 
  
Costar, Corning, USA 
14 ml PP round bottom tubes 
 
BD Falcon, Durham, USA 
6- and 12-well test plates 
  
TPP, Trasadingen, Switzerland 
25 cm2, 75 cm2 and 150 cm2 tissue flasks  TPP, Trasadingen, Switzerland 
1000 μl, 200 μl, 20 μl and 10 μl PIPETMAN 
Neo® 
Gilson, Middleton, USA 
1000 μl, 250 μl, 50 μl and 25 μl MICROMAN® Gilson, Middleton, USA 
Nitrile gloves  
  
Freeform®SE, The Hague, 
Netherland 
Latex gloves 
  
Blossom, Madrid, Spain 
Disposable scalpel  
  
Feather, Osaka, Japan 
Discofix multidirectional stop cock 
 
Braun, Melsungen 
1 ml Injekt-F single use syringe 
 
Braun, Melsungen 
12-channel Finnpipettes, 5-50 μl, 10-100 μl  Thermo Scientific, Waltham, USA 
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BioRad columns 1 × 10 cm, 8 ml  
 
BioRad, München 
Rotilabo-FEP tubing, inside diameter: 0.8 mm Roth, Karlsruhe 
outside diameter:1.58 mm 
  
 
 Software 
Adobe Acrobat Professional X 
 
Adobe, San Jose, USA 
Clone Manager 9.0 for Windows  
 
Scientific & Educational Software, 
Cary, USA 
GraphPad Prism 5.0  
  
GraphPad Software, La Jolla, USA 
Microsoft Office 2010  
  
Microsoft, Redmond, USA 
Microsoft Windows 7  
  
Professional Microsoft, Redmond, 
USA 
Wallac 1420 Workstation  
  
Perkin Elmer, Norwalk, USA 
Wallac EnVision Manager  
  
Perkin Elmer, Norwalk, USA 
Living Image® 2.50.1  
  
Xenogen/Perkin Elmer, Norwalk, 
USA 
Unicorn 5.0 
  
GE Healthcare, Uppsala, Sweden 
ORF script  
  
Agnes Hotz-Wagenblatt, DKFZ, 
Heidelberg 
EndNoteX5 
  
Thomson Reuters, New York, USA 
ImageJ 1.40 
  
NIH, Bethesda, USA 
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 Methods 
 Manipulation of DNA and cultivation of bacteria 
3.1.1 Polymerase chain reaction (PCR) 
PCR is the main method used to amplify specific DNA fragments exponentially 
through enzymatic action of a polymerase in vitro. A standard PCR protocol 
was employed to generate the nanoparticles with monomeric or multimeric Trx-
L2 constructs by using the KOD HiFi polymerase. The pipetting scheme and 
cycling parameter were as follows: 
The reaction was prepared on ice, and the cycling parameters were: 
Cycling parameters: (1) Denature 15 sec 98 °C 
(2) Anneal 2 sec (Tm of primers - 5) °C 
(3) Extend 20 sec 72 °C, 25 cycles 
(4) 4 °C ∞ 
3.1.2 Gate-way cloning Polymerase chain reaction (PCR) 
 Homo ferritin was provided as complete Gateway®-compatible entry-vectors to 
shuttle into a destination vector with the LR Clonase™ II enzyme mix. All the 
  KOD HiFi DANN polymerase PCR 
Reaction mix 26.1 μl autoclaved MilliQ H2O  
5 μl 10 × Buffer #2 
5 μl dNTPs (final concentration 0.2 mM) 
2 μl MgCl2 (final concentration 1 mM) 
1 μl ~2 μg/ml template DNA 
4 μl fwd primer (5 pmol/μl, final concentration 0.4 μM) 
4 μl rev primer (5 pmol/μl, final concentration 0.4 μM) 
2.5 μl DMSO (final concentration 5% v/v) 
0.4 μl KOD HiFi DNA polymerase (2.5 U/μl) 
50 μl total volume 
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reactions were done using the Fast Gateway® LR protocol. It was performed 
according to the manufacturer´s instructions. The scheme of pipetting for the 
reaction and cycling parameter were as follows: 
Reaction mix 1-7 µl Entry clone                                                                              
1 µl  Destination vector                                                                   
8 µl  TE buffer                                                                                      
2 µl  LR ClonaseTM II enzyme mix 
The reaction was processed at 25 °C for 1 hr followed by treatment with 1 μl 
proteinase K at 37 °C for 10 min to stop the reaction. 1 μL of the LR reaction 
was transformed into 40 μL of electrocompetent bacteria and then resuspended 
in 500 μL LB, shaken at 37 °C for 1 h, followed by spreading on agar plates with 
the appropriate antibiotic to obtain colonies at 37 °C overnight. Colonies were 
picked and cultivated for DNA plasmid extraction, restriction digests and 
sequencing to confirm correct insertion. Glycerol stocks of the correct colonies 
were prepared and stored at -80 °C. 
3.1.3 Blunt end PCR cloning 
Blunt-ended KOD HiFi generated PCR products can be cloned into a vector by 
combining the activities of topoisomerase I and Cre recombinase. The kit was 
used according to the manufacturer’s instructions with minor modifications.  
Reaction mix 3 µl StrataClone Blunt Cloning Buffer                                
2.5 μl 1:10 diluted PCR product                                              
0.5 μl StrataClone Blunt Vector Mix amp/kan 
The solution was gently mixed, incubated for 5-10 minutes at room temperature, 
then placed on ice before subsequent chemical transformation of SoloPack 
cells. 
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3.1.4 Chemical transformation of bacteria 
There are StrataClone SoloPack cells in the StrataClone Blunt PCR Cloning kit, 
the cells were going to be transformed with PCR DNA ligated into the blunt end 
vector mix. For each transformation, 50 μl of cells were employed. The 
transformation procedures as following: 
The transformation 
components: 
50 μl StrataClone SoloPack cells ( thawed on ice) 
1 µl  cloning reaction 
The reaction was gently mixed and incubated on ice for 20 minutes.  
In the meantime, LB medium without any antibiotic was pre warmed to 42 °C in 
water bath. 
The transformation reaction was heat-shocked for 45 seconds at 42 °C, then 
placed n on ice for 2 minutes. Afterwards, 250 μl pre-warmed LB medium was 
added to the reaction and incubated at 37 °C and 250 rpm for 1 hour.  
During the incubation time, the LB-agar plate with ampicillin or kanamycin were 
spread with 40 μl of 2% X-gal to select blue-white colonies. 
Finally, 200 μl of transformation reaction were spread on the plates, and 
incubated overnight at 37 °C. The white colonies which contain ligated PCR 
product were picked on the second day.  
3.1.5 Transformation of bacteria by electroporation 
E. coli MxDH10, Rosseta, and multibac bacteria were transformed by 
electroporation. The procedure was as follows: 
The electroporation cuvettes were chilled on ice, and in the meantime, bacteria 
were thawed on ice as well; 2 μl of DNA was gently mixed with 40 μl of bacteria 
and transfer to the chilled electroporation cuvette. The mixture was pulsed once 
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with 2.5 kV (around 5 mini seconds) and then suspended in 300 μl pre warmed 
LB medium (37 °C). The transformed bacteria were transfered to a new 2 ml 
eppendorf tube and incubated on a shaker at 37 °C and 250 rpm for at least 1 
hour (for the multibac bacteria the incubation time was extended up to at least 
6 hours). Finally, up to 50 μl of bacterial culture were spread onto LB-agar 
plates containing the appropriate resistance and the plates were incubated at 
37 °C overnight. 
3.1.6 Electrocompetent bacteria preparation 
The electrocompetent bacteria used for transformation were derived from the 
bacterial strain MegaX DH10 or Rosseta. Before preparing the starting culture, 
MegaX DH10 were plated from a glycerol stock on a LB agar plate without 
antibiotics and incubated at 37 °C overnight. A single colony was transferred to 
25 ml LB medium and inoculated at 37 °C overnight on a shaker with 200 rpm. 
After overnight incubation, 5ml of the bacterial culture were transferred to 400 
ml of fresh LB medium and inoculated at 37 °C and 200 rpm for 2-4 hours until 
the culture reached an optical density (OD600) of 0.5-0.6. The bacterial culture 
was then chilled on ice for 30 min and harvested by centrifugation at 6.000 rpm 
for 10 min at 4 °C. This pellet was re-suspended in 30 ml ice-cold H2O and 
transferred to a dialysis tube and dialyzed against H2O overnight at 4 °C. The 
bacterial cells were then harvested by centrifugation at 4,000 rpm for 10 min at 
4 ⁰C and resuspended in 600 µl ice-cold 10% glycerol solution. 10 µl of the 
bacterial suspension were diluted 1:100 in 990 µl 10% glycerol and the OD600 
was measured. The obtained OD600 was multiplied with the volume of the stock 
suspension (600 µl) and the calculated value in µl of glycerol was added to the 
bacterial solution. Aliquots of 40, 80 and 120 µl were prepared and snap-frozen 
in liquid nitrogen and stored at -80 ⁰C. 
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3.1.7 Bacteria cultivation on agar plates and in suspension 
Bacteria were cultured in LB medium at 37 °C and 250 rpm, then the bacterial 
culture was spread onto agar plates. Subsequently the inoculated agar plates 
were incubated upside down at 37 °C to prevent condensed water from 
collecting on the colonies. Proper antibiotics were added to liquid LB-agar 
medium or solid plates to prevent contamination. 
3.1.8 Bacterial storage at -80°C 
For the purpose of long term storage of bacteria, 1 ml overnight bacteria culture 
was mixed with 300 μl sterile glycerin in a sterile, screw-cap cryo tube, mixed 
by pipetting up and down and stored at -80 °C.  
3.1.9 Small scale purification of plasmid DNA (Mini-prep) 
A bacteria culture was prepared by inoculating a single colony or glycerol stock 
in 5 ml LB medium with appropriate antibiotic and incubated at 37 °C and 250 
rpm overnight. The next day, 2 ml bacteria culture were transferred into a 2 ml 
reaction tube, and centrifuged at 13,000 rpm for 1 minute at room temperature. 
The supernatant was discarded and the pellet was re-suspended in 100 μl 
glucose buffer and the suspension was incubated at room temperature with 
shaking for 5 minutes. 200 μl lysis buffer was added into the suspension and 
the reaction was incubated on ice for 5 minutes. Then 150 μl of 3 M sodium 
acetate (pH 5.3) was added, and incubated on ice for another 5 minutes. 450 
μl of phenol-mix was added to remove proteins from the reaction, and 
vigorously shaken to mix all the components for 5 minutes and then centrifuged 
at room temperature and 13,000 rpm for 5 minutes Later, 380 μl of aqueous 
supernatant were transferred into a new reaction tube, and 450 μl isopropanol 
was added. Incubated at -80 °C for 15 minutes, followed by centrifugation at 
13,000 rpm and 0 °C for 30 minutes. The supernatant was removed carefully 
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and the DNA pellet washed with 500 μl 70% ethanol. Another centrifugation at 
13,000 rpm and 0 °C for 5 minutes was carried out. The ethanol was carefully 
discarded, and the DNA pellet was dried under the hood and later resuspended 
with 30 μl autoclaved MilliQ water. The DNA was either analyzed by restriction 
enzyme digest (section 3.1.12) or stored at -20 °C. If the DNA needed to be 
sent for sequencing, then high quality DNA was required. For this purpose the 
DNA was purified using the QIAprep Spin Miniprep Kit according to the 
manufacturer's instructions. The DNA was eluted with autoclaved MilliQ H2O 
and 20-30 μl was sent for sequencing. 
3.1.10 Large scale purification of plasmid DNA (Maxi-prep) 
A bacteria culture was prepared by inoculating a single colony or glycerol stock 
in 250 ml LB medium with appropriate antibiotic and incubated on the shaker 
at 37 °C and 250 rpm overnight. The next day, the whole bacteria culture was 
transferred into a 500 ml centrifuge tube and centrifuged at 5,000 rpm for 10 
minutes at room temperature. Then the DNA was purified with the QIAGEN 
Plasmid Plus Maxi Kit according to the manufacturer's introduction. 
3.1.11 DNA concentration and purity determination 
For sequencing purpose or for digestion, the DNA concentration and purity 
needed to be determined. We can use the property that DNA, RNA and protein 
have specific absorption maxima (DNA at 260 nm and proteins at 280 nm) to 
calculate a samples purity. A pure DNA solution results in absorption ratio (Abs 
260 nm/Abs 280 nm) =1.8, if the value is greater than 1.8, it indicated there was 
a RNA contamination; while a value lower than 1.8, means the DNA contains 
proteins. Before each measurement, a blank measurement with 1.5 μl of the 
solution that the DNA was dissolved in (autoclaved MilliQ H2O) followed by 1.5 
μl of undiluted DNA sample. 
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3.1.12 Restriction enzyme digestion 
DNA was digested by restriction enzymes for two purposes: namely to analyze 
the plasmid DNA and to digest the plasmid into fragments for further use.. For 
the different purposes, a different mixture was used. To analyze the plasmid 
DNA, the components were as follows: 
DNA                      0.5-1 μg  
10 x reaction buffer               2 μl 
100 μg/ml Rnase                                            0.2 μl 
restriction enzyme              0.2 μl 
  /add autoclaved MilliQ H2O upto 20 μl 
The reaction was incubated at 37 °C for 1-3 hours.  
Later, 5 μl of digest reaction was mixed with 1 μl 6 × DNA dye, and loaded onto 
1% -2% agarose gel to separate the digested fragments.  
After checking the size of fragments, the potential candidates of plasmid were 
digested in bigger reaction system to  prepare DNA. The reaction components 
were as follows: 
DNA                         15-50 μg 
10 x reaction buffer              20 μl 
100 μg/ml Rnase                2 μl 
Restriction enzyme               2 μl 
  /add autoclaved MilliQ H2O upto 200 μl 
The reaction was incubated at 37 °C overnight.  
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Then the entire digestion reaction was mixed with 40 μl 6 × DNA dye and loaded 
onto 1% agarose gel. The DNA fragments of interest were subsequently 
extracted from the gel. 
3.1.13 Horizontal agarose gel electrophoresis 
Gel electrophoresis was used to separate nucleic acid fragments by size. 
Nucleic acids are negative charged because of their phosphate residues and 
will move in an electric field through an agarose polymer matrix from the 
negative cathode to the positive anode. The speed at which the nucleic acids 
will travel not only depends on the size and conformation of the fragments but 
also the density of the agarose gel matrix. If small fragments are desired, more 
concentrated gels will be employed since the nucleic acids move slower in them. 
Generally, smaller molecules of nucleic acids travel faster on the agarose gels, 
since they are presented with less resistance in the gel matrix. Linear DNA 
fragments travel slower than the supercoiled ones since they have a larger 
surface area and are retained in the agarose gel matrix longer than supercoiled 
DNA. In order to determine the size of the DNA fragments, a DNA marker 
containing different fragments of DNA with known sizes was applied on the gel 
with the samples. The DNA fragments were displayed as bands on the gel using 
ethidium bromide which intercalates into DNA and emits fluorescence when 
exposed to UV light.  
Preparation of agarose gel as following: 
Agarose                         1 g (1% gel)/2 g (2% gel) 
1x TAE buffer                      100 ml 
The solution was heated in a microwave and allowed to cool down briefly before 
6 μl ethidium bromide (1 mg/ml) was added. 
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3.1.14 DNA extraction from agarose gel 
DNA fragments were extracted from agarose gel using the QIAquick Gel 
Extraction Kit from Qiagen according to manufacturer’s instructions. 
3.1.15 Dephosphorylation of 5'-DNA ends and ligation 
5'-phosphates of DNA vectors were removed by phosphatase to avoid re-
circularization of the linear DNA plasmid vector and phosphodiester bonds 
formations. By dephosphorylating 5'-DNA ends DNA fragments can be ligated 
into the dephosphorylated vector effectively without re-ligation of themselves. 
In order to put the DNA fragment of interest into a suitable vector, DNA ligation 
was employed. A linear vector plasmid with 5'-ends dephosphorylated was 
inserted into  linear DNA through covalent phosphodiester bonds involving the 
3'-hydroxyl end of one nucleotide and the 5'-phosphate of another. T4 DNA 
ligase (Invitrogen Life Technologies, Darmstadt) was employed. The reaction 
system was made as follows: 
Incubated at 16°C overnight. 
The second day, bacteria were transformed via electroporation with the ligated 
DNA (as described in 3.1.5). 
 
Vector DNA (- 15 μg)                      1 μl 
insert DNA (- 50 μg)                       9 μl 
5 × ligase buffer                           4 μl  
MilliQ H2O                               6 μl 
T4 ligase                                 1 μl 
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 Protein purification and analysis 
3.2.1 Expression of encapsulin and ferritin in E.coli 
In order to produce the native encapsulin and ferritin nanoparticle for further 
experiments, the encapsulin and ferritin were transformed into E.coli Rosseta, 
and the expression procedures were as follows:    
A single colony was inoculated in 20 ml LB medium overnight at 37 °C, next 
day, 4 ml of bacteria culture were used to inoculate 400 ml LB medium in a 1 L 
Erlenmeyer flask at 37 °C and 200 rpm for 4-5 hours. Once the bacteria culture 
reached OD600 0.5-0.6, it was induced with 1 mM IPTG overnight at 30 °C or at 
room temperature and 200 rpm. On the third day, the bacterial culture was 
centrifuged at 5,000 rpm for 10 minutes, the pellet resuspended with 100 ml 1 
× PBS, and centrifuged again.The supernatant was discarded and the pellet 
stored at -20 °C for extraction later.  
3.2.2 Protein extraction from E.coli 
The bacteria pellet was re-suspended in 40 ml lysis buffer, and incubated at 
room temperature for 10 minutes then another 20 minutes on ice. Afterwards, 
the bacteria were lysed with an Emulsi Flex-C5 (also called French Press) with 
three to five cycles at 15,000 psi. Between samples, the French Press was 
washed thoroughly with 0.5 M NaOH, 10 mM HCl, autoclaved MilliQ H2O and 
lysis buffer. Bacteria lysate was centrifuged at 17,000 rpm and 4 °C for 1 hour. 
The supernatant which contained soluble protein was subsequently purified, 
and the pellet was discarded. 
3.2.3 Purification proteins with GST-tag  
The pGex-4T-3 plasmids with native ferritin, encapsulin and human ferritin were 
transformed in E.coli Rosseta bacteria and cultivated in LB medium 
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supplemented with 100 µl/ml ampicillin and 20 µg/ml chloramphenicol at 37 °C 
overnight (pre-culture). 50 ml of pre-culture medium was diluted into 1 L LB 
containing the respective antibodies and grown at 37 °C until OD600 reached 
approximately 0.6. Then the culture was set to rest at 4 °C for 30 minutes, then 
induced with 250 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). After 
cultivation at 27 °C overnight, the pellets were collected by centrifugation for 20 
minutes at 5,000 rpm at 4 °C in Sorvall GS-3 rotor. The pellets were 
resuspended in 10 ml GST-lysis buffer containing 0.5 mol complete protease 
inhibitor cocktail and 2 mM DTT. Then subjected to the French Press and then 
centrifuged at 14,000 rpm for 1 hour at 4 °C. Finally, the supernatant was mixed 
with 100% glycerol at 1:1 ratio and stored at -20 °C.  
3.2.4 Endotoxin removal 
The purified thioredoxin-L2 protein was mixed with 1% Triton X-114 and 
incubated on ice for 5 minutes followed by 5 minutes at 37 °C. In order to 
remove the Triton X-114, the samples were centrifuged for 1 minute at 12,000 
rpm and 37 °C after which the supernatant was transferred into a new reaction 
tube. All of the procedures were repeated twice. 
3.2.5 SDS- polyacrylamide gel electrophoresis  
Proteins were separated by size on SDS polyacrylamide gels. The proteins 
were mixed with 3 × protein loading buffer which contains SDS that is negatively 
charged, and the reducing agent β-mercaptoethanol. When the voltage is 
applied, the proteins gain an overall negative charge and migrate to the positive 
anode because of SDS. The SDS-polyacrylamide gel has two parts, a stacking 
and a separating gel. The stacking gel with 3% acrylamide takes up the upper 
fourth of it, the separating gel with 12.5% acrylamide which is 3/4 of the gel. 
After the voltage is applied, all proteins start at the same position between the 
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stacking gel and the separating gel where they move according to size, the 
larger slower and the smaller faster.  
SDS-PAGEs were placed in electrophoresis chambers and filled with 1 × TGS. 
The proteins were mixed with 3 × protein loading buffer, then denatured at 95 °C 
for 10 minutes. Afterwards, short centrifugation was carried out before loading 
the samples onto the gels. Electrophoresis was run at 90 V for 20 minutes, then 
set to 110 V. After running, the gels were either stained with Coomassie blue 
staining solution, or moved on to western blot.  
3.2.6 Coomassie blue staining of SDS-PAGEs 
In order to have better staining, the polyacrylamide gels were rinsed in water at 
room temperature for 30 minutes, then transferred to Coomassie blue staining 
solution overnight. The proteins were fixed to the gel matrix by acetic acid which 
is in Coomassie blue staining solution. Next day, the Coomassie solution was 
discarded. Then the gels were washed in water several times to reduce the 
background color. The protein size could be determined by comparing the 
visible protein bands to the protein marker. 
3.2.7 Western blot 
For western blot analysis, the proteins were transferred from the SDS-PAGE to 
the nitrocellulose membrane, where the proteins could be analyzed by specific 
antibody detection. According to the transfer direction determined by the 
western blot transfer chamber, the polyacrylamide gel, soaked in 1 × EMBL was 
placed on top of the nitrocellulose membrane which was previously placed on 
top of three 1 × EMBL saturated Whatman papers. The stack was covered with 
another three Whatman papers that had also been immersed in 1 × EMBL. The 
transfer was then performed at 150 mA/gel for 75 min to ensure an adequate 
transfer of all proteins to the nitrocellulose membrane. To block remaining 
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protein binding sites on the nitrocellulose membrane, the membrane was 
incubated in 5% skim milk dissolved in 1 × PBS-T at RT for 1 hour. Meanwhile, 
the primary antibody, directed against the protein of interest, was diluted in 5% 
skim milk PBS-T, according to manufacturer´s instructions. The antibody 
solution was then applied to the membrane and incubated either at RT for 1 
hour or at 4 °C overnight. After incubation with the primary antibody, excess 
antibody was removed by washing the membrane three times with 1 × PBS-T 
for 1 min. The corresponding secondary antibody conjugated with horseradish 
peroxidase (HRP) was diluted 1:10,000 in 5% skimmed milk PBS-T and added 
to the membrane (room temperature for 1 hour). The washing steps were 
repeated after incubation of the secondary antibody to remove unbound 
antibodies from the membrane. To detect the protein solution A, containing 
luminol plus enhancer and solution B, a peroxide solution of the 
chemiluminescence kit were mixed in a 1:1 ratio and the membrane was 
incubated in the substrate solution for 1 min. The position of the bound 
secondary antibody and therefore indirectly the protein of interest were 
visualized using light sensitive ECL films exposed to the emitted light of the 
luminescence reaction. 
3.2.8 Chemical reduction of proteins 
The proteins which were going to be used in mice or guinea pig immunization, 
were all treated with 1mM DL-Dithiothreitol (DTT). 
 Antigens production in insect cells. 
3.3.1 Generation of recombinant baculovirus 
The generation of recombinant baculovirus was performed as previously 
described with some modification (Vinzon et al., 2014). Briefly, recombinant 
baculovirus was produced by transfecting Sf9 insect cells with recombinant 
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MultiBac bacmids via calcium phosphate precipitation method. At the time of 
transfection, the optimal confluency for adherent Sf9 cells was 75% in 25 cm2 
flask. After washing, the medium of the cells was replaced by 1 ml Grace’s 
insect medium supplemented with 1% L-glutamine. The MultiBac bacmid DNA 
(1 µg) was diluted in 1 ml transfection buffer and addeddropwise to the Sf9 cells. 
After incubation at 27 °C for 5 hours, the cells were washed twice and then 
maintained in 10 ml TNM-FH supplemented medium for 6 days. The 
supernatant was used to generate of a high-titer baculovirus stock. Sf9 cells 
with a density of 2×106 were seeded in a T25 flask and infected with 1 ml 
supernatant for virus amplification over 6 days. This step was repeated by 
passaging the cells to increase the virus in the supernatant for at least two 
weeks (3 ml medium for 1×107 Sf9 cells in a 75 cm2 flask and 5 ml medium for 
2.5×107 Sf9 cells in 175 cm2 flask).  
3.3.2 Expression test of Recombinant Baculovirus 
Sf9 cells in a 25 cm2 flask were infected with 1 ml supernatant from Passage 2 
and incubated for 3 days at 27 °C. Proteins were extracted and the expression 
of different nanoparticle antigens was analyzed by SDS-PAGE with Coomassie 
blue staining and western blot.  
3.3.3 Nanoparticle antigens production and purification.  
TN-High Five cells were cultivated to a density of 2.5×106/ml in 250 ml 
suspension culture. The cells were pelleted and resuspended in 42 ml EX-
CELLTM 405 serum free medium and 8ml high titer virus stock. The cells were 
thereafter shaken at a low speed for 1 hour at room temperature and then 
incubated within 250 ml final volume of medium for 3 days at 27 °C. Cell pellets 
were harvested by centrifugation (4,000 rpm, for 10 minutes at 4 °C in Sorval 
GS-3 rotor) and washed in pre-chilled 1 × PBS twice. Dry pellets were 
resuspended in 10 ml insect cell extraction buffer containing 200 µl 100 mM 
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PMSF, and then followed by sonication three times. A two-step gradient 
consisting of 7 ml of 40% sucrose on the top of 7 ml of CsCl solution (5.8g CsCl 
in 8ml insect cell lysis buffer) was prepared. Clear lysate was obtained by 
centrifugation (10,000 rpm for 10 minutes at 4 °C in Sorvall F-28/50 rotor) and 
carefully loaded onto the top of CsCl. After centrifugation (27,000 rpm for 3 
hours at 10 °C in SW-31Ti rotor), the interphase between sucrose and CsCl 
together with the complete CsCl layer was transferred into a Quickseal tube. 
The fraction was collected in 1 ml aliquot after 16 hours centrifugation at 48,000 
rpm at 20 °C in a Beckman 70Ti rotor and analyzed by SDS PAGE with 
Coomassie blue staining and western blot. Small aliquots from the fractions 
with the highest and lowest protein yield were dialyzed against H2O on a 
membrane filter and sent for later Electron Microscopy, Size exclusion 
chromatography and DLS. 
 Dynamic Light Scattering (DLS)  
The machine was turn on in advance and set at 4-60 °C to let it warm up. The 
nanoparticle antigens were prepared at concentration of 1 mg protein/ml. The 
samples were filtered through 0.1 µm filter and placed on ice. A water and buffer 
baseline was measured before measurement of the samples. Then 30 µl of 
samples were applied to the cuvette and the cuvette was cleaned properly with 
lens paper to remove any dust. The cuvette was inserted into the sample holder 
with the forested side to the left. The samples were equilibrated at least 15 
minutes, then tested and repeated it at least 5-10 times. 
 Electron microscopy (EM) 
The micrographs were taken with Zeiss EM912 and EM910 electron 
microscopy by Dr. Michelle Neßling or with the help of Dr. Karsten Richer and 
Dr. Michelle Neßling.  
3. Methods 
70 
3.5.1 Negative staining 
The nanoparticle antigens were visualized by negative staining in electron 
microscopy. Samples were applied on carbon coated grids and stained with 2% 
uranyl acetate. 
3.5.2 Immune staining  
The carbon-coated Formvar grids were activated by glow-discharge at 400 
mesh Au and grids placed on the nanoparticle drop to adsorb particles for 10 
minutes, then grids washed 3 times by passing through drops of 20 mM Tris. 
The protein-block PB Aurion blocking agent was used to coat gold conjugates 
full strength for 15 minutes then incubate with primary antibody anti-L2 antibody 
in the dilution of 1:50 with 20 mM Tris with protein-block PB for 30 minutes at 
room temperature. For the control group, the grids went through the same 
procedure without antibodies. After the incubation, the grids were washed in 20 
mM Tris with protein-block 6 times, 3 minutes per wash. They were then 
incubated with IgG (rabbit anti mouse) in 1:150 dilution for 30 minutes at room 
temperature and washed 6 times with 20 mM Tris with protein-block. Next, they 
were incubated with PAG-10nm at 1:50 with 10% protein-block in 20 mM Tris 
for 30 minutes at room temperature follow 3 washes with protein-blocker and 3 
times without protein-blocker. Afterwards, the reporter was fixated with 
Glutaraldehyde: 1% in 20 mM Tris for 7 minutes, then passed through 20 mM 
Tris. Finally, the negative staining was conducted.  
 Size-exclusion chromatography 
Size exclusion chromatograph was carried out with a Superde×200 10/300 GL 
column using the Aekta purifier 900 FPLC system and operating with Unicorn 
5.0. The flow rate was set at 0.5 ml/min, and the maximum pressure was 1.5 
MPa. The running buffer was 1 × PBS, and the proteins were eluted with 2 
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column volumes (48 ml) of running buffer. During the elution, 1 ml fractions 
were collected, and stored at 4 °C for later analyzed with Bradford assay and 
SDS-PAGEs. 
 Formulation of nanoparticle antigens and immunization of 
mice and guinea pigs 
3.7.1 Formulation of nanoparticle antigens with AddaVax 
Antigens were formulated with IFA or AddaVax by v/v 50%. The adjuvanted 
mixture was vortexed until a homogenous solution formed. 
3.7.2 Formulation of nanoparticle antigens with Alum 
Antigens were adsorbed by Alum before administration. The Alum used in the 
underlying work was the Alhydrogel ‘85’ (aluminum hydroxide) from Brenntag 
which had a concentration of 10 mg/ml. The Alum was added to the 
nanoparticle antigen in a 1.5 ml reaction tube prepared under rotation on a 
wheel for 1 hour at room temperature.  
3.7.3 Formulation of nanoparticle antigens with Alum- MPLA 
For vaccine preparation with Alum-MPLA, the antigen and Alum were adsorbed 
independently of the Alum and MPLA and only right before administration the 2 
adsorption reactions were combined. The MPLA was a synthetic, lyophilized 
preparation from Avanti Lipids of which we usually ordered 5 mg and prepared 
a 1 mg/ml solution. The preparation of this 1 mg/ml MPLA solution will be 
describe first followed by the adsorption of antigen-Alum and Alum-MPLA.  
A 0.5% (v/v) solution of Triethanolamine (TEoA) in sterile, Endotoxin-free water 
was prepared. This solution was filter-sterilized through a 0.22 μm filter. To a 5 
mg vial of lyophilized MPLA ~1.5 ml of 0.5% TEoA were added and 
subsequently heated for 5 minutes in a 65 °C water bath followed by 5 minutes 
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of sonication in a large water bath. Approximately 6-8 cycles of this heating and 
sonication were performed until the solution became clear and slightly 
opalescent. In between each cycle the sample was vortexed vigorously. The 
1.5 ml dissolved MPLA were transferred to a sterile 15 ml reaction tube, the 
volume was filled up to 4.85 ml with 0.5% TEoA, one last cycle of heating and 
sonication was performed and finally the pH was adjusted to ~7.4 by adding 1 
M HCl dropwise. Usually, 30 μl 1 M HCl per 1 ml MPLA-TEoA were required. 
The MPLA was stored at 4 °C and was stable for at least 6 months.  
Mice were usually immunized with 50 μg Alum and 10 μg MPLA. Half of the 
Alum was added to the nanoparticle antigen while the other half was combined 
with the MPLA. The separate adsorption reactions were prepared in 2 ml 
reaction tubes under rotation on a wheel for 1 hour at room temperature. Before 
intramuscular administration in mice, the two adsorption reactions were 
combined and briefly mixed by inversion. 
3.7.4 Immunization of mice and guinea pigs with nanoparticle antigens. 
6-8 weeks old BALB/c female mice were immunized with 20µg antigen in 50 μl 
of formulated nanoparticle antigens intramuscularly into the left or right caudal 
thigh muscle. Mice were immunized 3 or 4 times normally, with 2 week intervals. 
One week after the third immunization, intermediate blood was collected and 4 
weeks after last immunization final blood was collected. Mice groups typically 
contained 8-10 mice.  
350-400g female Guinea pigs were immunized with 200 μl of formulated 
nanoparticle antigens subcutaneously at the left or right flank. They were 
immunized 3 or 4 times with 2 weeks intervals as well. One week after the third 
immunization, intermediate blood was collected and 4 weeks after the last 
immunization final blood was collected. Guinea pig groups typically consisted 
of 2 animals. 
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3.7.5 Blood samples in mice and guinea pigs 
Intermediate blood samples were collected by the submandibular vein punch 
at one week after third immunization. Normally, only 200-250 μl of blood could 
be collected by this way. Four weeks after the final immunization, the final blood 
sample was collected by cardiac puncture.  
Blood samples were incubated at room temperature for 2-3 hours or at 4 °C 
overnight. They were centrifuged at 4,500 rpm and 4 °C for 15 minutes Cleared 
serum was transferred to a new sterile 1.5 ml Eppendorf tubes. Two rounds of 
centrifugation were carried out. Sera were stored at 4 °C or -20 °C for long term 
preservation. 
 Cultivation and manipulation of cells 
3.8.1 Cultivation of Mammalian cells 
 Mammalian cells were grown at 37 °C in an incubator with 5% CO2 and 95% 
humidity. HEK 293TT and HeLaT K4 cells were grown in DMEM supplemented 
with 10% FCS, 1% Penicillin/Streptomycin and 1% L-glutamine. CHOΔfurin and 
pgsa-745 cells were cultivated in DMEM supplemented with 10% FCS, 1% 
Penicillin/Streptomycin and 200 μM proline while MCF10A cells were grown in 
DMEM: F12 medium supplemented with 5% horse serum, 1% 
Penicillin/Streptomycin, 1% L-glutamine, 500 ng/ml hydrocortisone, 10 μg/ml 
insuline and 20 ng/ml EGF. The HEK 293TT and HeLaT K4 cells were also 
selected with Hygromycin B diluted 1:800 and 1:400, respectively. Mammalian 
cells were cultivated in 150 cm2 and 75 cm2 culture flasks with medium volumes 
of 30 ml and 20 ml, respectively.  
Cells were passaged every 3-4 days according to cell density. The medium was 
aspirated, and the cells were treated with 4 ml of 0.05% or 0.25 % trypsin-EDTA 
for ~5 minutes to disrupt the intercellular contacts and allow for detachment. 
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Cells were resuspended in the trypsin-EDTA by gently pipetting up and down 
before transferring them to 15 ml centrifuge tubes filled with 10 ml medium. The 
cells were centrifuged at 1,900 rpm and room temperature for 5 minutes. The 
medium was aspirated and the cell pellet suspended in 10 ml fresh medium of 
which 1-2 ml were transferred to a cell culture flask with fresh medium. Cells 
were allowed to grow until further dissemination. 
3.8.2 Cultivation of insect cells 
Insect cells for the nanoparticle antigens production were grown at 27 °C in an 
incubator without CO2 and humidity restriction. Sf9 cells for recombinant 
baculovirus production were maintained in TNM-FH insect medium 
supplemented with 10% FCS, 1% Penicillin/Streptomycin, 1% L-glutamine and 
0.1% Pluronic F-68. TN-High Five cells for baculovirus expression were 
cultivated in EX-CELLTM 405 serum free medium supplemented with 1% 
Penicillin/Streptomycin and 1% L-glutamine.  
Adherent cells were detached by cell scraper and passaged at a ratio of 1:3. 
For cells grown in suspension, 50 ml of medium containing at 1×106 viable 
cells/ml were seeded with 200 ml supplemented medium in the spinner flask 
and cultivated with constant shaking speed of 125-150 rpm at 27 °C. Cell 
densities were measured by using a standard trypan blue dye exclusion 
procedure and counting under the microscope. After two or three days, when 
cell densities reached 1×106 viable cells/ml, cells were seeded into the culture 
flasks according to different amount requirements.  
3.8.3 Determination of cell count and viability 
Trypan blue (which stains only dead cells) and a Neubauer counting Chamber 
were used for determining the cell count and viability. To determine the number 
of viable cells, 10 µl of a cell suspension were mixed with 10 µl trypan blue. 10 
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µl of the mix were pipetted into the Neubauer counting chamber and viewed 
under a light microscope. Viable, unstained cells in 2 quadrants, each with 16 
inner squares, were counted, and a mean cell number was calculated. The cell 
numbers per ml can be calculated as follows: 
Cell number/ml= X×2×104 (X: cell number; 2: dilution factor) 
3.8.4 Cryo-conservation and thawing of cells 
For cryo-conservation, approximately 1×107 mammalian cells were harvested 
by centrifugation, the pellet was resuspended in 1 ml ice-cold freezing medium, 
and the cells were transferred to 2 ml cryo vials. The cells were slowly cooled 
to -80 °C overnight in a cryo box. The vials were transferred to the liquid 
nitrogen tank for long-term storage. 
For cryoconservation of insect cells, a cell pellet of approximately 1×107 cells 
was resuspended in 1 ml of Cryo Medium (10% FCS,10% DMSO, 80% TNM-
FH supplemented insect medium for Sf9 cells, for High5 cells,10% DMSO and 
90% EX-CELLTM 405 supplemented serum free medium) into a cryotube, 
which was then wrapped in several layers of papers and transferred to -80 °C. 
For longer storage, cells were transferred to liquid nitrogen after one day.  
For re-culturing cells, the cryo vials were placed in a 37 °C water bath until 2/3 
of the content was thawed. Using a glass Pasteur pipette the cells were pipetted 
up and down until complete thawing was achieved and the entire content was 
transferred to a centrifuge tube containing 10 ml appropriate cell culture 
medium. After centrifugation at 1,900 rpm and room temperature for 5 minutes, 
the medium was aspirated and the pellet resuspended in fresh medium and 
transferred to cell culture flasks. 
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3.8.5 HPV pseudovirion production and purification  
On the first day, 3-4×106 293TT cells per 10-cm dish were seeded in 10 ml 
DMEM, and ten 10-cm dishes were prepared for a standard pseudovirion 
preparation. Approximately 24 hours after seeding the cells, transfected with 
10-15 μg DNA (5 μg reporter plasmid + 5 μg L1 plasmid + 5 μg L2 plasmid) and 
2 volumes of TurboFect in 1 ml of unsupplemented DMEM per 10-cm dish  The 
transfection reaction was incubated for 15-20 minutes at room temperature and 
subsequently added dropwise to the 293TT cells. The cells were incubated for 
72 hours at 37 °C and 5% CO2 after transfection. The 293TT cells were 
harvested by resuspension and transferred to 50 ml centrifuge tubes. After 
centrifugation at 1,900 rpm and room temperature for 5 minutes, the 
supernatant was discarded, the cell pellet resuspended in 1 ml DPBS and 
transferred to a sterile 1.5 ml reaction tube (#1). After centrifuging in a table-top 
centrifuge for 5 minutes at 5,000 rpm, the supernatant was discarded and the 
pellet resuspended in approximately 150 μl of lysis buffer containing 140 μl 
DBPS, 9 μl 10% Brij58 (w/v) and 1 μl RNase A/T. Cells were rotated overnight 
at 37 °C to induce pseudovirion maturation. On the next day, the PSV were 
extracted. The 1.5 ml reaction tubes containing the PSV lysate were placed on 
ice for 5 minutes before 0.17 volume of 5 M NaCl was added to the samples 
and another 5 minutes incubation on ice followed. Then, the samples were 
centrifuged at 10,000 rpm and 4 °C for 10 minutes, the PSV-containing 
supernatant transferred to a second 1.5 ml reaction tube (#2) and the pellet re-
suspended in 300 μl DPBS with 0.8 M NaCl. The samples were centrifuged 
again at 10,000 rpm and 4 °C for 10 minutes before transferring the supernatant 
to tube #2. Next, 1 μl benzonase were added to the cleared supernatant and 
the sample was incubated at 37 °C for 1 hour. The sample was centrifuged 
once more  at 10,000 rpm and 4 °C for 10 minutes before the supernatant was 
transferred to a sterile 1.5 reaction tube. Approximately 50 μl of this PSV-
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containing crude extract were set aside and stored at -80 °C while the rest was 
immediately purified by OptiPrep.  
For the OptiPrep purification three initial solutions with 27%, 33% and 39% 
iodixanol were prepared by diluting the original iodixanol solution (60%) in 
DPBS with 0.8 M NaCl. Phenol red was added to the 39% solution (50 μl phenol 
red to 10 ml solution). In centrifuge tubes for the SW41Ti rotor 3.2-3.3 ml of 
each solution were added starting with 39% on bottom, 33% in the middle and 
the 27% on top. The tubes were left at 4 °C overnight to allow softening of the 
gradient edges. The gradients were prepared on the same day the 293TT cells 
were harvested and lysed. PSV-containing crude extract was applied on top of 
the 27% solution and tubes were balanced to 0.00 g using DBPS with 0.8 M 
NaCl. The gradients were centrifuged for 5 hours at 37,000 rpm and 16 °C in 
an ultracentrifuge. Approximately eight 500 μl fractions were collected by 
inserting a sterile needle 1 cm below the 33%-39% interphase thereby allowing 
the solution to drip out. PSV were collected in 1.5 ml LoBind reaction tubes and 
stored on ice. The crude extract as well as the purified fractions were analyzed 
in the in vitro neutralization assay, but in this case infection and not 
neutralization was measured. The crude extract was usually tested in eight 
serial 1:2 dilutions starting with a 1:500 dilution while the purified fractions were 
tested at a fixed 1:1,000 dilution. 
 In vitro and in vivo HPV pseudovirion-based neutralization 
assays  
3.9.1 In vitro standard (L1) neutralization assay  
The neutralization assay is used to detect neutralizing antibodies in sera 
against human papillomaviruses. In this assay pseudovirions of different HPV 
types are used to infect HeLaT cells. Due to the infection, the PSV release a 
plasmid in the cell encoding the reporter Gaussia luciferase. The extent of 
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infection can be determined by measuring the activity of secreted Gaussia 
luciferase in the culture medium upon substrate addition. If neutralizing 
antibodies are present in the sera, pseudovirion infection and in turn the 
expression of the Gaussia luciferase is prevented (figure 3.1).  
First, serum or antibody dilutions were prepared in supplemented DMEM and 
50 μl of these were added to each well of a 96-well tissue culture plate (in 
duplicates). The outside wells of the plate were left free from samples and 150 
μl medium or 1 × PBS were applied here. Next, 50 μl of the PSV diluted in 
DMEM were added to each sample well. While the serum-PSV complex 
incubated for at least 20 minutes at room temperature, the HeLaT K4 cells were 
harvested and 50 μl of cell suspension were added to each well (2.5×105 
cells/ml). The tissue culture plates were lightly wrapped in plastic foil, placed in 
a moist melamine chamber and incubated at 37 °C and 5% CO2 for 48 hours.  
On the day of the reporter gene assay, 10 μl of cell culture supernatant were 
transferred from the tissue culture plates to white luminescence plates. For 
preparation of the substrate, Coelenterazine was combined with the Gaussia 
glow juice 1 × PBS (100 μl Coelenterazine + 10 ml 1 × PBS) and 100 μl of this 
mix was added to each well of the luminescence plate already containing 10 μl 
cell culture supernatant. A microplate luminometer was used to measure the 
samples 15 minutes after substrate addition.  
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Figure 3.1 The theory of L1-based neutralization assay (Pinto et al., 2018). The assay uses 
pseudovirions that incorporated the minor capsid protein L2 and the major capsid protein L1, 
with the reporter gene Gaussia Luciferase. The PSV bind to and enter into HeLa T cells and 
the reporter plasmid is translocated to the nucleus and expressed A). If neutralizing antibodies 
are present, PSV infection is blocked with concomitant reduction in reporter signal B). 
3.9.2 In vitro L2 neutralization assay  
The L2 neutralization assay was prepared over the course of 8 days and 
entailed the production of an extracellular matrix (ECM), furin cleavage of HPV 
PSV for L2 epitope exposure, antibody incubation and infection of HSPG-
deficient target cells. On day 1, 1×106 CHOΔfurin cells were seeded in a 75 cm2 
tissue culture flask containing 17 ml medium. These cells were allowed to grow 
to confluence over the course of four days. On day 3 or the morning of day 4, 
MCF10A cells were plated on 96-well tissue culture plates with a density of 
2×104cells/well in 100 μl. On the morning of day 5 the ECM was prepared from 
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the MCF10A cells. First, the medium was removed from the cells and these 
were washed 3 times with 100 μl 1 × PBS. Next, 50 μl pre-warmed (room 
temperature) lysis buffer were added to each well and exactly 5 minutes of 
incubation at room temperature followed before 100 μl of 1 × PBS were gently 
added on top of the lysis buffer by steadying the pipette tips along the side walls 
of the wells. Then, 100 μl of liquid were carefully removed from the cells and 
fresh 100 μl of 1 × PBS were added. This removing and adding of 100 μl liquid 
was repeated one more time before all of the liquid was carefully removed and 
the ECM left behind on the plate was washed two times with 100 μl 1 × PBS. 
The 1 × PBS from the second wash remained on the plate until the next step; 
in fact it was of utmost importance to not aspirate the ECM at this time. Next, 
the cell culture supernatant from the CHOΔfurin cells was decanted into a 
centrifuge tube, centrifuged at 1,900 rpm and room temperature for 5 minutes 
and the cleared furin-containing supernatant was set aside. Heparin was added 
to the supernatant at an end concentration of 8 μg/ml. The 1 × PBS was 
removed from the ECM and 70 μl of the furin + heparin supernatant was added 
to each well. The HPV PSV were diluted in L2 assay medium and 50 μl of the 
dilution were added to each well already containing 70 μl furin + heparin 
supernatant. The reaction was incubated overnight at 37 °C and 5% CO2. On 
day 6 the supernatant-virus mix was removed from the wells, these were rinsed 
twice with 100 μl 1 × PBS and again, the PBS from the second wash remained 
on the plate until the next step. The antibody titrations were prepared with L2 
assay medium in separate 96-well U-bottom plates to have 120 μl of each 
dilution. The 1 × PBS was removed from the ECM-virus plate and 100 μl of the 
antibody dilutions were added to each well. The reaction was incubated for 2-6 
hours at 37 °C and 5% CO2. Finally, the pgsa-745 cells were harvested by 
trypsinization with 0.05% Trypsin-EDTA and centrifugation at 1,900 rpm and 
room temperature for 5 minutes. The cell pellet was resuspended in L2 assay 
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medium, the cell count was adjusted to 1.6×105/ml and 50 μl of this cell 
suspension was added to each well already containing 100 μl serum dilution. 
Incubation at 37 °C and 5% CO2 succeeded for 48 hours before the Gaussia 
luciferase reporter gene assay was performed as described in the last section 
(figure 3.2).  
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Scheme of L2-based neutralization assay (Day et al., 2012). 1, MCF10 cells were 
plated in a 96 well plates and grown for 24 hours to allow for ECM deposition; 2, the EM 
remained on the plastic following lysis of the MCF10A cells; 3, Pseudovirus were plated on the 
ECM, which results in a conformational change in the capsid allowing the N-terminus of L2 
expose; 4, exogenous furin which is produced by the CHOΔfurin cells was applied with 
pseudovirus to allow cleavage of the conserved N-terminal furin cleavage site of L2, which 
leads to exposure of the major cross neutralizing epitopes in L2; 5, removal the unbound 
pseudovirus, and antibody titration series is applied to the plate and incubated at 37 °C for 6 
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hours; 6, HSPG- deficient pgsa-754 cells were plated into the virus/antibody-containing wells. 
Infection is documented following a 48 hours incubation.  
3.9.3 In vivo neutralization in cervico-vaginal mouse model  
The cervico-vaginal mouse model can be employed to measure the efficiency 
of L1 or L2-directed antibodies neutralizing in vivo transducing HPV PSV. The 
whole procedure was performed over the course of 8 days (figure 3). On day 1, 
the cage bedding from males was transferred to the cages of female BALB/c 
mice to initiate hormonal synchronization of the females. On day 3, 100 μl of a 
30 mg/ml Depo-Provera solution was administered subcutaneously to the mice. 
100 μl of antibodies or serum (collected from the animals immunized with 
nanoparticle antigens, and the naïve mice as control) diluted in 1 × PBS were 
delivered intraperitoneally to each mouse on day 5. On day 5 mice were treated 
with 4% Nonoxynol-9 (N9) prepared fresh or the day before in 4% CMC in a 50 
ml reaction tube. A 20-50 μl positive displacement (PD) MICROMAN® pipette 
was used to deliver 50 μl N9 intra-vaginally. Approximately 4 hours after N9 
treatment HPV PSV was instilled intra-vaginally. For this, 5 μl PSV were mixed 
with 5 μl 1 × PBS and 10 μl 4% CMC and these 20 μl were applied using a 3-
25 μl PD pipette. On day 8 in vivo imaging was performed at a Xenogen IVIS 
imager. Images of the mice were acquired before substrate addition and then 
20 μl of 15 mg/ml luciferin substrate were instilled intra-vaginally using a 20 μl 
pipette. After 3 minutes of incubation an image with 30 seconds - 1 minute of 
exposure time (and medium binning) was acquired. A region-of-interest (ROI) 
analysis was performed with the Living Image software and average radiance 
was selected as the final read-out. 
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Figure 3.3 In vivo cervicovaginal challenge mouse model (Pouyanfard and Muller, 2017). 
The whole procedure was performed over a course of 8 days.  Naïve mice were hormonally 
synchronized on day 1 by taking bedding from the male cage and subsequently on day 3 by 
injection with progesterone subcutaneously. On day 5, immune serum (from the animals 
immunized with nanoparticle antigens, or from the naïve mice as control) are passively 
transferred intraperitoneally to the naïve mice. On day 6, vaginal epithelium was disrupted by 
using a surfactant N9 followed by intravaginal administration of HPV PSV encapsulating firefly 
luciferase 4 hours later. The activity of luciferase was measured on day 8 by IVIS imaging 
system upon intravaginal instillation of Luciferin.  
  Multiplex serology 
Multiplex serology was performed with GST-fusion proteins of Pf thioredoxin, 
human thioredoxin, Pf ferritin and human ferritin, verifying their correct 
identification. The principle of multiplex serology is illustrated in figure 3.4;  
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Figure 3.4 Principle of multiplex serology. The proteins were expressed as recombinant 
GST-fusion proteins and loaded on glutathione-casein coupled spectrally distinct fluorescence-
labeled polystyrene beads. Protein loaded beads were mixed and incubated with sera. Sera 
antibodies bound to protein loaded beads were quantified using a labeled secondary antibody 
(Hufnagel et al., 2018). 
3.10.1 Loading of glutathione-casein beads with GST-fusion proteins. 
The Pf thioredoxin, human thioredoxin, Pf ferritin and human ferritin GST-fusion 
protein lysates were diluted in multiplex serology blocking buffer to a final 
protein concentration of 1 mg/ml in a total volume of 1 ml. Each lysate dilution 
was mixed with a specific bead set and incubated for 1 hour at room 
temperature on a shaker protected from light. Protein-loaded beads were 
centrifuged at 1,300 rpm for 2 minutes. Then supernatant was discarded and 
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beads were resuspended in a multiplex serology blocking buffer. This step was 
repeated three times in order to wash the protein-loaded beads. After the third 
centrifugation the beads were resuspended in a storage buffer.  
3.10.2 Sera pre-incubation 
Serum dilutions were prepared in polystyrene flat-bottom plates by diluting 
serum samples 1:50 in a total volume of 100 µl with serum pre-incubation buffer. 
Dilutions were incubated at room temperature for 1 hour on a shaker. GST-tag 
lysate was added to the pre-incubation buffer in order to prevent unspecific 
binding of antibodies directed against remaining bacterial proteins. In addition 
PVP and PVA were added to the pre-incubation buffer to suppress unspecific 
binding of antibodies to the beads. 
3.10.3 Equilibration of filter plates 
96-well filter plates were incubated with 100 µl multiplex serology blocking 
buffer per well for 10 minutes at room temperature. Afterwards, the buffer was 
removed using a vacuum manifold and plates were dried. 
3.10.4 Incubation of beads and sera 
Protein loaded beads were mixed thoroughly by alternating sonification and 
vortexing (at least 5 times). All beads were combined in a 100 ml bottle 
protected from light. 50 µL of the bead mixture were transferred into each well 
of the equilibrated filter plates. Afterwards 50 µl of 1:50 serum dilution was 
added to 50 µl bead mix. Plates were incubated on an orbital shaker at 200 rpm 
for 1 hour at room temperature protected from light. 
3.10.5 Incubation of secondary antibody 
Serum dilutions were removed from the filter plates using the vacuum manifold. 
Plates were washed three times with 100 µl multiplex serology blocking buffer 
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per well and dried afterwards. The secondary antibody was diluted 1:1,000 in 
multiplex serology blocking buffer, added to the plates and plates were 
incubated on an orbital shaker at 200 rpm for 1 hour at room temperature 
protected from light. 
3.10.6 Incubation with Strepavidin-R-Phycoerythin (StrepPE) 
The secondary antibody was removed from the filter plates by the vacuum 
manifold. Three washing steps were performed using 100 µl multiplex serology 
blocking buffer per well and plates were dried afterwards. Strep-PE was diluted 
1:750 in multiplex serology blocking buffer and added to the plates. Plates were 
incubated on an orbital shaker at 200 rpm for 1 hour at room temperature 
protected from light. Then washed 3 times as described above, followed by the 
addition of 100 µl of storage buffer per well and plates were stored at 4 °C 
overnight. 
3.10.7 Quantification of serum antibodies using Luminex 200 analyzer 
Bead-bound proteins were able to capture serum antibodies. These antibodies 
were quantified using the Luminex 200 analyzer. The signal obtained by the 
secondary antibody which bound to the primary serum antibodies, was 
measured as the median fluorescence intensity (MFI) calculated for each bead 
set. MFI values were considered to be valid if a minimum of 100 beads per bead 
set were detected and measured. Net MFI values were generated by 
subtracting the bead-background and the GST-background. The bead-
background was determined by performing a measurement without serum while 
the GST-background was measured by using one bead set loaded with GST-
tag lysate. 
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 Results 
It is well known that, the commercial HPV VLP vaccines are highly 
immunogenic and that the neutralizing antibodies induced by the VLPs can last 
for at least nine years, but the responses are very type-restricted (Herrero et 
al., 2015). This prompted research on second generation prophylactic HPV 
vaccines based on the L2 minor capsid protein. L2 can elicit cross neutralizing 
antibodies, but has low immunogenicity. In recent years, efforts have been 
made on developing a method to improve the immunogenicity of L2 (Jagu et 
al., 2009; Jagu et al., 2013; Nieto et al., 2012b; Pouyanfard et al., 2018). In our 
lab, the immunogenicity of L2 has been improved by employing Pyrococcus 
furiosus thioredoxin (Pf Trx) as a “platform” (Pouyanfard et al., 2018; Seitz et 
al., 2015; Spagnoli et al., 2017). In the past, we inserted the repetitive HPV16 
L2 neutralizing epitope (aa20-33) into the active site loop of Pf thioredoxin, 
which made the recombinant antigen thermally stable, highly soluble and more 
immunogenic compared to the small peptide L2 antigen(Seitz et al., 2013), 
which shows broad protective activity but fails to induce neutralizing antibodies 
against some of the oncogenic HPV types, such as HPV31, and HPV51. Later, 
the cross-protective ability of recombinant antigens was improved by replacing 
3 copies of HPV16 L2 (aa20-38) with L2 epitopes of eight HPVs (HPV16, 18, 
31, 33, 35, 6, 51, and 59), and this antigen was thereby able to cover all the 
high-risk and two low-risk mucosal HPVs, though the antibody titers were much 
lower than commercial VLPs vaccines. Thereafter OVX313 was employed as a 
secondary scaffold, a heptametrical form, in order to further improve the 
immunogenicity of multimeric antigens, which was proven to be quite 
successful (Pouyanfard et al., 2018; Spagnoli et al., 2017). In order to efficiently 
produce neutralizing antibodies, the B cells must be activated and there are 
certain requirements for B cells activation. At first, the antigens need to bind to 
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B cell receptors and cross link B cells receptors. Secondly, the same antigens 
need to activate T helper cells for the co-stimulation. Thirdly, there are cytokines 
provided by T helper cells which also assist in the activation of B cells. To further 
optimize the minor capsid protein L2 vaccines, we tried to employ the 
nanoparticle, Pyrococcus furiosus ferritin and encapsulin as the platform to 
display the L2 epitopes (aa20-38). By using the suitably sized nanoparticles, 
the cross-link of B cell receptors would not only trigger maximum activation, but 
also improve uptake by APCs.  
 Optimization of L2-based HPV multimeric antigens  
Previous studies of our group had already proven that the tripeptide of aa20-38 
L2 sequence of HPV16 inserted into the active loop of Pf Trx is more 
immunogenic than the monomeric L2 antigen, but the multimeric peptide 
antigen of L2 (aa20-38) epitopes from 8 different HPVs was even better than 
the tripeptide. Previous research showed that the size of the antigen related to 
its immunogenicity, like L1 VLPs are more immunogenic than capsomeres and 
monomeric counter parts (Schadlich et al., 2009; Thones et al., 2008). To 
display the multimeric peptide antigens on the surface of self-assembling 
nanoparticles, two potential platforms, ferritin and encapsulin, were employed. 
Both of them are from the same strain as the primary platform Pf thioredoxin. 
24 identical subunits of Pf ferritin form an octahedral cage, and 60 subunits of 
Pf encapsulin assemble into an octahedral cage. Attachments to the N-terminus 
of Pf ferritin are then displayed evenly on the nanoparticle surface, and any 
protein attached on the COOH-terminal of encapsulin subunits is also 
presented on the nanoparticle surface. The HPVs L2 (aa20-38) epitopes are 
used in either monomeric (HPV16 L2), trimeric (HPV16 L2*3) or multimeric 
peptides (HPV16, 18, 31, 33, 35, 6, 51, and 59) and are fused with and without 
Pf Trx, either on the NH2-terminus of Pf ferritin or on the COOH-terminus of 
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encapsulin, respectively (figure 4.1). Antigens were designed with different 
numbers of L2 epitopes because it was uncertain whether larger insertions 
would interfere with the nanoparticle assembly. 
To understand the assembly abilities of nanoparticle antigens, the baculovirus 
expression system had been employed here. The insect cell-based system is 
more complicated than E. coli system but it is endotoxin free, and allows 
superstructure formation. After the production of the recombinant baculovirus, 
the un-purified nanoparticle antigens were analyzed by SDS-PAGE (figure 4.2). 
 
 
 
 
 
Figure 4.1 Molecule design of L2-based nanoparticle antigens. In the left panel the 
encapsulin constructs of L2-based HPV antigens are shown with or without Pf Trx. In the right 
the ferritin analogs are depicted. The construct contained, 1 copy of HPV16 L2 (aa20-38), 3 
copies of HPV16 L2 (aa20-38), or the L2 (aa20-38) sequences of HPVs (HPV16, 18, 31, 33, 
35, 6, 51, and 59) fused into C-terminus of encapsulin, with or without insertion into the activing 
loop of Pf Trx, 
For the purification, different structures behaved differently. The simplest 
structures was tried first, such as native Pf encapsulin and Pf ferritin, using a 
heat purification to enrich for the proteins. It was found that the samples were 
highly soluble, and stable even when treated at 80 °C. After conducting the heat 
treatment, the proteins were separated by SDS-PAGE, then analyzed by 
western blot with K4 or K18 antibody (L2 antibodies that can recognize aa 20-
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38 of most HPVs L2 contained in the structure) to verify the L2 epitopes, and 
with a monoclonal antibody against the Pf Trx scaffold (data not shown). The 
purity of all the antigen candidates reached 70-80%, the L2 epitopes with L2 
antibody, and Pf Trx structure with a monoclonal antibody against the Pf Trx 
scaffold were confirmed with western blot (data not shown). The purity of all 
antigen was considered sufficient for the subsequent immunization 
experiments (figure 4.3). 
 
 
 
 
 
 
Figure 4.3 SDS-PAGE analyses of nanoparticle antigens. After the production of baculovirus 
of each potential nanoparticle antigens, small scale of H5 insect cells infections were performed 
to determine the quality and correctness of the baculovirus constructs, the red arrows point out 
the target bands. The samples of lanes 1 to 16 are listed in the following table. 
Lane Full name Abbreviation Size 
1 Pf encapsulin-Pf Trx-HPV16 L2 (aa 20-38) Pf EnTrx1mer 43.3 kD 
2 PfTrx-HPV16 L2 (aa 20-38)-Pf ferritin Pf FTrx1mer 35 kD 
3 Pf encapsulin-PV16 L2 (aa 20-38) Pf En1mer 32 kD 
4 HPV16 L2 (aa 20-38)-Pf ferritin Pf F1mer 23.6 kD 
5 Pf encapsulin-Pf Trx-HPV16 L2 (aa 20-38)*3 Pf EnTrx3mer 48 kD 
6 Pf Trx-HPV16 L2 (aa 20-38)*3-Pf ferritin Pf FTrx3mer 40 kD  
7 Pf encapsulin-HPV16 L2 (aa 20-38)*3 Pf En3mer 36 kD  
8 HPV16 L2 (aa 20-38)*3-Pf ferritin Pf F3mer 28 kD 
9 Pf encapsulin-Pf Trx-HPV (HPV16, 18, 31, 33, 35, 6, 
51, and 59) L2 (aa 20-38) 
Pf EnTrx8mer 58.8 kD 
10 Pf Trx-HPV(HPV16, 18, 31, 33, 35, 6, 51, and 59) L2 
(aa 20-38)-Pf ferritin 
Pf FTrx8mer 50.2 kD  
11 Pf encapsulin -HPV (HPV16, 18, 31, 33, 35, 6, 51, and 
59) L2 (aa 20-38) 
Pf En8mer 47 kD 
12 HPV(HPV16, 18, 31, 33, 35, 6, 51, and 59) L2 (aa 20-
38) –Pf ferritin 
Pf F8mer 38.8 kD 
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13 Pf encapsulin with CpoI site (with RsRII restrict enzyme 
cutting site) 
Pf En-CpoI 29 kD 
14 Pf ferritin with CpoI site (with RsRII restrict enzyme 
cutting site) 
Pf F-CpoI 21 kD 
15 native Pf encapsulin Pf En 28 kD 
16 native Pf ferritin Pf F 20 kD 
17 Marker 
After heat treatment, samples were characterized by EM, size exclusion 
chromatography (SEC), and dynamic light scattering (DLS) to determine 
whether the fusion protein would influence the self-assembling ability of 
nanoparticles. The nanoparticle structures of Pf EnTrx3mer, Pf FTrx3mer, Pf 
En3mer, Pf F3mer were observed by electron microscopy (EM), but impurities 
were detected, such as subunits and aggregations; the size exclusion 
chromatography and DLS backed up this finding. All analyses suggested these 
antigens could not assemble properly into nanoparticles after heat treatment, 
even at lower temperature such as 55°C. Changing the condition of purification 
and including an assembly step after the purification was not successful. 
Therefore, for these specific structures, CsCl gradients were employed for the 
purification. In the end, all L2-based nanoparticles antigens were efficiently 
produced with 70-80% purity. However, how heat treatment disrupted the 
assembly ability of theses antigen remains unclear.  
 
 
 
 
Figure 4.3 Purity checked by SDS-PAGE; Antigens were analyzed by SDS-PAGE with 
Coomassie blue staining. Samples in lanes 1 to 14 are as follows: 
Lane Full name Abbreviation Size 
1 Pf encapsulin-Pf Trx-HPV16 L2 (aa 20-38) Pf EnTrx1mer 43.3 kD 
2 Pf Trx-HPV16 L2 (aa 20-38) Pf FTrx1mer 35 kD 
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3 Pf encapsulin- HPV16 L2 (aa 20-38) Pf En1mer 32 kD 
4 HPV16 L2 (aa 20-38)-Pf ferritin Pf F1mer 23.6 kD 
5 Pf encapsulin-Pf Trx-HPV16 L2 (aa 20-38)*3 Pf EnTrx3mer 48 kD 
6 Pf Trx-HPV16 L2 (aa 20-38)*3-Pf ferritin Pf FTrx3mer 40 kD  
7 Pf encapsulin-HPV16 L2 (aa 20-38)*3 Pf En3mer 36 kD  
8 HPV16 L2 (aa 20-38)*3-Pf ferritin Pf F3mer 28 kD 
9 
Pf encapsulin-Pf Trx-HPV (HPV16, 18, 31, 33, 35, 6, 
51, and 59) L2 (aa 20-38) 
Pf EnTrx8mer 58.8 kD 
10 
Pf Trx-HPV(HPV16, 18, 31, 33, 35, 6, 51, and 59) L2 
(aa 20-38)-Pf ferritin 
Pf FTrx8mer 50.2 kD  
11 
Pf encapsulin -HPV (HPV16, 18, 31, 33, 35, 6, 51, 
and 59) L2 (aa 20-38) 
Pf En8mer 47 kD 
12 
HPV(HPV16, 18, 31, 33, 35, 6, 51, and 59) L2 (aa 
20-38) –Pf ferritin 
Pf F8mer 38.8 kD 
13 marker 
14 
HPV(HPV16, 18, 31, 33, 35, 6, 51, and 59) L2 (aa 
20-38)-Pf Trx-OVX313 
Pf Trx8mer 
OVX313 
36 kD 
 Nanoparticle antigens retain their assembly ability after 
protein fusion.  
The delivery systems for the antigens were designed to mimic the properties of 
the pathogens with the aim of increasing the immunogenicity of the antigens 
(Jennings and Bachmann, 2007). In this thesis, I tried to use nanoparticles as 
a delivery system to have the similar dimensions as the HPV virus, such as Pf 
ferritin and Pf encapsulin.  
After purification of the candidates of nanoparticle antigens, SDS-PAGE, 
negative transmission electron microscopy (TEM), dynamic light scattering 
(DLS) analysis, and size exclusion chromatography (SEC) analysis were 
performed.  
EM analysis revealed that Pf EnTrx1mer, Pf FTrx1mer, Pf En1mer, Pf F1mer, 
Pf EnTrx3mer, Pf FTrx3mer, Pf En3mer, Pf F3mer, Pf encapsulin-Cpo, and Pf 
ferritin-Cpo , the native Pf encapsulin; and the native Pf ferritin after heat 
treatment, formed smooth spherical cage structures and the size of these 
nanoparticles in the same antigen sample were uniform (figure 4.4). However 
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there were also a large number of subunits present as well (figure 4.4). For 
further investigation and to prove that the L2 epitopes are displayed on the 
surface of the nanoparticles, an immune transmission electron microscopy 
(TEM) was performed. The L2 epitopes were indeed displayed on the 
nanoparticle surface as shown by immune EM with anti-L2 antibody K4, 
detected with anti-mouse IgG (rabbit) which is coupled with gold (figure 4.5).  
 
 
 
 
 
 
 
 
 
 
Figure 4.4 The uniform size of nanoparticle antigens was analyzed by EM. The grey bar 
represents 100 nm, and the red arrows refer to nanoparticles. 
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Figure 4.5 L2 epitopes verified by anti-L2 K4 immune EM. The left panel are the TEM image 
of nanoparticles coupled without anti-L2 K4 antibody linked anti-mouse IgG (rabbit) with 
immune-geld labeling. The right panel are the nanoparticle TEM coupled with anti-L2 K4 
antibody linked anti-mouse IgG (rabbit) with immune-gold labeling. (Electron dense particles in 
right panel).  The grey bar represented 100 nm.  
To further determine the formation of the nanoparticles, size exclusion 
chromatography (SEC) was performed. Results of SEC provided further 
evidence that there were un-identified structures in some samples after thermal 
purification, such as subunits of nanoparticles, or miss-assembled particles. For 
these samples, an alternative purification strategy was employed, using a two-
step density sucrose and CsCl gradient ultracentrifugation. More uniformly 
sized nanoparticle structures were found in these samples, especially for the Pf 
F3mer. There was only one structure detected in Pf EnTrx3mer, Pf FTrx3mer, 
and Pf FTrx8mer samples by SEC. However, as we observed with TEM, there 
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were several structures of different sizes in Pf EnTrx8mer and Pf En8mer 
preparations (figure 4.6). Pf FTrx8mer was purified by the heat treatment 
protocol, and the TEM images confirmed uniform size distribution and a smooth 
spherical cage, DLS showed the Pf FTrx8mer nanoparticles had a limited size 
distribution, which was consistent with the TEM results (figure 4.5). The SEC 
and DLS also confirmed there were neither subunits nor misshapen particles in 
these samples (figure 4.6 and 4.7). However, any nanoparticle for the Pf 
EnTrx8mer, or the Pf En8mer could not be found.  
 
 
 
 
 
 
 
 
Figure 4.6 Size exclusion chromatography (SEC) analysis of Pf FTrx8mer, Pf EnTrx8mer, 
and Pf Trx8mer OVX313. Chromatograms of Pf FTrx8mer, Pf EnTrx8mer, and Pf Trx8mer 
OVX313. A), a marker fractionated on a high resolution gel filtration column; thyroglobulin (669 
kD); APO ferritin (443 kD), β-amylase (200 kD), dehydrogenase (150 kD), albumin (66 kD), 
anhydrase (29 kD) were utilized as calibration standards; B)-D), Pf FTrx8mer, Pf EnTrx8mer, 
and Pf Trx8mer OVX313 fractionated on the column, respectively. The blue arrows on Marker 
SEC indicated the positions of proteins in different sizes. The blue arrows in B; C, D indicated 
the positions of nanoparticles antigens.   
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Figure 4.7 Size exclusion chromatograph (SEC) analysis of Pf FTrx8mer and SDS-PAGE 
verified fraction 1-24. A) Chromatograms of Pf FTrx8mer, fractionated on the column, the blue 
arrow pointed the fractions of nanoparticles of Pf FTrx8mer, B) Fractions analyzed by SDS-
PAGE staining with Coomassie blue. The major peak represents the nanoparticle Pf FTrx8mer.  
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Figure 4.8 Dynamic light scattering (DLS) reveals a homogeneous structure of 
nanoparticle antigens. Pf FTrx8mer A) and Pf Trx8mer OVX313, B) were found in uniform 
size, which are around 20nm and 12nm, respectively. But when analyzing Pf EnTrx8mer, which 
the nanoparticle of Pf EnTrx8mer should be bigger than 25 nm, there are two peaks indicating 
that this antigen preparation contains subunits or misassembled structures C), ,  indicating this 
antigen preparation contains subunits or miss-assembled structures.  
 Immunogenicity of L2-based nanoparticle antigens is 
adjuvant dependent. 
Adjuvants are already extensively used in vaccines, however, there are 
properties of adjuvants to be considered. On the one hand adjuvants help to 
improve the immunogenicity of antigens, but on the other hand, using adjuvants 
may cause problems in antigen formulation and administration. To determine 
whether L2-based nanoparticle antigens require the use of adjuvants. The best 
immune stimulating adjuvants were investigated with HPV16 trimer in context 
of L2-based nanoparticle antigens had been investigated. The candidates 
included: AddaVax, a squalene-based oil-in-water emulsion, stimulating both 
Th1 and Th2 immune responses, Aluminum hydroxide (Alum), inducing 
humoral immune responses and Alum in combination with monophosphoryl 
lipid A (Alum-MPLA), a TLR-4 agonist enhancing IL-10 production.  
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Figure 4.9 The immunization scheme for electing the adjuvants for L2-based 
nanoparticle antigens. Mice were immunized with 20 µg of Pf EnTrx3mer, Pf FTrx3mer and 
Pf Trx3mer OVX313, non-adjuvanted or adjuvanted 50% (v/v) AddaVax, 50 µg Alum, 50 µg 
Alum+ 10 µg MPLA, respectively A). The mice were immunized four times at biweekly intervals. 
Four weeks after the last immunization, sera were collected for L1 PBNA B). 
The animals were immunized with 20 µg of the L2-based nanoparticle antigens 
Pf EnTrx3mer and Pf FTrx3mer, formulated with either (1) no adjuvant, (2) 50% 
(v/v) AddaVax, (3) 50 µg Alum, or (4) 50 µg Alum + 10 µg MPLA (figure 4.9). 
As a comparison, Pf Trx-HPV16 L2 (aa20-38)*3-OVX313 (Pf Trx3mer OVX313) 
with 50% (v/v) AddaVax as adjuvants was used for the immunizations. Mice 
were immunized four times, once every two weeks and blood was collected by 
cardiac puncture four weeks after last immunization. The sera were analyzed 
by L1 PBNA to evaluate neutralizing antibody titers against HPV16, 18, 31, 39, 
45 and 51 PSV. The results indicated that the immune reaction to Pf Trx- L2 
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fused to nanoparticle Pf encapsulin was adjuvant dependent and in 
combination with Alum-MPLA elicited the highest immune responses (figure 
4.10). However, the antigen could not induce cross-protection against HPV31, 
39, 45, and 51. Pf FTrx3mer adjuvanted with 50% AddaVax not only induced 
the highest neutralizing antibodies against HPV16, HPV18, compared to the 
other two adjuvants, but also induced neutralizing antibodies titers against 
HPV45. No neutralizing antibodies against HPV31, 39, 51 were detected (figure 
4.11). Moreover, even without adjuvant, Pf FTrx3mer stimulated neutralizing 
antibody production, and provided protection against HPV16 and 18. To better 
understand which nanoparticle platform was able to induce the strongest 
immune response against HPV, the sera from the mice immunized with Pf 
EnTrx3mer formulated with Alum-MPLA, Pf FTrx3mer formulated with AddaVax 
and Pf Trx3mer OVX313 adjuvanted with AddaVax were tested by L1 PBNA 
side by side. Mice responded to Pf FTrx3mer and Pf Trx3mer OVX313 better 
than to Pf EnTrx3mer; the antibody responses against Pf FTrx3mer and Pf 
Trx3mer OVX313 were, however, comparable (figure 4.12).  
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Figure 4.10 Pf EnTrx3mer formulated with Alum-MPLA induced highest neutralizing 
antibody titers against HPV16 and HPV18. Mice immunized Pf EnTrx3mer without 
adjuvant or adjuvanted with Addavax, Alum, and Alum-MPLA, and sera were analyzed with 
L1 PBNA 4 weeks after last immunization. The symbols represent the neutralizing titers of 
individual mice. The means of the titers for each group are indicated by horizontal lines. The 
y axis displays EC50 titers. And a p value of ≤ 0.05 was considered significant.  
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Figure 4.11 Pf FTrx3mer formulated with 50% AddaVax induced highest neutralizing 
antibody titers against HPV16 and HPV18. Mice were immunized Pf FTrx3mer without 
adjuvant or adjuvanted with AddaVax, Alum, and Alum-MPLA, and sera were analyzed with 
L1 PBNA four weeks after the last immunization. The symbols represent the neutralizing titers 
of individual mice. The means of the titers for each group are indicated by horizontal lines. 
The y axis displays EC50 titers. And a p value of ≤0.05 was considered significant.  
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Figure 4.12 Pf FTrx3mer formulated with 50% AddaVax induced highest neutralizing 
antibody titers compared to Pf EnTrx3mer formulated with Alum-MPLA and Pf Trx3mer 
OVX313. Mice were immunized with Pf FTrx3mer formulated with AddaVax, Pf EnTrx3mer 
formulated with Alum-MPLA or with Pf Trx3mer OVX313 formulated with AddaVax. Sera were 
analyzed by L1-based PBNA four weeks after the last immunization. The symbols represent 
the neutralizing titers of individual mice. The means of the titers for each group are indicated 
by horizontal lines. The y axis displays EC50 titers. And a p value of ≤ 0.05 was considered 
significant.  
 Pf thioredoxin is essential for L2-based nanoparticle 
antigens.  
In order to increase the immunogenicity of L2-based HPV prophylactic vaccines, 
the following criteria should be considered: (1) the size of the vaccine, which 
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will influence the antigen uptake by dendritic cells (DC)s and cellular processing, 
(2) how the antigen is transported to the target immune organs, such as lymph 
nodes; (3) whether the antigen targets and activates B cells efficiently to 
produce the antibodies against the antigen; (4) whether the antigen is also 
sufficiently targeted by the DCs (Bachmann and Jennings, 2010). In this thesis, 
nanoparticles consisting of either Pf encapsulin or Pf ferritin were employed as 
the delivery platform to transport and display the L2 epitopes. Both structures 
are theoretically in the suitable size range and thus possess properties for 
increasing the antigen immunogenicity. The antigen structures described above 
all carry the L2 neutralization epitopes inserted into bacterial thioredoxin as a 
primary scaffold raising the question whether there is actually a need for 
thioredoxin for epitope presentation in context of ferritin and encapsulin 
nanoparticles? To answer this question, mice were immunized with Pf 
EnTrx8mer, Pf En8mer adjuvanted with Alum-MPLA (figure 4.14); Pf FTrx3mer 
without any adjuvant and Pf F3mer with/without AddaVax adjuvant (figure 4.13).  
The repetitive L2 epitopes increase the immunogenicity of the nanoparticle 
vaccines, presumably by causing a hyper-activation of B cell receptors. A Pf 
ferritin nanoparticle theoretically presents 24 copies of either Pf Trx-L2 or L2 on 
its surface. An encapsulin nanoparticle presents 60 copies. Both of them would 
sufficiently activate B cells to produce neutralizing antibodies due to the size 
and repetitive epitope presenting pattern. To answer the question of 
thioredoxin’s necessity for the nanoparticles, Neutralizing antibody titers 
against HPV16, 18, and 51 were measured using in the standard L1 PBNA. 
The data demonstrated that the presence of Pf Trx in the nanoparticle vaccines 
confers significantly stronger immunogenicity on the L2 epitopes even 
competing with Pf F3mer adjuvanted with AddaVax (figure 4.13).  
 
4. Results 
104 
 
 
 
  
Figure 4.13 Pf thioredoxin is critical in displaying L2 epitopes on Pf ferritin nanoparticles. 
Mice were immunized with 20 µg Pf FTrx3mer and Pf F3mer, with or without AddaVax, for four 
times at biweekly intervals. Four weeks after the last immunization, sera were collected and 
analyzed by L1 PBNA. The neutralizing antibody titers induced by Pf FTrx3mer without adjuvant 
are significantly higher than those induced by the Pf F3mer, even with the help of the adjuvant 
AddaVax. The symbols represent the neutralizing titers of individual mice. The means of the 
titers for each group are indicated by horizontal lines. The y axis displays EC50 titers. A p value 
of ≤0.05 was considered significant.  
Theoretically, Pf encapsulin would be the more suitable platform for the epitope 
presentation, considering the size of the particle which is 24 nm and also the 
higher repetition of subunits (60 subunits) per particle. However, the results do 
not support this hypothesis. A comprehensive analysis of the immunogenicity 
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was carried out by analyzing neutralizing antibodies against 15 HPV (14 high-
risk HPVs and HPV6). In most cases, only some of the mice responded to the 
vaccine, and limited cross-protection was detected. Neutralizing antibodies 
against HPV31, 33, 51, 56, 58 and 6 could not be detected. 
My former colleagues already confirmed that Guinea pigs showed stronger 
responses against PfTrx-L2-OVX313 antigens than mice (Pouyanfard et al., 
2018). To verify the results of L1 PBNA obtained with the mice sera, the guinea 
pigs were immunized with Pf EnTrx8mer and Pf En8mer adjuvanted with Alum-
MPLA 4 times every two weeks. One month after the last immunization, the 
guinea pigs were sacrificed and sera were collected. At first, the sera were 
tested by L1 PBNA, the results showed Pf EnTrx8mer induced higher titers than 
Pf En8mer. However, the sera failed to neutralize HPV31, 52, and 56 in the 
standard neutralization assay. Therefore a more sensitive neutralization assay 
L2-PBNA was employed. Again, no neutralizing antibodies were detected 
against HPV31 for both Pf encapsulin nanoparticle antigens. At the same time, 
the antibody titers against other HPVs were higher than the titers detected in 
the L1 PBNA confirming the higher sensitivity of the assay (data not shown). 
To sum up all the data, the results showed Pf En8mer failed as a suitable 
nanoparticle platform for presenting L2 epitopes, but Pf EnTrx8mer could 
induce cross-protection against 11 high-risk HPVs and 2 low-risk HPVs in some 
animals (figure 4.14). 
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Figure 4.14 Inclusion of Pf thioredoxin on Pf encapsulin nanoparticles displaying L2 
epitopes increases immunogenicity of the nanoparticle antigens. Mice were immunized 
with 20 µg Pf EnTrx8mer, Pf En8mer, with Alum-MPLA as adjuvant, four times at two weeks 
intervals. Four weeks after the last immunization, sera were collected for L1 PBNA. The titers 
of neutralizing antibodies induced by Pf EnTrx8mer are higher than those induced by the Pf 
En8mer. The symbols represent the neutralizing titers of individual mice. The means of the 
titers for each group are indicated by horizontal lines. The y axis displays EC50 titers. 
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 The Pf FTrx8mer nanoparticle antigen induces neutralizing 
antibody responses against 14 high-risk and one low-risk 
of HPV types. 
After selecting the adjuvant and determining the role of Pf Thioredoxin, we 
wanted to identify the best nanoparticle vaccine and determine the full 
broadness of protection. To allow side by side comparison, mice or guinea pigs 
were immunized with the nanoparticle antigens, and the sera were tested for 
reaction against pseudovirions of 15 HPV types by the L1 PBNA. Additionally, 
the more sensitive L2 PBNA was employed for HPV52, 56 and 31, since 
responses against these types which are generally difficult to detect by the 
standard L1 PBNA. The animals were immunized with either the Pf EnTrx8mer 
with Alum-MPLA as adjuvant, the Pf FTrx8mer with AddaVax, or Pf Trx8mer 
OVX313 with AddaVax as control. Using the insensitive L1 PBNA, the 
antibodies induced by the Pf FTrx8mer and Pf Trx8mer OVX313 were able to 
neutralize 13 high-risk HPVs, and one low-risk HPV. As for HPV56, none of the 
three antigens could induce measurable immune responses as judged by the 
L1 PBNA. The immune responses of mice inoculated by Pf FTrx8mer and Pf 
Trx8mer OVX313 were comparable, but there were some significant 
differences for certain HPVs, like HPV18, HPV58, and HPV59. For these types, 
higher antibody titers induced by Pf Trx8mer OVX313 than by Pf FTrx8mer 
were detected (figure 4.15). For the guinea pigs, a similar pattern was observed, 
no neutralizing antibodies against HPV31, 52 and 56 were detected using the 
L1 PBNA. In the L2 PBNA, however, neutralizing antibodies against HPV31 
induced by Pf FTrx8mer and Pf Trx8mer OVX313 could be detected (figure 
4.16). Unfortunately, L2 PBNA analyses to detect neutralizing antibodies 
against HPV52 and HPV56 could not be performed due to the lack of available 
HPV52 and HPV56 pseudovirions. 
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Figure 4.15 Pf FTrx8mer induced higher titers of neutralizing antibodies than Pf 
EnTrx8mer, and provided broad protection. Mice were immunized with 20 µg Pf EnTrx8mer 
with Alum-MPLA as adjuvant, Pf FTrx8mer with AddaVax as adjuvant, and Pf Trx8mer OVX313 
with AddaVax as adjuvant as control four times at two weeks intervals. Four weeks after the 
last immunization, sera were collected and analyzed by L1 PBNA. Pf FTrx8mer was highly 
immunogenic, comparable to Pf Trx8mer OVX313. Symbols represent individual neutralizing 
titers of mice for the HPV types indicated. The means of the titers for each group are indicated 
by horizontal lines. The y axis displays EC50 titers. A p value of ≤0.05 was considered 
significant.  
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Figure 4.16 Pf FTrx8mer with AddaVax as adjuvant induced high titers of neutralizing 
antibodies, and provided broad protection. Guinea pigs were immunized with 50 µg Pf 
EnTrx8mer with Alum-MPLA as adjuvant, Pf FTrx8mer with AddaVax as adjuvant, and Pf 
Trx8mer OVX313 with AddaVax as adjuvant as control for four times at two weeks intervals. 
Four weeks after the last immunization, sera were collected and analyzed by L1 PBNA and L2 
PBNA. Pf FTrx8mer was highly immunogenic, and comparable to Pf Trx8mer OVX313. 
Symbols represent individual neutralizing titers of guinea pigs for the corresponding HPV types. 
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The means of the titers for each group are indicated by horizontal lines. The y axis displays 
EC50 titers.  
 Time course of the development of neutralizing antibodies. 
Early analysis of sera in some of the immunization experiments shown above 
indicated that the Pf FTrx8mer induced higher titers than the control Pf Trx8mer 
OVX313 antigen, but these difference disappeared after the completion of the 
full immunization schedule. These results promoted me to further investigate 
the kinetics of antibody responses. Mice were immunized with Pf FTrx8mer and 
Pf Trx8mer OVX313 both with AddaVax as adjuvant and blood was collected 
one week after every immunization and one day before the next immunization 
(figure 4.17 A and B). The final blood was collected on day 70, one month after 
the last immunization. The sera were examined for neutralizing antibodies 
against HPV16 pseudovirions by L1 PBNA. Interestingly, there was a robust 
boost in titers after each immunization with Pf Trx8mer OVX313, however, there 
was a different trend for the mice which were immunized with PfFTrx8mer was 
antibody titers increased during the first three immunizations, however, the 
antibodies decreased after the fourth immunization (figure 4.17C). Moreover, 
the neutralizing antibody titers induced by Pf FTrx8mer were higher than those 
induced by Pf Trx8mer OVX313 on day 35 and 41. Afterwards, this superiority 
was lost.  
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Figure 4.17 Time course of neutralizing antibody development. A) Mice were immunized 
four times at two weeks intervals with 20 µg Pf FTrx8mer and Pf Trx8mer OVX313 with 
AddaVax as adjuvant. B) On Day 7, 13, 21, 27, 35, 41, and 49, intermediate blood was collected, 
and on day 70, the final blood was collected for the HPV16 L1 PBNA. C) the neutralizing 
antibody titers induced by Pf FTrx8mer were higher than those induced by Pf Trx8mer OVX313 
on day 35 and day 41. After this, the differences were no longer observed. Symbols represent 
individual neutralizing titer of mice for HPVs, respectively. The means of the titers for each 
group are indicated by horizontal lines. The y axis displays EC50 titers. A p value of ≤0.05 was 
considered significant. **, p value <0.01. 
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 Pre-immunization with Pf ferritin interferes with the 
neutralizing antibody response induced by the Pf 
FTrx8mer. 
In the previous experiment, a decreasing or even negative effect of booster 
immunization using the antigens based on the Pf ferritin scaffold was observed 
and I hypothesized that this might be due to antibodies evoked against the 
scaffold itself. To verify this, mice were immunized with Pf ferritin (without L2 
epitopes) for three times every two weeks to induce an antibody response 
against the empty ferritin scaffold. A control group was injected with PBS. After 
the pre-immunization with Pf ferritin (pre-immunized group) or PBS (non-pre-
immunized group), the mice were immunized with Pf FTrx8mer with adjuvant 
another 3 times. One month after the last immunization, the mice were 
sacrificed and the sera were collected and analyzed by L1 PBNA (figure 4.18). 
The results showed that the neutralizing antibody titers of the mice that received 
the pre-immunization led to a reduced immune response against the L2, of both 
HPV16 and 18. This suggests that the pre-immunization with Pf ferritin 
nanoparticle antigen interfered with neutralizing antibody production against the 
Pf FTrx8mer which might pose a limitation of the use of the Pf ferritin platform 
in the future.  
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Figure 4.18 Pre-immunization against the ferritin scaffold interfered with the induction 
of neutralizing antibodies. Mice were immunized three times with PBS or Pf ferritin. Then 
animals were immunized with Pf FTrx8mer. All the immunizations were with 50% AddaVax as 
adjuvant. One month after the last immunization, the sera were collected and antibody titers 
against HPV16 and HPV18 were analyzed by the L1 PBNA. The symbols represent the 
neutralizing titers of individual mice. The means of the titers for each group are indicated by 
horizontal lines. The y axis displays EC50 titers. A p value of ≤0.05 was considered significant.  
 Neutralizing antibodies induced by the L2-based 
nanoparticle antigen Pf FTrx8mer are stable over 1 year 
after immunization.  
The HPV VLP vaccines induce a high level of neutralizing antibodies with high 
avidity, which can leak into the mucosal surfaces. This is how HPV vaccines 
provide protection against natural infection (Artemchuk et al., 2019; Petaja et 
al., 2011; Schwarz et al., 2010). The duration of the immune response induced 
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by the vaccines determines the timing of the boost doses in order to achieve 
the strongest immune protection to cover the vulnerable time span of infection 
during the whole life, or at least the time of life in which most of the HPV 
transmissions occur. For HPV vaccines, several studies indicate that the 
antibody titers induced by the HPV VLP vaccines can last for at least eight years 
(Ferris et al., 2014; Nygard et al., 2015). In order to determine the duration of 
immunity induced by the best L2-based nanoparticle candidate antigen, mice 
were immunized with Pf FTrx8mer and compared to mice immunized with Pf 
Trx8mer OVX313. The mice were immunized three times every two weeks, one 
month after the last immunization intermediate blood samples were collected 
and one year after the last immunization the final blood samples were taken. 
All sera were tested by L1 PBNA. The neutralizing antibody titers induced by Pf 
FTrx8mer and Pf Trx8mer OVX313 were robust and comparable, which was 
consistent with former results. The antibodies decreased over time after one 
year the titers were around 1/10 of values after one month. However, one year 
later, the neutralizing antibodies against HPV16 were still detected in nine out 
of ten mice of both groups; and antibodies against HPV18 were detected in 
seven out of ten mice which were immunized with Pf FTrx8mer and 6 out of 10 
mice which were immunized with Pf Trx8mer OVX313 (figure 4.19).  
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Figure 4.19 L2-based Pf ferritin nanoparticle antigen can induce long term protection 
against HPV16 and HPV18. Mice were immunized with Pf FTrx8mer or with Pf Trx8mer 
OVX313 with 50% AddaVax as adjuvant three times every two weeks. One month and one 
year after the third immunization, the intermediate and final blood sample was collected for L1 
PBNA. The symbols represent the neutralizing titers of individual mice. The means titers for 
each group are indicated by horizontal lines. The y axis displays EC50 titers.  
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 Neutralizing antibodies induced by L2-based nanoparticle 
antigen Pf FTrx8mer can provide cross-protection against 
HPVs infection in a cervico-vaginal challenge model.  
The data presented above provide evidence in both mice and guinea pigs that 
proves that neutralizing antibodies induced by the Pf FTrx8mer nanoparticle 
antigens are produced in high titers and are cross protective against several 
HPV according to the L1 PBNA and L2 PBNA assays. To evaluate the efficacy 
of Pf FTrx8mer nanoparticle antigens in cervico-vaginal challenge models, 
passive transfer of immune sera from guinea pigs, immunized with the Pf 
FTrx8mer nanoparticle antigens, to naïve mice was performed. Sera from two 
immunized guinea pigs were pooled and passively transferred into mice 
intraperitoneally followed by a challenge with HPV16, 18, 33, 39, 45, 51, 56, 6, 
and 11 pseudovirions, respectively. Pre-immune sera were used as control. 
The degree of infection was determined by luciferase activity two days after the 
HPV pseudovirions instillation. The luminescence signals were measured in 
vivo by IVIS. Passively transferred sera from guinea pigs immunized with the 
Pf FTrx8mer nanoparticle antigens provided protection against all the HPVs we 
tested in a 1:40 dilution (figure 4.20).  
 
 
 
 
 
 
 
4. Results 
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Results 
122 
   
   
   
4. Results 
123 
Figure 4.20 Transfer of sera of guinea pigs immunized with Pf FTrx8mer can provide 
protection against HPV infection in vivo. A pool of sera from 2 guinea pigs which were 
immunized with the Pf FTrx8mer and the sera of mice which were not immunized as control 
was passively transferred into mice which were then infected with HPV PSV intravaginally. The 
antibodies elicited by Pf FTrx8mer afforded broad protection against the HPV PSV infection 
compared to sera from pre-immunized mice. The y axis displays the average radiance 
measured as photons per second per square centimeter per steradian. The representative 
images showed the magnitude of vaginal infections. The color scale shown on the right 
indicates the intensity of luciferase expression, an ROI analysis for average radiance (photons 
per second per square centimeter per steradian) was performed with Living Image 2.50.1 
software. Due to the different in vivo transduction activities of the various HPV pseudovirions 
types, different scales were used. A p value of < 0.05 was considered significant. *. 
 Antibodies induced by Pf FTrx8mer do not cross-react with 
human ferritin.  
Given that the sequence homology between Pf ferritin and human ferritin is 
26.7%, and between the thioredoxin is, I was concerned that using either Pf 
ferritin or Pf thioredoxin could possibly cause an autoimmune reaction. To verify 
this, multiplex serology, a high-throughput bead-based fluorescent method to 
detect antibodies simultaneously against multiple antigens in one reaction 
vessel (Brenner et al., 2018; Waterboer et al., 2005), was employed. The 
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human ferritin heavy chain was selected for the development and validation of 
multiplex serology assays. Pf ferritin and human ferritin were expressed as 
recombinant GST-fusion proteins. The mice were immunized four times with 
antigens fused either with or without Pf ferritin, such as Pf Trx8mer OVX313 or 
Pf Trx8mer ferritin, etc.; or fused with or without thioredoxin, such as Pf F3mer 
or Pf FTrx3mer, etc. One month after the last immunization, the mice were 
sacrificed and the sera were either used without prior treatment or after blocking 
with E. coli lysate. The results indicated there is no difference between the 
antibody reactions against human ferritin in the sera of all the mice. But there 
is a significant difference in the antigenicity against Pf ferritin in sera of the mice 
immunized with antigens containing Pf ferritin and antigens containing other 
platforms. Similar results were found for human thioredoxin and Pf thioredoxin. 
The results indicated that the antibodies induced by the Pf FTrx8mer are 
targeting neither human ferritin nor human thioredoxin (figure 4.21).  
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Figure 4.21 Quantitative antibody measurements (MFI) with reference to sero status in 
ferritin and thioredoxin species-specific monoplex serology. A), Pf ferritin was loaded on 
the beads; B), human ferritin was loaded on the beads; C), human thioredoxin was loaded on 
the beads; D), Pf thioredoxin was loaded on the beads. The beads were either not pretreated 
or blocked with E. coli. Although the immunization with Pf ferritin or Pf thioredoxin induced 
strong responses against these Pf proteins, the antibodies did not cross-react with the human 
counterparts. 
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 Discussion 
 The current status of commercial vaccines and the need 
for second generation prophylactic HPV vaccines.  
Unquestionably, current commercial HPV virus like particles (VLP) vaccines are 
immensely powerful strategies to prevent HPV-associated cancers. After 
implementation of HPV vaccinations in the last decade, the morbidity and 
mortality of HPV-related diseases has dramatically decreased (Hall et al., 2019). 
Currently, there are three prophylactic HPV vaccines on the market (a 2-valent 
HPV vaccine (HPV16/18) called Cervarix; a 4-valent HPV vaccine (HPV6, 11, 
16 and 18) called Gardasil/Silgard, and a nonavalent HPV vaccine (HPV6, 11, 
16, 18, 31, 33, 45, 52, and 58) called Gardasil 9, which are all HPV VLPs 
vaccines). All of them have been proven safe and highly immunogenic. They 
can provide protection against HPVs that are responsible for almost 90% of 
cervical cancers. Moreover, the 4-valent and nonavalent HPV vaccines contain 
VLPs of HPV6 and HPV11, which are the two main types mainly causing benign 
genital warts. There is also research illustrating that the neutralizing antibodies 
induced by Cervarix and Gardasil can stably protect from infection up to at least 
8 years (De Carvalho et al., 2010). However, the cross-protection against the 
HPVs not included in the vaccines is limited. The bivalent VLPs vaccine can 
provide restricted cross-protection against HPV31, 33 and 45 (Brown et al., 
2009; Wheeler et al., 2009), but the cross-protection induced by the 4-valent 
vaccine against HPV31, 33 and 45 is even lower. It is still not clear whether the 
nonavalent vaccine can also induce cross-protection against the HPVs not 
included in the vaccine.  
As of the 4th October, 2018, there are 91 countries that have included the HPV 
vaccine in their national immunization program, which also means that more 
than half of the countries in the world failed to do so (Sterbenc et al., 2018). 
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There are several reasons that may cause this unfortunate situation. First of all, 
the high cost of HPV vaccination is the main reason why most developing 
countries can still not benefit from it. This is such an important challenge to 
overcome since the majority of cervical cancers occurs in these developing 
countries. Secondly, it is difficult to reach the target population and make the 
vaccine schedule endurable. According to World Health Organization 
guidelines, the HPV vaccine needs to be administered in at least 2 doses to the 
population which is younger than 15 years and 3 doses to those who are over 
15 years of age in order to induce efficient immune responses against possible 
HPV infections later in life. The multiple immunizations over a long period hinder 
the compliance of patients (Meites et al., 2016). Thirdly, in many developing 
countries, the healthcare infrastructure including the vaccination system is not 
well established for adolescent vaccinations (Meites et al., 2016; Sterbenc et 
al., 2018).  
Despite the success of the current commercial vaccines, the drawbacks drive 
a lot of efforts on developing second generation HPV vaccines that provide 
protection against more HPVs and push the use of HPV vaccines in developing 
countries. Different strategies have been used for this development. One of the 
strategies is trying to produce the VLPs in an E. coli system which lowers the 
cost of manufacture and speeds up the cycle of production. There is a trivalent 
HPV VLPs vaccine generated in an E.coli system currently being studied in a 
rhesus macaque model for immunogenicity and dosing (Yin et al., 2017). This 
trivalent prophylactic vaccine contains three different types of VLPs: HPV16, 
18, and 58. The reason HPV58 was included might be that it’s the third most 
prevalent HPV related to cervical cancer in Asia, but is hardly found it in other 
regions. Therefore, the vaccine is targeting the Asian markets, such China, 
Japan and Korea (Yin et al., 2017). 
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Research has revealed that the minor capsid protein L2 is less type specific 
and can therefore induce broader immune responses than the L1 capsid protein 
(Day et al., 2012). However, the immunogenicity of L2 is far lower than that of 
L1 VLPs due to the linear nature of the conserved epitopes which is used to 
elicit the cross-neutralizing antibodies. There is a lot of research going on to 
optimize the presentation of L2 epitopes to the immune system in order to 
increase their immunogenicity without compromising the cross-protection. The 
most well-known region of L2 cross-neutralizing epitope is aa17-36, which is 
located at the L2 N-terminus and is conserved among several HPVs (Gambhira 
et al., 2007). Efforts have been made focusing on the presentation of this region 
of L2 to B cells repetitively, to evoke sensitivity and stronger immunogenicity. 
One approach was by the attempt to insert the L2 epitopes into the DE loop of 
L1 VLPs of HPV16 in order to increase cross-protection (Schellenbacher et al., 
2013; Schellenbacher et al., 2009) without losing the high immunogenicity of 
L1 VLPs. Other authors used the capsomeres which contain both L1 and L2 
epitopes. They can be produced in E.coli reducing the cost of production and 
their thermal stability is higher than that of VLPs, which makes the distribution 
easier, and more cost efficient. Unfortunately, this method compromised the 
cross-protective ability (Wu et al., 2011). Other approaches are displaying the 
L2 epitopes on adeno-associated virus particles (Jagu et al., 2015), or using 
bacteriophages to present the L2 epitopes (Tumban et al., 2011), or simply 
conjugating a longer portion of L2 which contains the cross protective regions 
from different HPVs (Jagu et al., 2009; Jagu et al., 2013). 
In our group, we focus on how to improve the immunogenicity of L2 epitopes 
without compromising the ability to elicit cross-protection. We already proved 
that using Pf thioredoxin as a platform to display the L2 epitopes (aa20-38) 
increases the immunogenicity (Rubio et al., 2011) and multimerizing the L2 
epitopes, using aa20-38 from different HPVs can induce broad cross-protection 
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among oncogenic HPVs (Seitz et al., 2014). For further improvement, we 
employed the heptamerization platform OVX313 as the second platform, and 
instead of one type of L2 epitope, we conjugated the L2 (aa20-38) epitopes of 
eight different HPVs to Pf Trx. We achieved efficient protection against fourteen 
high-risk HPVs and two low-risk HPVs.  
The work of this PhD thesis focuses on further developing second generation 
prophylactic vaccines based on the minor capsid protein L2 by employing 
nanoparticle platform. Nanoparticles are used to present L2 (aa20-38) epitopes 
to improve L2 immunogenicity and obtain broad protection against all of the 
high-risk and two low-risk (HPV6 and HPV11) HPVs. An additional aim was that 
the vaccine would be cost-effective, and thermally stable.  
 Pyrococcus furiosus ferritin as a promising nanoparticle 
to present L2 epitopes. 
The protection provided by prophylactic vaccines depends on IgG expression 
or production and the classical development of prophylactic vaccine optimizes 
for the B cell responses. In order to induce efficient protective responses. The 
various steps are involved. With the aim of activating both T cell and B cell 
responses, the principle of vaccine design is trying to have (1) a similar size to 
the native pathogen, (2) repetitive epitopes to stimulate B cells responses, and 
(3) the vaccine needs to be recognized by antigen presenting cells and 
activates T helper cell to help B cells to produce antibodies.  
5.2.1 The effects of the nanoparticle size of on the immunogenicity of L2-
based antigens 
In order to stimulate immune responses, the antigens size has several effects: 
i. The suitable size of the antigen helps the uptake and processing by 
antigen presenting cells. 
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There are two ways to elicit immune response by vaccination. One is activating 
B cells directly by interaction with the B cell receptors, the other is the vaccine 
antigen uptake by antigen presenting cells (APCs), which is then degraded into 
peptides, and further presented by MCH II that induce CD4+ T helper cell 
responses, which finally induce B cells to produce antibodies against the 
infection (figure 5.1). To stimulate T cell responses, the antigen needs to be 
taken up by APCs, mainly dendritic cells (DCs), these then travel to the lymph 
nodes and trigger DC maturation to generate potent immune responses. It has 
been proven that APCs cannot take up and present small soluble proteins 
efficiently. In contrast, particles which have similar sizes as the pathogens can 
be taken up and presented by APCs efficiently (Kovacsovics-Bankowski et al., 
1993; Swartz et al., 1996; Unanue, 1981). 
ii. The antigen with the right size can be transported efficiently to secondary 
lymphoid organs.  
The general methods of vaccine administration are injections either 
subcutaneously or intramuscularly. Then in order to activate the immune 
responses, the antigen needs to be transported to lymphoid organ through 
lymphatic system. There are several factors that affect the efficiency of the entry 
of antigens into the lymphatic vessels, one of the important factors is the size 
of the antigen. The optimal size of the antigen which can efficiently enter into 
the lymphatic system is ~40 nm (Oussoren et al., 1997; Reddy et al., 2006; 
Swartz, 2001). If the antigen is too small (<10 nm), it will directly enter the blood 
circulation system after injection; if the antigen is too big (>200 nm) it cannot 
efficiently enter the lymphatic system since a special carrier is needed to help 
do so, and thus the antigen takes more time to reach the lymph nodes(Reddy 
et al., 2007). 
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From Bachmann, M.F. and G.T. Jennings, Nat Rev Immunol, 2010. 
Figure 5.1 The process of the protective immune responses induced by antigens 
(Bachmann and Jennings, 2010). In order to generate efficient immune responses, there are 
steps and critical factors of the antigen that affect the procedure. a) the size and the epitopes 
repetitive organization would affect the efficiency of antigens uptake by DCs; b) to activate B 
cells, the antigens’ size and the repetitive epitope displayed on the surface of antigens, and the 
pathogen-associated molecules pattern (PAMPs) influence the efficiency of direct activation of 
B cells by the antigens; c) Toll-like receptors (TLRs) and other receptors which are also used 
for pattern-recognition of the antigen PAMPs for APCs activation; d) T helper cells activation is 
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influenced by the prolonged presence of antigens; e) T helper cells play an essential role in the 
activation of B cells for antibody generation.   
iii. The size of antigen directly affects B cell activation. 
There are three critical points for the B cells activation. At first, the antigen 
needs to stay in its native configuration when the B cell follicles access it in the 
lymph nodes. Second, a repetitive structure can facilitate the cross-linking of B 
cell receptors, which is a strong signal for B cells activation (Bachmann et al., 
1993; Chackerian et al., 2001; Leadbetter et al., 2002). Third, Toll-like receptor 
ligands can improve antibody production (Eckl-Dorna and Batista, 2009; 
Leadbetter et al., 2002; Pasare and Medzhitov, 2005).  
 
 
 
 
 
 
From Spagnoli, G. Reformulation of a thermostable broadly protective recombinant vaccine 
against human papilloma virus. 2016. 
Figure 5.2 Different structures of platforms to present HPV antigen (Spagnoli, 2016). The 
realistic size of different epitopes presenters.  
To optimize the L2-based antigen, the nanoparticles Pf encapsulin and ferritin 
are employed in this thesis, the sizes of these nanoparticles are 24 nm and 10 
nm in diameter, respectively (figure 5.2). Pf encapsulin we used in this thesis is 
assembled by 60 copies of the subunits, and 24 copies of the subunit assemble 
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into one Pf ferritin nanoparticle. The OVX313, a heptamerization domain, has 
been used for vaccines and immunotherapies, here all antigens are in the 
optimum dimensions in order to target adaptive immune responses. The HPV 
L2 epitopes conjugated with or without Pf thioredoxin were inserted at the C-
terminus of Pf encapsulin and N-terminus of Pf ferritin. Theoretically, there are 
60 copies and 24 copies of L2 epitopes displayed on the surface of 
nanoparticles, respectively. One of the reasons behind the high immunogenicity 
of HPV VLP vaccines is that the size of VLPs resembles that of authentic native 
HPV viruses, which is 60 nm in diameter, and can thus be taken up by APCs, 
transported to the lymph node and activate B cells. Encapsulin with Pf Trx-HPV 
L2 (aa20-38) insertions assembles into a larger structure than that of the native 
encapsulin (section results 4.2), reaching a similar dimension of VLPs, which 
can improve the recognition and presentation of L2 epitopes. Pf ferritin is 
smaller than Pf encapsulin with a diameter of 10 nm and with the L2 epitopes 
its size is also slightly bigger than native Pf ferritin. The heptamerized Trx-L2 
antigen is smaller than Pf ferritin and presents eight copies of L2 epitopes 
(section 4.2). According to the structural prediction, the OVX313 supermolecule 
is much smaller than Pf ferritin, Pf encapsulin and VLPs (figure 5.2). 
Surprisingly, the DLS and SEC shows a different picture. The DLS results 
indicated the diameter of Pf Trx8mer OVX313 to be 12 nm, which is much 
bigger than the native OVX313 which is around 5 nm, which may be due to the 
Pf Trx8mer attachments, and the results of SEC supported this. As for Pf 
encapsulin, nicely assembled nanoparticles of Pf EnTrx1mer and Pf EnTrx3mer 
were found by TEM, but subunit structures were also observed and the results 
were verified by SEC and DLS. Unfortunately, nicely assembled nanoparticles 
of Pf EnTrx8mer could not be found by TEM. SEC and DLS also showed there 
were un-uniform structures in the antigens. With Pf ferritin, nicely assembled 
nanoparticles with all the constructs were produced. The size of nanoparticles 
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was uniform, such as the diameter of Pf FTrx8mer being 20nm, which is twice 
as big as the native Pf ferritin. Theoretically, all the nanoparticle antigens, 
except the Pf EnTrx8mer, are in the right size for uptake and processing by 
APCs, trafficking to lymph nodes, and interacting with B cells directly to elicit 
adaptive immune responses.  
5.2.2 The highly organized and repetitive nature of the L2 epitopes helps 
recognition by B cells and T cells. 
72 capsomeres assemble into one HPV VLP. These consist of L1 in a highly 
organized and repetitive manner, similar to that of the native HPV virus. It can 
efficiently activate B cells and T helper cells since both of them can recognize 
this significant structure. To activate B cells, the highly repetitive patterns of the 
VLPs surface play a very important role (Bachmann and Zinkernagel, 1997).  
They can activate the cross link of B cell receptors, passing the strong signal to 
B cells in order to activate them. The research shows that in order to activate B 
cells, the ideal geometry are the 15-20 hapten molecules which are spaced 5-
10 nm apart (Vogelstein et al., 1982). VLPs share a similar geometry to the 
HPV viral capsid proteins which are in the average space to activate B cells 
(Bachmann and Jennings, 2010). This is another explanation of the high 
immunogenicity of VLP vaccines. With this in mind, I designed the nanoparticles 
displaying L2 epitopes in the 5-10 nm space to optimize the antibody responses. 
Pf encapsulin nanoparticles present 60 copies of L2 epitopes on their surface. 
The geometry of the L2-based Pf encapsulin nanoparticle antigens are similar 
to VLPs. Theoretically, they could efficiently cross-link the B cell receptors to 
activate B cells. Pf ferritin only contains 24 subunits, and displays 24 copies of 
L2 epitopes. It is smaller than Pf encapsulin and VLPs, but I presumed it should 
be better than Pf Trx8mer OVX313 which only presents eight copies of L2 
epitopes.  
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However, the immunogenicity of L2-based Pf encapsulin antigen did not show 
the superiority over the other smaller particles. Mice were immunized with three 
different constructs displaying Pf Trx-HPV16 L2 (aa20-38)*3 and the immune 
responses were evaluated by L1 PBNA (section 4.3). The results showed that 
Pf Trx3mer OVX313 induced a significantly higher response against HPV16 
than Pf EnTrx3mer did. Moreover, Pf FTrx3mer provided more cross-protection 
against HPV45 than Pf EnTrx3mer (section 4.3). The size of all three particles 
is within 10-50 nm and all in an efficient range, and it would be expected that 
the encapsulin construct would be more immunogenic than the other two if one 
would only consider the impact of size, since bigger antigens can be recognized 
by APCs more efficiently. A potential explanation of this surprising outcome is 
that the different immune responses induced by the three particles are 
influenced by the orientation of the Pf Trx-HPV16 (aa20-38)*3 insertion, which 
determines how the epitopes are being displayed on the surface of the particle 
and the density of packing, especially between nanoparticle Pf encapsulin and 
ferritin. This may influence the epitopes accessibility, how they are approached 
by B cell receptors and how they present to the T helper cells after processing 
by DCs. The distance of L2 epitopes on Pf ferritin and OVX313 may allow better 
cross linking of B cells receptors to further increase the stimulation of B cells. 
Another explanation of why the immunogenicity of Pf Trx3mer OVX313 is high 
even as a small antigen is that the central core domain of OVX313 has been 
proven to contribute to binding of the antigen to CD40 on B cells (Brodeur et al., 
2003).  
 The L2-based prophylactic nanoparticle vaccines are 
adjuvant dependent.  
Adjuvants have been used to increase the immunogenicity of vaccines for more 
than 100 years. One function of adjuvant employment during the vaccination is 
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to create an antigen depot, which means it can prolong the antigens exposure 
to the immune system. As mentioned before, the IgG responses induced by 
antigens are T helper cells dependent, so the adjuvant role here is to boost T 
helper cells responses by acting as an antigen depot rather than stimulate B 
cells directly (Zinkernagel, 2003). There are many kinds of adjuvants employed 
in vaccines, they all have different applications as immune-stimulators or 
antigen depots (figure 5.3).  
 
 
 
 
From Guy, B., Nat Rev Microbiol, 2007. 
Figure 5.3 Different properties of adjuvants (Guy, 2007). The main properties of adjuvants 
are antigens depots, carriers and immunostimulators. Those that can stimulate T helper 
responses are shown with red background. ISCOMs, immunostimulating complexes; O/W; oil-
in-water emulsion; PRR, pattern-recognition receptor; TLR, Toll-like receptor: W/O, water-in- 
oil emulsion.  
Despite the boosting effect that adjuvants provide, there are also some 
limitations or complications that the adjuvants may cause in vaccination. The 
adjuvant may complicate the vaccine formulation procedure, which makes the 
vaccine more expensive, or may cause acute reactogenicity and toxicity issues 
(Guy, 2007). 
In this thesis, in order to find out whether the nanoparticle antigens would still 
require adjuvants to help reach efficient immune responses, three adjuvants 
were tested with L2-based nanoparticle antigens in comparison to plain 
antigens. Alum, acts as an antigen depot and can also stimulate T helper 2 cell 
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responses (HogenEsch, 2002). Alum-MPLA, besides the benefit Alum provides, 
can agitate the TLR4 receptors which can induce both Th1 and Th2 responses 
(Iwasaki and Medzhitov, 2004). The commercial HPV vaccine Cervarix employs 
Alum-MPLA as an adjuvant to further increase the immunogenicity. AddaVax is 
an oil-in-water nano emulsion, generating a pro-inflammatory environment to 
facilitate further immune responses (Tritto et al., 2009).  The adjuvants tested 
with nanoparticle antigens revealed the following results. Pf EnTrx3mer with 
Alum-MPLA as adjuvant induced the highest neutralizing antibodies against 
HPV 16 and HPV18, and limited cross-protection against HPV45. Pf FTrx3mer 
with 50% AddaVax induced the highest titers of neutralizing antibody against 
HPV16, 18 and 45 (section 4.3). Interestingly, mice responded to Pf FTrx3mer 
without any adjuvant. It is possible that the nanoparticle Pf ferritin itself works 
as an antigen depot, and that the T helper epitope, which Pf thioredoxin has, 
can stimulate T helper cells responses, making it self adjuvanted. Later, I 
compared different adjuvants with Pf FTrx8mer, verifying that Pf FTrx8mer was 
able to induce neutralizing antibodies against HPV16 and 18, but the titers 
induced by Pf FTrx8mer with Alum, Alum-MPLA or without any adjuvant were 
lower than with 50% AddaVax, and could not induce cross-protection against 
the HPVs not included in the antigen. Comparing the two nanoparticles, the 
reasons why Alum-MPLA is the best adjuvant to Pf encapsulin, but not for Pf 
ferritin, might be the antigen pH and the isoelectric point. Moreover, ferritin with 
AddaVax’s help creates an immune competent environment which drove more 
antigen presenting cells to the injection site and induced the higher production 
of cytokines and chemokines, which also helps B cells to be stimulated by the 
antigen and produce antibodies. 
 Comprehensive analysis of immunogenicity of L2-based 
nanoparticle prophylactic HPV vaccines  
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5.4.1 Nanoparticles cannot fully substitute for Pf Trx.  
In order to investigate the role of Pf Trx in the nanoparticle platform, the mice 
and guinea pigs were immunized with Pf EnTrx8mer and Pf En8mer with Alum-
MPLA, or Pf FTrx3mer and Pf F3mer with 50% AddaVax. Then the 
immunogenicity of antigens was investigated by using L1 and L2 PBNA. Our 
data indicated that the nanoparticle platforms fused with L2 epitopes in the 
context of Pf Trx scaffold had improved immunogenicity in comparison to the 
L2s displayed on the nanoparticle directly (section 4.4). This finding is 
consistent with our previous findings, which confirms that Pf Trx is an efficient 
platform to present L2 neutralizing epitopes (Pouyanfard et al., 2018). As 
mentioned before, the reason for this meaningful immune response being 
evoked might be the size of the antigens. Without Pf Trx, the size of 
nanoparticles would be smaller, and also Pf Trx contains T cell epitopes, which 
are also important in activating B cells to produce neutralizing antibodies. 
Moreover, the optimal scenario is that the insertion of the active site of the L2 
does not change the structure of Pf thioredoxin, nor the insertion itself, which is 
the likely case here. Despite all the advantages that Pf thioredoxin provides, 
another aspect might be that without Pf thioredoxin as the primary platform to 
display the L2 multimeric epitopes, the orientation of epitopes and how they are 
displayed on the nanoparticles might be changed, which makes some epitopes 
were more difficult to reach and thus affected the immunogenicity of the 
nanoparticle antigens.  
5.4.2 Pf ferritin fused with Pf Trx 8mer is the most immunogenic 
candidate. 
To determine the most immunogenic antigen, the sera from the animals which 
were immunized with Pf EnTrx8mer with Alum-MPLA as adjuvant, Pf FTrx8mer 
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with 50% AddaVax, and Pf Trx8mer OVX313 with 50% AddaVax were analysed 
in cell culture and in vivo assays.  
The cell culture assays are L1 and L2 pseudovirion-based neutralization assays 
(PBNA). The L1 PBNA is the standard PBNA, but shows lower sensitivity. The 
L2 assay was developed to detect L2-specific antibodies of which titers are very 
low in L1 assays. Neutralizing antibody titers in L2 PBNA are 10-20 times higher 
than those in the L1 PBNA. The L2 PBNA tries to mimic the natural HPV 
infection, but the extensive furin cleavage and prolonged exposure of L2 
epitope may not happen during the natural HPV infection in humans. The L1 
and L2 PBNA can only give an indication of the immunogenicity of the antigens 
and the results should be viewed side by side.  
In this thesis, the in vivo challenge assay was also employed to evaluate the 
antigen candidates. The sera of guinea pigs which were immunized with the 
antigen candidates were transferred into naïve mice and these were transduced 
with pseudovirions one day later. This assay is a sensitive and stringent 
measurement of antibody-mediated protection, since neither L1 nor L2 PBNA 
can reflect the natural neutralization of HPVs in vivo in humans, as Joura et al. 
determined. They found undetectable HPV18 L1 antibody in L1 PBNA can still 
neutralize HPV18 in vivo (Joura et al., 2008).  
The mice and guinea pigs sera were tested with thirteen high-risk and one low-
risk HPVs. The antibody titers are displayed on the heat map (table 5.1). Pf 
EnTrx8mer could not induce sufficient antibody production. The reason might 
be that the antigen I immunized the mice with did not form nanoparticles, since 
I could not produce well assembled nanoparticle Pf EnTrx8mer. Thus the L2 
epitopes were not exposed and could not be presented well to activate B cells 
causing the low immunogenicity of Pf EnTrx8mer. However, the results of Pf 
FTrx8mer and Pf Trx8mer OVX313 were comparable with the commonality that 
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none of the mice produced antibodies against HPV56. The reason might be that 
HPV 56 aa20-38 sequences are different from the HPVs included in the 8mer. 
Also, in 6 out of 10 mice, efficient antibodies induced by Pf FTrx8mer against 
HPV 52 could not be detected, but further L2-based neutralization assay may 
reveal the truth of antibodies against HPV52. Additionally it seems like one 
mouse in the Pf FTrx8mer group did not respond well since the mouse could 
not induce antibodies against several HPVs.  
The inbred animal models like BALB/c mouse I employed cannot accurately 
reflect the immune responses to the antigens in humans. Additionally, the T 
helper epitopes and antigen uptake efficiency are also different in different 
animals. To gain a better understanding of how the antigen would behave in 
humans, another animal model, guinea pigs, was also employed. Moreover, the 
guinea pig sera were also tested with thirteen high-risk and two low-risk HPVs 
by L1 and L2 PBNA. The results were consistent with the data from the mice 
experiments. Pf EnTrx8mer still could not elicit efficient neutralizing antibody 
production. For HPV31, I could not detect neutralizing antibodies by the L1 
PBNA, but there were high titers of neutralizing antibody detected in the L2 
PBNA, and the titers of the antibodies induced by Pf FTrx8mer was ten times 
higher than the titers induced by Pf Trx8mer OVX313. But I could not detect 
antibodies against HPV52 and 56 by the L1 PBNA and I could not perform L2 
PBNA due to our supply constraints of HPV52 and 56 pseudovirions. The 
antibody titers in guinea pigs sera are much higher than those in of mice sera 
and in the same sera, the titers detected by L2 PBNA are much higher than 
those analysed in the L1 PBNA.  
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Table5.1 Heatmap of the titers of neutralizing antibodies in mice immunized with Pf 
EnTrx8mer, Pf FTrx8mer, and Pf Trx8mer OVX313 four times at two weeks intervals 
formulated with Alum-MPLA, 50% AddaVax, and 50% AddaVax respectively. Final sera 
were collected one month after the last immunization and titrated in the standard L1 PBNA. 
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Table 5.2 Heatmap of the titers of neutralizing antibodies of guinea pigs immunized with 
Pf EnTrx8mer, Pf FTrx8mer, and Pf Trx8mer OVX313 four times at two weeks intervals 
formulated with Alum-MPLA, 50% AddaVax, and 50% AddaVax, respectively. Final sera 
were collected one month after last immunization and titrated in the standard L1 PBNA and L2 
PBNA.  
 
 
 
 
 
 
 
 
 
In order to verify the neutralizing antibodies in guinea pigs induced by the Pf 
FTrx8mer cervico-vaginal challenge in vivo experiments were performed. 
Guinea pig sera were passively transferred to naïve mice intraperitoneally, then 
the mice were challenged with HPV16, 18, 33, 35, 39, 45, 51, 56, 6, and 11, 
respectively. Guinea pig sera provided clear protection against all HPV 
infections. Even against HPV56 where the neutralizing antibody could not be 
detected by the L1 PBNA, sera from guinea pigs immunized with Pf FTrx8mer 
were able to provide protection against infection in vivo. However, these results 
should be retested in large scale experiments, since there is a variability of the 
infection efficiency in the mice. This inspired another question: at what scale 
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can titer tested in vitro give us an expectation about whether it is sufficient to 
provide protection against natural infection? 
5.4.3 Pf FTrx 8mer could provide long-term protection against HPVs  
The HPV vaccines are mostly administered to young adolescent girls. However, 
women face the risk of HPV infection throughout their whole life, which makes 
the duration of the protection critical to the effectiveness of HPV prophylactic 
vaccines. There is a proof that the current HPV VLPs vaccines can provide 
protection against HPV infection for 8 years after administration of the vaccines. 
Another experiment had to be performed to evaluate if the nanoparticle vaccine 
could offer a similar long term protection. The mice were immunized three times 
with Pf FTrx8mer and Pf Trx8mer OVX313, with 50% AddaVax at two week 
intervals, then the antibody responses checked1 month after the last 
immunization. One year after the last the immunization, the mice were 
sacrificed and the sera were collected for antibody detection. The results 
showed both antigens provide long-term protection against HPV16 and 18 in 
vitro, and the Pf FTrx8mer showed a slight advantage over Pf Trx8mer OVX313, 
but the difference was not significant (figure 4.19). There are several factors 
which influence long-term protection induced by vaccination. In humans, the 
peak of antibody responses induced by vaccination is 1 month after the last 
immunization then the rates decay. The proliferation rate of B cells, the 
immunologic memory of B cells, individual variability in the immunity response 
are all factors that influence the duration of effectiveness of vaccines (De 
Vincenzo et al., 2014). In order to provide long term protection, one important 
aspect of the vaccine is the ability of immune memory development, which also 
means inducing long lived memory immune cells, such as memory B cells, that 
should be activated when an individual is re-exposed to the antigen in a relative 
vigorous infection (Stanley, 2010). Different scenarios are then possible, one 
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can induce memory lymphocytes which may not generate high titers of serum 
antibodies, such as hepatitis B vaccine (Ward et al., 2008); or one could 
continue to provide high titers of neutralizing antibodies by generating long-lived 
plasma cells, with the induction of memory B cells, and then supply antibody-
secreting cell pools, such as HPV VLP vaccines (Stanley, 2010). In the long 
term experiments when the antibody titers were tested one month after the 
three-dose series, all the mice showed high levels of specific anti-HPV antibody 
production, which means the antigens efficiently activate B cells to produce 
anti- antigen antibodies. But one year later, the neutralizing antibodies against 
HPV16 were still detected, which may indicate that these two antigens induced 
the production of long-lived plasma cells, and maybe the production of memory 
B cells, which would need to be tested by a fourth dose. In addition, the results 
of the long-term experiments when gave us further evidence of whether another 
booster would be required, in this case the 3-time dosage proved sufficient.  
 Pf ferritin induced pre-existing anti-ferritin antibodies that 
interfered with anti-L2 antibody production.  
During the experiments, I found that the titers of L2-antibodies tested one week 
after immunizing the mice with Pf FTrx8mer were higher than those of Pf 
Trx8mer OVX313, but one month later this particular advantage disappeared. 
Then the kinetics of the antibody levels had been investigated because the 
fourth booster of Pf FTrx8mer negated the former advantage of this antigen. 
There was a hypothesis that pre-existing antibodies against Pf ferritin would 
interfered with L2-specific antibody production. To test this, two groups of mice 
were immunized 3 times with either Pf ferritin or 1 × PBS with a biweekly interval, 
then both groups were immunized with Pf FTrx8mer. The mice were sacrificed 
and sera were investigated by L1 PBNA for neutralizing antibody detection. The 
results confirmed our hypothesis. The pre-existing anti-ferritin antibodies 
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interfered with the neutralizing antibody production against the HPV L2. As 
discussed before, in order to activate B cells to produce antibodies against 
specific antigens, not only do the antigens need to bear the appropriate B cell 
epitopes to directly activate the B cells, but the epitopes also have to be 
presented to MHC II to stimulate T helper cells activation and maturation in 
order to further activate B cells to produce neutralizing antibodies (Okada et al., 
2005; Parker, 1993; Ruprecht and Lanzavecchia, 2006). The point here would 
be that the epitopes which were recognized by B cells directly, should be the 
same ones to present to T helper cells. Otherwise, the immune response to the 
protein presenter will dominate over the target antigen (Peeters et al., 1991; 
Pobre et al., 2014; Schutze et al., 1985). I think that it is possible that Pf ferritin 
epitopes are also presented to T helper cells, which then interfered with the L2 
specific B cell activation. On the other hand, the primary purpose of the immune 
system is to identify foreign substances, such as antigens. Then the immune 
response induced by the foreign antigens develops a defence against it. The 
whole procedure normally includes antibody production by activating B cells, 
and T cells in order to eliminate the foreign antigens. The influence of the 
antibodies against Pf ferritin may involve both. One reason might be that the 
anti-Pf ferritin hinder the binding of neutralizing antibody, the other possibility 
might be the T cell responses induced by the antigens eliminate themselves 
during further immunization, which makes the boost inefficient.  
 Auto immune responses against human ferritin and human 
thioredoxin 
Safety is always the first concern in vaccine development. Despite the toxicity 
of antigens, there are rising concerns regarding molecular mimicry. Molecular 
mimicry can occur when there is significant similarity between human proteins 
and the proteins contained in vaccines (Kanduc, 2010; Kanduc et al., 2008; 
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Oldstone, 1998). This homology between antigens and self-proteins might lead 
to immune cross reactivity, which means that the antibodies produced by the 
vaccines mean to target the pathogens, they may target the human proteins as 
well, which may cause autoimmune diseases (Agmon-Levin et al., 2009). In an 
attempt to understand the potential ability for vaccine driven autoimmune 
responses, I compared the sequence of human ferritin and Pyrococcus furiosus 
ferritin and it is 27.749% homologous is compared (figure 5.4) Multiplex 
serology was used to detect if the antibodies induced by the antigens recognise 
human ferritin or thioredoxin (section 4.10). The antibodies induced by the 
antigens, especially Pf FTrx8mer did not target human ferritin, and meanwhile, 
all antigens containing Pf Trx induced antibodies that did not target the human 
thioredoxin either. There is no doubt that the relationship between human and 
their disease-inducing micro-organisms is complicated, but this result affirms 
our hopes to further investigate nanoparticles as promising vaccines.  
 
 
 
 
Figure 5.4 Alignment of Pyrococcus furiosus ferritin and human ferritin. Predicted ferritin 
polypeptides from humans are aligned with Pyrococcus furiosus. Amino acids that are identical 
in both are shown with a dark background with ‘*’, closely similar sequences are shown in grey 
with ‘:’.  
 Conclusions & Outlook 
Despite the success of current commercial HPV VLP vaccines, their limitations 
cannot be ignored. These limitation include low cross-protection, cost 
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inefficiency, and need for multiple administrations over a long time period 
causing poor compliance of patients. The L2-based second generation 
prophylactic HPV vaccine approach provides new perspectives to overcome 
these limitations. We fused the Pf Trx with different copies of HPV L2 epitopes 
complexes to the NH2- or COOH- terminus of Pf ferritin or encapsulin, purified 
and characterized the antigens with different methods. We produced nicely 
assembled nanoparticles except of the Pf EnTrx8mer, which may be due to the 
different charges between Pf Trx 8mer and the Pf EnTrx8mer protein resulting 
in the inability to assemble into native-like nanoparticles properly. Separate 
immunizations were carried out in mice and guinea pigs, the cell culture based 
neutralization L1 and L2 PBNA, and animal in vivo infection assays were 
employed to investigate the neutralizing antibodies induced by the antigens. 
The best adjuvant for each platform was determined. With nicely assembled 
particles, the animal responses to Pf EnTrx3mer were not as good as to Pf 
FTrx3mer or to Pf Trx3mer OVX313. This observation highlights the importance 
of adequate antigen presentation, such as how well the conformational 
authenticity of functional domains, in this case the HPV L2 epitopes, referenced 
the quality of immune response. The diameter of Pf FTrx8mer and Pf 
EnTrx8mer nanoparticles are between 10-50 nm, and are therefore within the 
efficient range to traffic through lymph cords to lymph nodes, which means the 
capacity of trafficking should be the same as that of the natural virus. Once they 
reach the lymph nodes, they would be taken up by DCs and macrophages to 
activate B cells, here the Pf encapsulin platform should be more advantageous, 
but it is not One potential explanation for the surprising difference in 
immunogenicity is the orientation of L2 epitopes displayed by Pf encapsulin 
relative to the surface of the particle, as well as the packing density. These may 
affect how efficiently the L2 epitopes are accessed by the immune receptors, 
which results in different responses of animals.  
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If the nanoparticles contained ferritin instead of encapsulin as in the case of Pf 
FTrx8mer these showed a lot of strengths. The antibodies induced by Pf 
FTrx8mer could neutralize a large panel of high-risk oncogenic HPVs, and 1-2 
low-risk HPVs, both in vitro and in vivo. I believe that this nanoparticle antigen 
comprised of HPV L2 epitopes can provide broad cross-protection against 
oncogenic and other disease related HPV types. 
However, there are certain limitations about this nanoparticle antigen: a), the 
antigens were produced in H5 insect cell systems, which makes them more 
expensive than the antigens produced in E.coli or other systems, but there is 
evidence that the same nanoparticle antigen construct can also be produced 
successfully in an E.coli system. b), there is a big concern about the pre-existing 
anti ferritin antibodies inferring with the production of neutralizing antibodies, 
further investigation about heterologous immunization may give us the 
opportunity to overcome it. Since nicely assembled Pf encapsulin nanoparticles 
with Pf Trx8mer could not be produced up to now, there are several strategies 
that could be employed to solve this problem, such as spytag-spycatcher, and 
streptomycin avidin-avitag technologies. In addition, the opportunity to combine 
the nanoparticle with E7 epitopes and/or E2 epitopes, which are HPV onco-
proteins, would produce a combined vaccine with prophylactic and therapeutic 
benefits. 
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 Summary 
Over 200 different types of human papillomaviruses (HPV) have been identified 
based on their DNA sequences.  Some of them are highly associated with the 
development of cancer, such as HPV 16 and 18 which are responsible for 70% 
of cervical cancer in the world. Thirteen other oncogenic HPVs are also related 
of cervical cancer. HPV infections have also been proven highly related to anal 
cancer, penile cancer and others (such as head and neck cancers). There are 
three HPV prophylactic vaccines currently available, all composed of virus-like 
particles (VLPs) based on the HPV major capsid protein L1. They have been 
proven safe and highly immunogenic, but they are HPV type specific. They all 
need at least two to three administrations which results in low medicine 
compliance. Moreover, they are not cost efficient, which means that most 
developing countries could not benefit from them. All of these shortcomings 
pushed the development of a second generation of HPV prophylactic vaccines. 
The minor capsid protein L2, in contrast to the major capsid protein L1, contains 
cross neutralization epitopes which can elicit cross-protective responses, but 
the immunogenicity of L2 is low since the cross-neutralizing epitope is linear. 
Former colleagues showed that inserting the cross-neutralization epitope 
(aa20-38) of L2 into Pyrococcus furiosus thioredoxin (Pf Trx) greatly enhanced 
the immunogenicity of L2 and could induce the production of neutralizing 
antibodies.  The objective of this thesis is the development of cross-protective 
L2-based HPV nanoparticle vaccines. To this final goal, I 1) verified the best 
adjuvant for the nanoparticle antigens; 2) identified Pf Trx’s role in the 
nanoparticle antigenicity; 3) determined the best nanoparticle antigen 
candidate; 4) determined the influence of the antibodies induced by the 
nanoparticle platform on the production of neutralizing anti-HPV antibodies; 5) 
defined the effective nanoparticle antigen dose; 6) demonstrated the 
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immunogenicity of nanoparticle antigens in vivo; and, 7) assessed the immune-
relationship between Pf ferritin and human ferritin.  
Pf ferritin and encapsulin were employed as nanoparticle platforms to carry and 
display the trimeric and multimeric L2 epitopes with/without thioredoxin. 
Correctly assembled and uniformed nanoparticle antigens were produced with 
all platforms except with the exception of the multimeric L2 epitopes inserted 
into Pf encapsulin.  
The best adjuvant for Pf encapsulin is Alum-MPLA, and the best adjuvant for 
Pf ferritin is AddaVax. However, high titer antibodies against HPV16 induced 
by Pf ferritin even in the absence of an adjuvant were detected, which indicated 
that Pf ferritin based L2 prophylactic vaccine work in a self-adjuvanted way. 
And the nanoparticle antigens with Pf thioredoxin elicited much higher 
immunological responses in mice compared to constructs that did not contain 
Pf Trx. The nanoparticle antigen consisting of  Pf ferritin fused with eight 
different HPV L2 epitopes displayed by Pf Trx (Pf ferritin-Trx-HPVL2(aa20-
38)*8) was identified as the best candidate as it could induce high titers of 
neutralizing antibodies against 13 types of high-risk HPVs and HPV6 tested by 
Pseudovirus based neutralization assay (PBNA). Moreover, the capacity of the 
neutralizing antibodies induced by the nanoparticle antigen Pf ferritin-Trx-
HPVL2(aa20-38)*8 was verified in an in vivo cervico-vaginal challenge animal 
model with HPV16, 18, 33, 35, 39, 45, 51, 56, 6, and 11. By tracking the 
antibody levels during the course of the immunizations I found that three doses 
would be efficient to induce high titers of antibodies. 
Experiments testing the influence of the Pf ferritin platform on the immune 
responses revealed that pre-existing anti-Pf ferritin antibodies interfered with 
the induction of L2-specific neutralizing antibody production. Serology 
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experiments verified that the antibodies produced by the nanoparticle L2 
antigens containing Pf ferritin could not target the human ferritin.  
All in all, Pf ferritin Trx-HPVL2(aa20-38)*8 proved to be an excellent candidate 
for the presentation of epitopes that could elicit high titers of neutralizing 
antibodies that were effective in vitro and in vivo.  
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 Zusammenfassung 
Über 200 verschiedene Arten von humanen Papillomaviren (HPV) wurden 
anhand ihrer DNA-Sequenzen identifiziert.  Einige von ihnen sind in hohem 
Maße mit der Entstehung von Krebs verbunden, wie HPV 16 und 18, die für 70% 
der Gebärmutterhalskrebse auf der Welt verantwortlich sind. Dreizehn weitere 
onkogene HPVs sind ebenfalls mit Gebärmutterhalskrebs verbunden. HPV-
Infektionen sind auch in hohem Maße mit Analkrebs, Peniskrebs und anderen 
Krankheiten (z.B. Kopf- und Halskrebs) assoziiert. Es gibt derzeit drei 
prophylaktische HPV-Impfstoffe, die alle aus virus-ähnlichen Partikeln (VLPs) 
auf Basis des HPV major capsid protein L1 bestehen. Sie sind nachweislich 
sicher und hoch immunogen, aber sie sind HPV-typenspezifisch. Sie benötigen 
alle mindestens zwei order drei Verabreichungen, was zu einer geringen 
Impfkonformitat führt. Außerdem sind die Impfstoffe teuer, was bedeutet, dass 
die meisten Entwicklungsländer nur schwer von ihnen profitieren können. Alle 
diese Mängel trieben die Entwicklung der zweiten Generation eines 
prophylaktischen HPV-Impfstoffs voran. Das Nebenkapsidprotein L2 enthält im 
Gegensatz zum major capsid protein L1 Kreuzneutralisationsepitope, die 
Kreuzschutzreaktionen gegen andere HPV Spezies hervorrufen können, aber 
die Immunogenität von L2 ist gering, da das L2 Epitope linear ist. Ehemalige 
Kollegen zeigten, dass die Einführung des hockkonservierten Epitops (aa20-
38) von L2 in Pyrococcus furiosus Thioredoxin (Pf Trx) die Immunogenität von 
L2 stark erhöht und die Produktion von neutralisierenden Antikörpern 
induzieren kann. Das Ziel meiner Arbeit war die Entwicklung von 
kreuzschützenden L2-basierten HPV-Nanopartikel-Impfstoffen. Zu diesem 
Zweck haben ich 1) das beste Adjuvans für die Nanopartikelantigene überprüft; 
2) die Rolle von Pf Trx im Nanopartikelantigen identifiziert; 3) den besten 
Nanopartikelantigenkandidaten bestimmt; 4) den Einfluss der durch die 
Nanopartikelplattform induzierten Antikörper auf die Produktion 
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neutralisierender anti-HPV Antikörper bestimmt; 5) die effektive Nanopartikel-
Antigendosis definiert; 6) die Immunogenität von Nanopartikel-Antigenen in 
vivo nachgewiesen; und (7) die Immunrelation zwischen Pf-Ferritin und 
menschlichem Ferritin bewertet.  
Pyrococcus furiosus Ferritin und Encapsulin wurden als 
Nanopartikelplattformen eingesetzt, um die trimeren und multimeren L2-
Epitope mit oder ohne Thioredoxin zu inkoroprieren und zu präsentieren. Mit 
alle Platformen wurden korrekt zusammengesetzte und uniformierte 
Nanopartikelantigene hergestellt, mit Ausnahme der multimeren L2-Epitope, 
die mit Pf-Encapsulin zusammengesetzt eingesetzt wurden.  
Das beste Adjuvans für Pf-Encapsulin ist Alum-MPLA, das beste Adjuvans für 
Pf-ferritin ist AddaVax, aber ich konnte auch ohne Adjuvans nachweisen, dass 
Pf-Ferritin-basierte L2-e-Impfstoffe selbst-adjuvant wirken und effektive 
Antikörper produziert wurden. Nanopartikel-Antigene die Pf Thioredoxin 
enthielten riefen bei Mäusen eine viel höhere Reaktionen hervor als Konstrukte 
ohne Pf Thioredoxin. Somit is Pf Thioredoxin ein wichtiges Immunstimulans. 
Das Nanopartikel Konstrukt mit Pf-Ferritin, das mit acht verschiedenen durch 
Pf Trx präsentierten HPV L2-Epitopen (Pf-ferritin-Trx-HPVL2(aa20-38)*8) 
fusioniert ist, wurde als bester Kandidat identifiziert. Es konnte führte zu hohen 
Titer von neutralisierenden Antikörpern gegen 13 hoch riskante HPVs und 
HPV6, wie ich in derPseudovirus-basierter Neutralisationstest zeigen konnte. 
Darüber hinaus wurde die Kapazität der neutralisierenden Antikörper, die durch 
das Nanopartikelantigen Pf ferritin-Trx-HPVL2(aa20-38)*8 induziert wurden, in 
einem in vivo zervikal-vaginalen Challenge-Tiermodell überprüft. Durch 
Überprüfung der Antikörpertiter während der Impfungen fanden ich heraus, 
dassdrei Dosen effizient sein würden, um hohe Titer von Antikörpern zu 
induzieren. 
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Experimente, die den Einfluss der Pf-Ferritin-Plattform auf die Immunantwort 
untersuchten, zeigten, dass nach der ersten Impfung gebildete Anti-Pf-Ferritin-
Antikörper die Induktion der L2-spezifischen neutralisierenden 
Antikörperproduktion behinderten. Serologische Experimente bestätigten, dass 
die von den Pf Ferritin-Nanopartikel-L2-Antigenen produzierten Antikörper das 
menschliche ferritin nicht erkennen konnten.  
Insgesamt erwies sich Pf Ferritin-Trx-HPVL2(aa20-38)*8 als hervorragender 
Kandidat für die Präsentation von Epitopen, die hohe Titer neutralisierender 
Antikörper hervorrufen konnten, die in vitro und in vivo wirksam waren.  
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